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Part 1: Introduction 
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2 
Short introduction 
In 1952 an experimental drug (4560 RP) that had major therapeutic effects in 
schizophrenic patients was introduced in the clinic (see Deniker, 1983) This drug was 
later called chlorpromazine it was the beginning of a revolution in the treatment of 
schizophrenia Since then a large number of drugs that ameliorate symptoms in 
schizophrenia (neuroleptics) have been developed, and many are clinically used at present 
The advent of neuroleptics has dramatically decreased the number of hospitalised patients 
However, the discovery of neuroleptics is not the end of schizophrenia, the amelioration 
of symptoms does not mean that the patient is cured Moreover, not all patients are 
susceptible to neuroleptics, and not every symptom can be ameliorated Finally, treatment 
with neuroleptics often results in serious side-effects Most prominent are the 
neurological, so-called extrapyramidal side-effects, such as muscle rigidity and 
hypokinesia However, at least one neuroleptic, viz clozapine, appears to have a better 
clinical profile it ameliorates many symptoms, it is therapeutically effective in (some of 
the) patients that are unresponsive to other neuroleptics, and it induces hardly any 
extrapyramidal side-effects However, this drug can have severe and, sometimes, fatal 
side-effects on white blood cells which seriously limit extensive use of clozapine 
Therefore, developing drugs like clozapine without these haematological side-effects is of 
great importance for the treatment of schizophrenia In the present thesis some aspects of 
the working mechanism of neuroleptics are studied Hopefully, a broader understanding 
of the receptors and structures involved in therapeutic effects as well as extrapyramidal 
side-effects of neuroleptic drugs facilitates the development of superior drugs for the 
treatment of schizophrenia 
Outline thesis 
Part 1 starts with a short introduction on schizophrenia and the clinical effects of 
neuroleptics (chapter 1) It is concluded that at the moment there is no optimal treatment 
for a large number of patients Dopaminergic, serotonergic and noradrenergic systems are 
thought to play a role 
in the pathophysiology of schizophrenia In chapter two the most important hypotheses on 
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Ihe working mechanisms of neuroleptics are presented. Subsequently, the putative 
neurobiological substrate of the therapeutic effects and the neurobiological substrate for 
the extrapyramidal side-effects of neuroleptics are discussed. It is concluded that 
dopaminergic receptors play a key role in the effects of neuroleptics, however, 
serotonergic and noradrenergic receptors may also be involved Much is still to be learned 
about the role of these receptors in the effects of neuroleptics. 
Part 2 consists of studies using the paw test, an animal model with predictive validity for 
the antipsychotic efficacy and the extrapyramidal side effects of drugs. First, chapter 3 
describes the interaction between dopamine D, and D2 antagonists Chapter 4 describes 
the role of serotonergic receptors, and chapter 5 describes the role of noradrenergic 
receptors in the effects of neuroleptics Chapter 6 presents a study that may explain the 
working mechanism of the prototypic atypical neuroleptic, clozapine The role of 
dopamine D2 receptors in different striatal structures in the effects of neuroleptics in the 
paw test is described in chapter 7. 
Part 3 consists of studies on oro-facial dyskinesia, one of the most serious extrapyramidal 
side effects that, in contrast with the other extrapyramidal symptoms, is induced only 
after prolonged treatment with neuroleptics The effects on oral behaviour of different 
dopaminergic agonists after administration in the nucleus accumbens, a structure believed 
to be involved in oro-facial dyskinesia, are described (chapters 8-10) In the final chapter 
of this part, it is shown that the dyskinetic effects of the dopamine agonist (3,4-
dihydroxyphenyhmino)-2-imidazohne (DPI) are attenuated by ¿-sulpiride, a drug that may 
be of interest as an anti-dyskinetic agent (chapter 11). Part 4 summarizes the studies 
presented and discusses the clinical predictions in relation to other studies (chapter 12) 
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Chapter 1 
Clinical effects of neuroleptic drugs 
1 1 Short introduction on schizophrenia 
The disease schizophrenia affects about 1% of the total population (Jablensky, 1986). 
Within this patient group there is a great variety of symptoms, which makes the diagnosis 
of schizophrenia very complex In order to improve the diagnosis of schizophrenic 
patients, many subgroups of symptoms have been discerned The last decade or so the 
clustering of symptoms into two great categories (Crow, 1980; Andreasen and Olson, 
1982) has been very valuable, both from theoretical and from therapeutic point of view. 
The first category encompasses so called positive symptoms, defined as representing a 
surplus of behaviour or perceptions, like delusions, hallucinations and stereotypy These 
symptoms can be ameliorated by neuroleptics The second category is that of the so-called 
negative symptoms that are defined as a lack of normal behaviours, like decreased 
emotional expression, anhedonia and decreased social behaviour (Andreasen and Olsen, 
1982) These negative symptoms do not respond well to treatment with (classical) 
neuroleptics 
The age of onset of schizophrenia vanes widely with a median value of 30 (Tsuang and 
Winokur, 1974) Premorbid characteristics may be present long before the outbreak of 
disease (Albee et al , 1964) With respect to the course of schizophrenia, it has been 
shown that the negative symptoms increase, or remain constant, in time (Pfohl and 
Winokur, 1982), while the positive symptoms occur in periods (psychoses), and may 
disappear and reappear in time (Winokur et al 1985) 
In the etiology genetics play an important role Genetic factors are thought to determine 
for about 70% the development of schizophrenia (Rao et al , 1981) Other etiological 
factors may be the season of birth (for review, see Bradbury and Miller, 1985) and the 
social environment (Brown et al , 1958) 
Studying the pathophysiology of a disease like schizophrenia has proven to be a major 
challenge A large number of biochemical studies have been performed in schizophrenic 
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patients, showing abnormalities in a number of neurotransmitters and their metabolites 
However, since nearly all patients have been treated with neuroleptics, it is extremely 
difficult to determine to what extent these findings are due to the disease and to what 
extent they are due to the medication To minimize medication effects, biochemical data 
are taken from patients that have been off neuroleptics (often for 2-4 weeks) However, 
since neuroleptics may influence aminergic systems for a very long time period, even 
after single administration (Antelman et al , 1992), this neuroleptic free penod does not 
seem adequate Notwithstanding these shortcomings, the overall research has suggested a 
role for dopamine (for review, see Ellenbroek, 1988), noradrenaline (Van Kammen et al , 
1986) and serotonin (Joyce, 1993, Ohuoha et al, 1993) in schizophrenia 
On the other hand, schizophrenic-like symptoms (e g hallucinations) can also be induced 
in normal individuals by drugs In non-schizophrenic subjects, hallucinations can be 
induced by drugs such as amphetamine and cocaine, drugs that increase dopamine, 
serotonin and noradrenaline levels (for review, see Sedvall, 1990) Thus, it may be 
hypothetized that endogeneous disturbances in dopaminergic, serotonergic and 
noradrenergic systems are present in schizophrenia and cause symptoms like 
hallucinations (Sedvall, 1990) This is underscored by the fact that amphetamine 
aggravates symptoms in schizophrenia (Janowsky and Davis, 1974) 
Studies on anatomical and functional abnormalities have implicated a large part of the 
forebrain in the pathophysiology of schizophrenia We summarize the most important 
findings 1) An enormous amount of studies have shown anatomical abnormalities in the 
temporal lobe, especially the hippocampus (for review, see Meltzer, 1987) Anatomical 
findings include a reduced volume of the hippocampus and a decrease in cell loss in 
schizophrenic patients (for review, see Bogerts et al, 1993) Functional studies have 
shown a reduced metabolism in the hippocampus in schizophrenic patients (Tamminga, 
1987) Finally, pharmacological post-mortem studies have shown abnormalities in 
dopaminergic, serotonergic and noradrenergic receptors in the hippocampus of 
schizophrenic patients (for review, see Joyce, 1993) 2) Both anatomical and functional 
studies have shown abnormalities in the prefrontal cortex to occur in schizophrenic 
patients Anatomical studies show a decrease in the total volume and reduced cell 
numbers in the frontal cortex (Andreasen et al , 1986 Colon, 1972) A large number of 
functional studies have shown that schizophrenic patients have a decreased ratio of 
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prefrontal cortex/ occipital cortex metabolism, caused by a decreased prefrontal activity in 
these patients (for review, see Buchsbaum, 1990). 3) A number of anatomical studies 
have shown post-mortem abnormalities in the basal ganglia, especially the caudate-
putamen (i.e. dorsal striatum). The volume of the caudate nucleus, but not the putamen or 
the nucleus accumbens, is decreased in schizophrenic patients (for review, Bogerts et al., 
1993). On the other hand, biochemical abnormalities (e.g. increase in homovanillic acid, 
and increase in noradrenaline) in post-mortem schizophrenics have been reported for the 
caudate-putamen and the nucleus accumbens (part of the ventral striatum; for review, see 
Ellenbroek, 1988). The absolute metabolic rate in the basal ganglia was decreased in 
never-medicated schizophrenic patients (Buchsbaum, 1990). 
Interestingly, cluster analysis on metabolic data indicate that schizophrenic patients show 
a low activity in all three areas (prefrontal lobes, temporal lobes and basal ganglia) rather 
than a pattern of three independent clusters (Buchsbaum, 1990). This is understandable in 
view of the fact that these areas are closely connected: both the prefrontal cortex and the 
hippocampus project to the basal ganglia (Groenewegen et ai, 1991). Thus, changes in 
one structure will have consequences for the functioning of the structures innervated by 
that structure (cf. Jaspers, 1991). 
1.2 Beneficial effects of neuroleptics 
An enormous amount of clinical studies have shown that neuroleptics ameliorate 
schizophrenic symptoms during a psychotic period (for review, see Kane and Marder, 
1993). Moreover, neuroleptics postpone the next psychosis in the period following a 
psychosis (relapse prevention; Davis et al., 1980). The time period for the therapeutic 
effects to take place following the start of treatment with neuroleptics is generally thought 
to be a few weeks, although a number of studies have suggested that they already occur 
within a few days (for review, see Ellenbroek, 1993). There are some limitations to the 
therapeutic effects of neuroleptics: the effect on more chronic, negative symptoms is 
minimal (Schizophrenia Research Group, 1987) and a number of patients is unresponsive, 
also with respect to positive symptoms (Kane et al., 1989). 
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Table 1. Estimations of the therapeutic efficacy on positive and negative symptoms 
and the EPS for a number of neuroleptics (estimations by the author of this thesis, 
based on Bobon et al., 1972; Den Boer et al. 1991; The British Isles Raclopride Study 
Group, 1992; Chouinard et al., 1993; review by Ellenbroek, 1993). *: generally 
considered an atypical neuroleptic; -: no effect; +: weak effect; + + : moderate 
effect; + + + strong effect; ?: effect unknown. 
Clozapine * 
Chlorpromazine 
Fluphenazine 
Haloperidol 
Prothipendyl * 
Raclopride * 
Remoxipride * 
Risperidone * 
Sulpiride 
Thioridazine * 
Positive 
+ + + 
+ + + 
+ + + 
+ + + 
+ 
+ + 
+ + + 
+ + + 
+ 
+ + 
Negative 
+ + + 
+ 
+ 
+ 
•> 
+ 
+ 
+ + 
+ 
+ 
EPS 
-
+ + 
+ + · 
+ + • 
-
+ 
+ 
+ 
+ + 
+ 
On the other hand, some atypical neuroleptics may have a better profile e g clozapine is 
relatively effective on negative symptoms and in part of the 'treatment resistant' patients 
(Kane et al , 1988) Preliminary studies have suggested that the same may apply to 
risperidone (Meert and Awouters, 1991) 
Traditional neuroleptics are thought to be effective via their blockade of dopamine D2 
receptors (Creese et al , 1976, Seeman et al , 1976, Richelson and Nelson, 1984) On the 
other hand, the fact thai clozapine that has only a relatively weak affinity for D2 receptors 
(Leysen et al , 1993), is yet therapeutically active in treatment-resistant patients, suggests 
that its working mechanisms is not just D2 blockade Moreover, clozapine has a higher 
affinity for serotonergic (5-HT1A) and noradrenergic (a,) receptors than for dopamine 
receptors (Leysen et al 1993) Thus, non-dopaminergic receptors may play a role as 
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well. However, until now, selective drugs for serotonergic or noradrenergic receptors 
have not been found to be very effective (Albus et al., 1986; Berlant, 1987; Meert and 
Awouters, 1991). On the other hand, a number of such drugs given on top of a 
neuroleptic, may affect the clinical effect Thus, when given on top of conventional 
neuroleptics the 5-HT2A/c antagonist ntansenn enhances the effects on negative symptoms 
(see Meert and Awouters, 1991). The a2-antagonist idazoxan is shown to enhance the 
therapeutic effects of fluphenazine (Litman et al, 1993), while the β blocker propranolol 
is shown to enhance the therapeutic efficacy of neuroleptics in chronic, treatment-resistant 
schizophrenic patients (for review, Berlant, 1987). 
1 3 Adverse effects of neuroleptics 
Neuroleptics can induce a large range of side-effects Depending on the neuroleptic used, 
sedation, haematological, autonomic, endocrine and neurological side-effects may occur. 
Of the haematological side-effects, agranulocytosis (the destruction of white blood cells) 
may be fatal (for review, see Krupp and Barnes, 1989). Especially the neurological side-
effects (usually called extrapyramidal side-effects; EPS) are a major problem in the 
clinical use of neuroleptics Most neuroleptics used in the clinic produce these EPS. 
Unfortunately, the neuroleptic that almost completely lacks EPS, clozapine (Baldessanm 
and Frankenburg, 1991), has a relatively high propensity for inducing agranulocytosis 
(about 1% ; Krupp and Barnes, 1989), which seriously limits its clinical usefulness. The 
propensity of other relevant neuroleptics to induce EPS can be seen in Table 1 (section 
1 2) and is described briefly at the end of this section. 
The EPS include a large number of different symptoms. The occurence of these 
symptoms vanes greatly in time, and several symptoms show great overlap (e.g. akathisia 
and dyskinesia). Moreover, EPS may also be hard to discern from the disease itself (e.g. 
akinesia and negative symptoms), making the diagnosis of these side-effects difficult (see 
Kane et ai, 1993). Within the EPS the following symptoms are discerned: 1) dystonia 
(the occurence of abnormal postures and slow abnormal movements). 2) parkinsonism 
(hypokinesia, rigidity and tremor). 3) akathisia (motor restlessness that also has a 
cognitive component (feelings of restlessness)) 4) dyskinesias (fast abnormal movements). 
In its acute form, dyskinesias are mostly lumped together with dystonia 
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The percentage of EPS in first-episode patients for the classical neuroleptic fluphenazine 
for instance is as follows- 36% for dystonia, 18% for akathisia and 15% for parkinsonism 
(Chakos et al., 1992). Some patients may have more than one of these symptoms; they 
may occur at the same time (e.g. parkinsonism and dystonia) or follow each other in time 
(Chakos et ai, 1992). Generally, after starting neuroleptic medication all of these 
symptoms may appear within one day or a few days after the start of medication. Of the 
EPS, dystonia occurs earliest, then akathisia and then parkinsonism (Ayd, 1961), but all 
of them occurring within 70 days (Chakos et al 1992) However, akathisia has also been 
reported to occur within hours after administration of a neuroleptic (Farde et al., 1988). 
It is now generally accepted that after prolonged continuous medication the acute 
symptoms attenuate in time (Barnes and Edwards, 1993). Later in time, another group of 
symptoms with similar morphology but a different pathophysiology may appear: the so-
called tardive symptoms (Kane and Smith, 1982). These tardive symptoms may appear 
following years of continuous medication. Especially tardive dyskinesia (TD) is a serious 
problem because of its high incidence (about 20% of the patients chronically treated with 
neuroleptics; Kane and Smith, 1982) and because it often persists after withdrawal of the 
neuroleptic (Kane et al , 1986). Although chronic neuroleptic treatment was thought to be 
the principle cause for inducing TD, recent studies suggest that it may be more 
complicated A large number of factors determine the vulnerability of an individual to 
develop TD: there is a correlation between tardive oro-facial dyskinesia (OFD) and 
patients with negative symptoms and patients that show cognitive hypofunction 
(Waddington, 1989). Moreover, OFD is dependent on gender and especially age (it 
appears more in woman and in aged persons) as well as the way of administration of the 
neuroleptic (Waddington, 1989) It can be concluded that neuroleptics induce TD in 
vulnerable individuals. However, it also has a high incidence in patients with an organic 
brain diseases, like dementia (Waddington, 1989) 
The occurrence of the different EPS is not unrelated the degree of parkinsonism 
following neuroleptic treatment predicts the occurrence of TD 5 years later (Chouinard et 
al., 1986). In chronic patients akathisia is positively associated with TD (Kucharski et al., 
1987) Indeed, TD has been suggested to be a final stage of akathisia (Barnes and Braude, 
1985) 
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The acute EPS, especially parkinsonism, may be ameliorated by lowering the dose of the 
neuroleptic or by the administration of L-DOPA (Crossman, 1987). However, this is not 
desirable since both strategies may lead to an increase in psychotic symptoms. The most 
common way of treating patients with acute EPS is the co-administration of 
anticholinergics. Especially patients with dystonia and akathisia respond well to 
anticholinergics (Stem and Anderson, 1979; Fleischhacker et al., 1990). Parkinsonism 
can be partly improved by anticholinergics (Korsgaard and Friis, 1986; Wirshing et al., 
1989). However, anticholinergic treatment may lead to cognitive deficits (Van 
Spaendonck et al., 1993) and may worsen TD (see below). Recently, the serotonergic 
system became of interest in the treatment of EPS: 5-HT2A/c antagonists ameliorate all the 
acute EPS to some extent, but especially akathisia and tremor (Bersani et al., 1986). 
With respect to the role of the noradrenergic system in the treatment of EPS, both the a7 
agonist Clonidine and the β antagonist propranolol have been reported to ameliorate 
akathisia (Fleischhacker et al., 1990) and tremor (zie Wilbur et ai, 1988), but not the 
other acute EPS. 
Tardive dyskinesia can be ameliorated by depleting dopamine (reserpine) or by increasing 
the dose of neuroleptics (Jeste and Wyatt, 1982), suggesting that it is caused by dopamine 
hyperactivity, rather than by dopamine hypoactivity. However, treating neuroleptic-
induced dyskinesias with neuroleptics is an irrational approach, since it will only delay 
the problem. On the other hand, the atypical neuroleptic clozapine, which does not induce 
TD itself (Casey, 1989), attenuates existing dyskinesias (Simpsom et al, 1978). This may 
be an important treatment for TD, although the haematological side-effect of clozapine 
will limit its clinical use. 
In contrast to their effects on acute EPS, anticholinergics usually worsen TD, while 
cholinergic agonists have some therapeutic value (Jeste and Wyatt, 1982; Lieberman et 
ai, 1988). Other therapeutic agents for TD include GABA agonists, benzodiazepines, 
Clonidine and propranolol; all of these compounds have very limited effects (Jeste and 
Wyatt, 1982). Taken together, there is no optimal treatment for TD at this moment. 
As mentioned before, the propensity of neuroleptics for inducing EPS differs strongly, 
and neuroleptics are often divided into two groups: the so-called classical neuroleptics that 
strongly induce EPS, and the so-called atypical neuroleptics that are relatively devoid of 
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inducing EPS. We briefly describe some neuroleptics lhat are relevant for this thesis (cf. 
Table 1). Clozapine and prothipendyl are almost devoid of EPS (for reviews: see 
Baldessarini and Frankenburg, 1991 and Ellenbroek, 1993). Thioridazine, on the other 
hand, induces EPS in some patients (8 to 16%), although less than classical neuroleptics 
(23 to 40%; Laskey et al., 1962; Galbrecht and Klett, 1968). Remoxipride induces 
significantly less rigidity and dystonia than classical neuroleptics, but induces akathisia 
and tremor to a similar extent (a.o. Den Boer et al., 1990). Raclopride has a lower 
incidence in all acute EPS compared with haloperdiol (British Islands Raclopride Study 
Group, 1992). Finally, risperidone induces significantly less EPS compared with 
haloperidol (Meert and Awouters, 1991). 
These data suggest that the classes of classical and atypical neuroleptics do not exist, but 
that, instead, there is a continuum of neuroleptics with respect to their propensity to 
induce EPS. Furthermore, this propensity to induce EPS is dependent on the symptom 
under study: remoxipride is generally seen as an atypical neuroleptic, but does not differ 
with respect to akathisia with classical neuroleptics (Den Boer et al., 1990). 
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Chapter 2 
Preclinical studies on neuroleptic drugs 
2.1 Animal models for the therapeutic effects of neuroleptics 
Before discussing the preclinical studies with relevance for the therapeutic effects of 
neuroleptic drugs, we first discuss the paradigms used in these studies. 
To help elucidating the working mechanism of neuroleptics, a number of strategies have 
been followed. First, in pharmacological studies binding data of neuroleptics have been 
correlated with the clinical dose (e.g. Creese et ai, 1976). Second, the effects of 
neuroleptics on the electrophysiology of dopamine systems have been determined: chronic 
treatment with neuroleptics has been found to attenuate the spontaneous firing in the 
dopamine AIO cell group. On the other hand, chronic treatment with classical, but not 
atypical neuroleptics, has been found to attenuate the spontaneous firing in the dopamine 
A9 cell group as well (Chiodo and Bunney, 1983; White and Wang, 198J). It has been 
hypothetized that the effect on the dopamine AIO and A9 cells reflect the therapeutic 
effects and the extrapyramidal side-effects of neuroleptic drugs, respectively. Third, the 
disturbance of distinct spontaneous or learned behaviours by neuroleptics: for example, 
conditioned avoidance response [CAR; in which animals leam to respond in a certain way 
in order to avoid an unpleasant stimulus; neuroleptics decrease the number of correct 
responses] and dopamine related locomotor activity [activity induced by dopaminergic 
agonists is blocked by neuroleptics]. A more recent model is the paw test [in which 
neuroleptics prolong the retraction time of hind- and/or forelimbs of a rat placed on a 
platform with its paws in four separate holes]. It has been shown that classical 
neuroleptics enhance the hindlimb retraction time (HRT) and the forelimb retraction time 
(FRT) at similar doses, while atypical neuroleptics enhance specifically the HRT at lower 
doses (Ellenbroek et al., 1987). On basis of these and related findings it has been 
postulated that the HRT models antipsychotic efficacy while the FRT models EPS of 
drugs. 
The predictive validity of these models can be assessed with the help of a number of 
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criteria (EUenbroek, 1993): the dependent variables modelling the therapeutic effects 
should be affected by neuroleptics of different chemical classes, show no false positives 
and no false negatives, and the neuroleptic-induced effects should not be attenuated by 
anticholinergics, but should be potentiated by benzodiazepines. Finally, chronic treatment 
with neuroleptics should produce enduring effects, and there should be a positive 
correlation between the potency of the neuroleptic in the test and the average daily dose 
of the neuroleptic in the clinic. Using these criteria, Ellenbroek (1993) discussing a large 
number of publications, has shown that both the CAR and dopamine related locomotor 
activity fulfil a number of criteria but, on the other hand, show many false positives as 
well as a non-desired attenuation of neuroleptic-induced effects by anticholinergics. 
The HRT in the paw test fulfilled all seven criteria, indicating that this test may be 
especially useful to study the working mechanism of neuroleptic drugs. This, indeed, is 
one of the goals of the present thesis (chapters 3-7). 
Figure 1. The paw test box 
As far as we know, the electrophysiological model on dopamine A9/A10 cells has not 
been systematically validated. However, it seems to fulfil at least a number of criteria as 
a model for neuroleptic drugs (cf. Chiodo and Bunney, 1985). 
2.1.1 The role of dopaminergic, serotonergic and noradrenergic receptors in the 
therapeutic effects of neuroleptics 
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In 1976, two independent studies have shown a strong positive correlation between the 
average daily clinical dose of neuroleptics and the in vitro affinity for dopamine receptors 
(Creese et al., 1976; Seeman et al., 1976). This correlation has been used to state that the 
dopamine receptor antagonist properties of neuroleptics are responsible for the therapeutic 
effects of neuroleptics. Later, it has been shown that D2 receptors are involved in these 
effects (Richelson and Nelson, 1984). D2 blockade is still believed to be the key process 
by which (classical) neuroleptics exert antipsychotic effects. However, given the adverse 
effects of the classical D2 blocking neuroleptics, other receptors, such as dopamine D, 
receptors, serotonin 5-HT2A/c receptors and α-adrenoceptors have also been studied for 
their putative antipsychotic effects. Such research is stimulated by the fact that clozapine, 
having antipsychotic effects in neuroleptic-treatment resistant patients (see section 1.2), 
has only a moderate D2 antagonistic effect compared with classical neuroleptics as well as 
a significant affinity for a number of other receptors (Leysen et al., 1993). Indeed, paw 
test studies have shown that the D,, and not the D2 antagonist property is important for 
the effects of clozapine on the HRT (Ellenbroek et al., 1991). However, given its broad 
effect on diverse receptors (including 5-HT2A/c receptors, α-adrenoceptors and cholinergic 
receptors; see references in chapter 6), it is unlikely that clozapine produces its 
antipsychotic effects solely through blockade of D, receptors (cf. chapter 6). 
On the other hand, the selective D, antagonist SCH 23390 has been found to attenuate the 
CAR (a.o. Iorio et al., 1983), implying that D, blockade alone can be therapeutically 
effective. This is strengthend by the outcome of a paw test study: the D, antagonist SCH 
23390 prolongs the HRT (Ellenbroek et al., 1987). Moreover, a preliminary study has 
shown that another D, antagonist, NNC 756, has indeed antipsychotic properties in 
schizophrenic patients (Lublin et ai, 1994). 
Given the diverse interactions between dopamine D, and D2 receptors (Clark and White, 
1987), it is not unlikely that these interactions also play a role in the effects of 
neuroleptics. However, the inhibitory effects of a number of neuroleptics in the CAR 
have been found to correlate only with their affinity for dopamine receptors, when the Ό
ι 
selective and D2 selective drugs are considered separately, indicating that D, and D2 
blockade independently inhibit the CAR (McQuade et al., 1992) and that interactions play 
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no, or just a minor, role in the therapeutic effects of neuroleptics. However, direct studies 
have not been performed this is subject of study in the present thesis (chapter 3) 
An ineffective dose of the atypical neuroleptic raclopnde (that is selective for D2 
receptors; Leysen et al , 1933), combined with the 5-HT1A agonist 8-hydroxy-2-(di-/z-
propylamino)tetrahn (8-OHDPAT) produces synergistic effects on the CAR; similar 
effects have been found with halopendol and 5-HT,A agonists (Shropshire and Marquis, 
1992) These studies indicate that combining blockade of D2 receptors and stimulation of 
5-НТ1л receptors may produce strong antipsychotic effects 
Studies on CAR have shown that a number of α,-antagonists lead to specific effects in the 
CAR (Arnt, 1982) Moreover, the (^-antagonist prazosin, in an ineffective dose, 
decreases the minimal effective dose needed to induce an effect when combined with cis-
flupenthixol, but not with halopendol (Amt, 1982) It has therefore been suggested that 
the αϊ-antagonist property of some neuroleptics may contribute to their effects in CAR 
(Arnt, 1982) 
Thus, although a few поп-dopaminergic receptors have been studied as target sites for 
some neuroleptics, a lot of open questions remain The present thesis further analyses the 
role of these receptors in the effects of neuroleptic drugs in the paw test (chapters 4 and 
5) 
2 12 Anatomical target sues for the therapeutic effects of neuroleptics 
The last part of this section deals with the putative anatomical substrate for the therapeutic 
effects of neuroleptics Obviously, the electrophysiological model on dopamine A9 and 
AIO cells indicates that the mesohmbic dopamine (AIO) system is involved in the 
therapeutic effects of neuroleptics, while the nigroslnatal dopamine (A9) system is 
involved in the EPS of neuroleptics (see above) On the other hand, studies on the CAR 
have indicated a role both for the dopaminergic mesolimbic and nigrostnatal systems in 
the disruption of the CAR (Fibiger et al , 1974, Zis et al , 1974, Koob et al , 1984) 
Recently, Wadenberg and colleagues have studied the effect of the D2 antagonist and 
neuroleptic /-sulpiride in several brain structures on the CAR it was highly effective in 
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the nucleus accumbens (ACC), weakly effective in the dorsolateral stnatum and the 
amygdala and ineffective in the posterior lateral stnatum and prefrontal cortex 
(Wadenberg et al , 1990) Furthermore, studies using intra-cerebral administration of 
drugs have indicated that both the DS and the ACC play a role in the effects of 
halopendol in the paw test (Ellenbroek and Cools, 1991) Finally, the hippocampus and 
the prefrontal cortex are structures that may also contain target sites for the therapeutic 
effects of neuroleptics (Deutch, 1993, Joyce, 1993) Taken together, there may be 
multiple sites where neuroleptics can induce therapeutic effects Chapter 7 focuses on the 
role of the different striatal structures in the effects in the paw test [dorsal stnatum (DS), 
ACC and olfactory tubercle (ОТ)] As a first step to explore these intra-cerebral target 
sites for neuroleptics in the paw test, we decided to study dopamine D2 receptors 
2 2 Animal models for the extrapyramidal side-effects of neuroleptic drugs 
An often studied animal model for extrapyramidal side-effects (EPS) is catalepsy, viz. a 
state of profound movement inhibition, charatenzed by the inability to correct abnormal 
postures (Sukul et al , 1988) Although never systematically analyzed, as far as we know, 
neuroleptic induced catalepsy appears to have some validity as an animal model for 
neuroleptic-induced EPS (cf Ellenbroek et al , 1993) However, many different methods 
and paradigms are used to measure catalepsy, producing different results (Sanberg et al , 
1984) Moreover, contradictory effects are often found (e g identical effects of 5-HT2A/r 
agonists and antagonists, see below), suggesting that the specificity of the catelepsy model 
is not very high This is underscored by the large number of false positives that are 
observed 
Another animal model for neuroleptic-induced EPS is the forehmb retraction time (FRT) 
in the paw test (Ellenbroek et al , 1987, Ellenbroek and Cools, 1988) This model fulfills 
a number of criteria for an animal model for EPS (Ellenbroek, 1993) it is affected by 
neuroleptics of different chemical classes, shows few false positives and no false 
negatives, and the neuroleptic-induced effects are attenuated by anticholinergics Finally, 
chronic treatment with neuroleptics produces attenuating effects, as should be expected 
(section 1 3, Ellenbroek, 1993) On the other hand, the effects of neuroleptics are not 
attenuated by benzodiazepines (Ellenbroek, 1993), as would be expected (cf section 1 2) 
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Another animal model for EPS in man is the attenuation of dopamine related stereotypy 
(Costali and Naylor, 1976), as far as we know, this model is not systematically validated 
Finally, animal models with putative face validity for EPS are etnologica! studies on the 
effects of (chronic administration of) neuroleptics in monkeys, the EPS observed 
(dystonia, parkinsonism, dyskinesia) seem to have face validity (e g Liebman and Neal, 
1980) 
2 2 1 The role of dopaminergic, serotonergic and noradrenergic receptors in the 
extrapyramidal side effects of neuroleptics 
It is generally thought that D2 blockade is responsible for the EPS of neuroleptics, since 
classical neuroleptics like halopendol that are predominantly D2 antagonists, induce the 
whole pattern of EPS (e g Den Boer et al , 1991) The fact that TD (and possibly 
dystonia, cf Marsden and Jenner, 1980) is a hyperdopaminergic symptom (section 1 3), 
and yet is induced by a dopamine antagonist, is explained by supersensitivity of the 
dopamine system (cf Jenner and Marsden, 1980) 
Not all D2 antagonists are classical neuroleptics, the substituted benzamides raclopnde and 
remoxipnde are atypical neuroleptics (see section 1 3) This is possibly related to their 
regionally selective binding (cf section 12 2) The development of selective D, 
antagonists has given nse to much research on the preclinical efficacy of these 
compounds These studies indicate that, although D, antagonists are capable of inducing 
EPS, they have less propensity than classical neuroleptics to do so (electrophysiological 
study on A9/A10 cells Goldstein and Litwin, 1988, paw test Ellenbroek et al , 1987, 
following chronic administration in monkeys Coffin et al , 1989, Gerlach and Hansen, 
1992) With respect to the interaction between D, and D2 receptors, preclinical studies on 
catalepsy predict that combining D, and D2 receptor antagonists will potentiate the EPS 
(Undie and Friedman, 1988, Parashos et al , 1989, Wanibuchi and Usuda, 1990) In the 
present thesis the interaction between the selective D, antagonist SCH 39166 and the D2 
antagonists raclopnde and halopendol in the paw test is analyzed (chapter 3) 
Serotonergic receptors may play a role in the propensity of neuroleptics to induce EPS 
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Meltzer and colleagues (1989) have shown that the EPS profile of neuroleptics could be 
explained by their relative affinity for D2 and 5-HT2A receptors A low D2/5-HT2A ratio 
would be the characteristic of atypical neuroleptics, suggesting that 5-ΐΠ2Α blockade 
counteracts the EPS induced by D2 blockade (Meltzer et al , 1989). Indeed, as discussed, 
it has been shown that a 5-HT2A/c antagonist ameliorates some of the neuroleptic-induced 
EPS (section 1 3) However, some comments on this theory are necessary. 1) this theory 
does not explain the clinical effects of the atypical neuroleptics raclopnde and 
remoxipnde that have no apparent affinity for 5-HT2A receptors (Leysen et al., 1993). 2) 
The theory does not take into account the role of ACh receptors: namely it has been 
shown that the strength of antagonism at cholinergic receptors is inversely correlated with 
the amount of EPS that neuroleptics induce in humans (Snyder et al , 1976). 3) 
Preclinical studies do not unanimously support this theory- in monkeys, the balance 
between 5-HT2A and D2 receptors plays no role in the level of dystonia (Casey, 1989). 
Moreover, catalepsy studies produced confusing data serotonin 5-HT2A agonists and 
antagonists attenuate the halopendol-induced catalepsy (Hicks, 1990; Neal-Behveau et 
al, 1993), while а 5-ΗΤ2Λ antagonist does not affect the SCH 23390- or raclopnde-
ìnduced catalepsy (Wadenberg, 1992) Taken together, the role of 5-HT2A receptors in the 
EPS profile of neuroleptics is still unclear On the other hand, the 5-HT1A agonist 8-
OHDPAT produces a very consistent attenuation of neuroleptic-induced catalepsy (for 
references, see chapter 4) However, since most neuroleptics have no or marginal affinity 
for this receptor (Meltzer and Nash, 1991), it cannot explain the differences between 
classical and atypical neuroleptics The role of 5-HT]A and 5-HT2A receptors in the effects 
of a number of neuroleptics is subject of study in the present thesis (chapter 4) 
Finally, the noradrenergic system may be involved in the EPS of neuroleptics (section 
1 3) Some preclinical studies have been devoted to this subject An electrophysiological 
study has suggested that strong α,-antagonism on top of halopendol may produce an 
atypical profile, viz a selective effect on dopamine AIO cells (Chiodo and Bunney, 
1985) Catalepsy studies in mice have suggested the opposite: огі-agonists attenuate and 
a, antagonists enhance the halopendol-induced effects (Pichler and Kobinger, 1985). 
Catalepsy studies on the effects of a7 noradrenergic drugs produce confusing results, both 
an a2-agonist and an a2-antagonist attenuate the halopendol-induced catalepsy (Honma 
and Fukushima, 1977, Bende et al , 1990) Finally, Honma and Fukushima (1977) have 
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shown that the /3-antagonist propranolol does not affect the halopendol-induced catalepsy. 
Taken together, the role of the noradrenergic system in the EPS induced by neuroleptics 
is far from clear. In the present thesis, this is subject of study in the paw test (chapter 5). 
2 2 2 Anatomical target sues for extrapyramidal side-effects of neuroleptics 
As described earlier (section 2 12), electrophysiological studies have suggested that the 
nigrostnatal system is related to neuroleptic-induced EPS. These electrophysiological 
findings are supported by behavioural studies, showing that neuroleptics may discriminate 
between the attenuation of apomorphine hyperactivity (reflecting mesolimbic activity, i.e 
the ACC, Pijnenburg and Van Rossum, 1973) and the attenuation of apomorphine 
stereotypy (reflecting nigrostnatal activity, ι e the DS; Costali et al, 1978) Classical 
neuroleptics are found to attenuate especially the apomorphine-induced stereotypy while 
atypical neuroleptics attenuate especially the apomorphine-induced hyperactivity (Costali 
and Naylor, 1976, Ljungberg and Ungerstedt, 1978). On the other hand, Cools and 
colleagues (1992, 1994) have shown a division within the mesolimbic dopamine system-
classical neuroleptics attenuate the ergometnne-induced locomotor activity elicited from 
the ACC stronger than the dopamine-induced locomotor activity elicited from the ОТ, 
while the reverse is true for atypical neuroleptics. Together, these studies suggest that the 
EPS profile of a neuroleptic depends on its regional effect" neuroleptics that act in the DS 
> ACC > ОТ are classical neuroleptics, while the reverse is true for atypical 
neuroleptics 
To further analyze this theory, the present thesis studies the role of D2 receptors in the 
distinct striatal structures in the effects in the paw test 
In the last part of this section the pathophysiology of the different EPS is discussed 
Generally it is thought that parkinsonism (rigidity, hypokinesia, tremor) is due to 
dopaminergic blockade in the DS (Marsden and Jenner, 1980) Indeed, the DS seems to 
play a important role in rigidity (Johnels, 1983; Ellenbroek et al , 1985), although the 
same may be true for the ACC (Ellenbroek et al , 1988) Moreover, with respect to 
hypokinesia, the ACC, a part of the ventral striatum, is thought to play a crucial role 
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(Pijnenburg et al , 1976) Taken together, both the DS and the ACC seem to be involved 
in neuroleptic-induced parkinsonism 
Dystonia is readily induced by pharmacological manipulations in the DS in monkeys 
(Murphy and Dill, 1972, Cools et al , 1974), implying an important role for the DS in 
dystonia 
In akathisia, the mesocortical dopamine projection to the prefrontal cortex, has been 
suggested to play an important role (cf Jenner and Marsden, 1980), on the basis of the 
fact that dopaminergic blockade in the prefrontal cortex enhances locomotor activity 
(Carter and Pycock, 1978) 
TD is thought to be a hyperdopaminergic syndrome (section 1 3) Given the strong D2-
antagonist properties of most neuroleptics, it has been speculated that supersensitivity of 
these receptors may be the key disturbance causing TD (Klawans, 1973, Baldessanni, 
1979) However, a large number of arguments [e g the time of appearance of 
supersensitivity vs that of TD (3 weeks as opposed to months or years)] oppose this 
theory (Fibiger and Lloyd, 1984) Later studies have focused on the involvement of other 
dopamine receptors in TD, and especially in oro-facial dyskinesia (OFD), the most 
prominent symptom Indeed, administration of the dopamine D, agonist SKF 38393 leads 
to an increase in vacuous chewing movements in rats (Rosengarten et al , 1983, 1986) 
However, the observed behaviours themselves are not abnormal On the other hand, 
administration of the dopamine DA, agonist DPI into a subarea of the nucleus caudatus 
(viz the r-CRM) leads to clear oro-facial dyskinesia (OFD) in cats (Spooren et al , 
1991) In the rat, a large number of studies on oral behaviour have been performed 
These studies have confirmed the role of striatal structures in oral behaviour, 
dopaminergic Di and D2 stimulation in both the ventrolateral striatum (Koshikawa et al, 
1990, Kelley and Delfs, 1990) and the ACC (Bordi et al , 1989, Koshikawa et al, 1990) 
strongly enhances oral behaviour However, again, no induction of abnormal, dyskinetic, 
behaviours is seen Therefore, the present thesis focuses on the characterisation of the 
role of the DA, receptor in OFD For practical reasons, this research is performed in the 
rat Since in the rat, DA, receptors are concentrated in the ACC, but not the DS (Cools 
and Van Rossum, 1980), the ACC is subject of study Moreover, for sake of comparison, 
the effect of D, and D2 receptor stimulation in the ACC is studied as well To determine 
whether the expected enhancement of oral behaviour in rats is related to dyskinesias, the 
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oral behaviour of rats is analyzed in detail. 
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2.4 Introducing the experiments 
From chapter 2 it can be concluded that many animal models for the clinical effects of 
neuroleptics have been developed. Notwithstanding the enormous research effort that has 
been performed, there are still large gaps in our knowledge about the role of dopamine D, 
and D2 receptors, serotonin and noradrenaline receptors* in the effects of neuroleptic 
drugs. The second part of the present thesis tries to fill some of these gaps by studying 
the role of these receptors in the generation of neuroleptic-induced effects (chapters 3-6). 
Furthermore, for a better understanding of the underlying neuronal system, which itself 
may help to develop superior neuroleptics, the anatomical target site for the clinical 
effects of classical neuroleptics is studied (chapter 7). The animal model used is the so-
called paw test, a well validated animal model for the therapeutic efficacy and EPS of 
drugs. The third part of the present study focuses on the possible pathophsysiology and 
therapy of the most serious EPS: tardive OFD (section 1.3). As discussed in section 2.2, 
it is thought that the mesolimbic dopamine system (viz. the ACC) plays a crucial role in 
this syndrome. Therefore, the role of the different dopamine receptors in the ACC on oral 
behaviour is studied (chapters 8-11). 
* Both the sub-type» and the nomenclature of the dopaminergic, serotonergic and noradrenergic systems 
studied in the present thesis are subject to rapid changes. So, the originally labeled dopamine D, receptors 
form a class of D, and D5 receptors (cf. Waddington, 1993): these so-called D,-hke receptors are labeled D, 
receptors in this thesis, unless otherwise mentioned. The same holds true for dopamine D2 receptors that 
form a class of D2, D3, and D4 receptors1 these so-called D2-hke receptors are labeled D2 receptors in this 
thesis, unless otherwise mentioned (cf. chapter 11). The 5-HTlc receptor has recently been relabeled as the 
5-HT:c receptor (Humphrey el al., 1993). From that lime on, 5-HT2 receptors were labeled 5-HTJA 
receptors In this thesis, both labels '5-HT,c' and '5-HT2c' are used to describe the same receptor. The 
same holds true for the labels '5-HT2' and '5-HTM '. 
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Part 2: The paw lest: an animal model for antipsychotic effects and extrapyramidal 
side-effects of neuroleptics 
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Chapter 3 
The effects of Haloperidol and raclopride in the paw test are influenced similarly by 
SCH 39166 
Abstract 
We investigated the role of D, and D2 receptors in the paw test, an animal model used to 
assess both the antipsychotic potential and extrapyramidal side effects of drugs. The D[ 
receptor antagonist, SCH 39166, as well as the D2 receptor antagonist raclopride, 
increased the hindlimb retraction time (HRT), viz. a parameter that models antipsychotic 
potential, at doses that were lower than those that increased the forelimb retraction time 
(FRT), viz. a parameter that models extrapyramidal side effects. In contrast, the same 
dose of halopendol enhanced both parameters. 
SCH 39166 enhanced the halopendol- and raclopride-induced effects on FRT, whereas 
neither haloperidol nor raclopride enhanced the SCH 39166-induced effects upon this 
parameter. Except at very high doses, SCH 39166 did not alter the haloperidol- and 
raclopride-induced effects on HRT, and vice versa. No difference between haloperidol 
and raclopride was found in the interaction experiments. The clinical impact of these 
findings is discussed. 
Introduction 
In 1976 it was postulated that D2 receptor blockade is responsible for the antipsychotic 
action of neuroleptics (Creese et al., 1976). Recently, however, alternative mechanisms 
by which drugs may have antipsychotic effects have been suggested, e.g. blockade of the 
5-HT3 receptor, blockade of the D, receptor, or stimulation of the NMDA receptor (for 
review see Meltzer, 1991). In the present study we examined the role of D, and D2 
receptor antagonists as well as their interaction in an animal model that distinguishes 
between classical and atypical neuroleptics: the paw test (Ellenbroek et al., 1987). In this 
test a rat is placed on a platform with each paw in a separate hole. Two variables are 
measured in this test, namely the time it takes the animal to retract its first hindlimb 
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(hindlimb retraction time; HRT) and the time it takes the animal to retract its first 
forelimb (forelimb retraction time; FRT). Classical neuroleptics (e.g. haloperidol) 
increase HRT and FRT at the same dose, whereas atypical neuroleptics (e.g. clozapine) 
increase HRT at much lower doses than those required to increase FRT. On the basis of 
these findings, it was postulated that HRT and FRT are measures of antipsychotic 
potential and extrapyramidal side effects, respectively (Ellenbroek et al., 1987). This 
model has been extensively validated (Ellenbroek and Cools, 1988). Recently, the 
mechanisms by which haloperidol and clozapine produce their effects in the paw test have 
been studied (Ellenbroek et al., 1991). It was found that the effects of haloperidol on 
HRT and FRT are blocked by the D2 receptor agonist LY 171555, but not by the D, 
receptor agonist SKF 38393. On the other hand, the effects of clozapine on HRT are 
blocked by SKF 38393, but not by LY 171555, suggesting a preferential role of the D, 
receptor in the effects of clozapine. A preferential effect on the D, receptor by clozapine 
has also been found in other in vivo experiments (Murray and Waddington, 1986; Altar et 
al, 1988; Imperato and Angelucci, 1989; Chipkin and Latryani, 1987; Criswell et al., 
1989). These data raise the question to what extent blockade of D, and/or D2 receptors is 
required to increase HRT and FRT. These questions are vital from a clinical point of 
view, since the role of the D, receptor and its interactions with D2 receptors in 
antipsychotic effects and extrapyramidal side effects are unknown. For this reason, the 
present study deals with the effects of single and combined administration of selective D, 
and D2 receptor antagonists in the paw test. The drugs chosen were SCH 39166, a 
selective D, receptor antagonist (Chipkin et al., 1988; McQuade et al, 1991), raclopride, 
a selective D2 receptor antagonist (Köhler et al., 1985) and haloperidol, a D2 receptor 
antagonist with low affinity for D, receptors and moderate affinity for αϊ-noradrenergic 
and 5-HT2 receptors (Chnstensen, 1985). 
Materials and methods 
Male Wistar rats (Central Animal Laboratory, University of Nijmegen) were housed in 
groups of 3. At least 24 h before the experiments the animals (weighing between 200 and 
250 grams) were housed individually. Housing conditions included the availability of 
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water and food ad libitum and a light regime with a 12-h light-dark cycle (lights on 8 
a.m.)- Experiments were performed between 10.00 a.m. and 4.00 p.m., and rats were 
used only once. Thirty minutes before the experiment the animals were transported to the 
experimental room. Each rat was injected intraperitoneally with a vehicle, a drug or a 
cocktail of two drugs (injection volume 1 ml/kg). Thirty minutes after the injection the 
paw test was performed and repeated 10 and 20 min later. In the paw test a rat was 
placed on a Perspex platform, measuring 30 by 30 cm with a height of 20 cm. This 
platform has four holes, two holes of 5 cm diameter for the hindlimbs and two holes of 4 
cm diameter for the forelimbs, and an opening for the tail (Ellenbroek et al., 1987). The 
rat was held behind the forelimbs and placed on the platform by positioning first the hind-
and then the forelimbs in the holes. Hindlimb retraction time (HRT) and forelimb 
retraction time (FRT) were measured with a minimum time of 1 s and a maximum time 
of 30 s. The individual score was calculated for each animal as the mean of the three 
trials (at 30, 40 and 50 min; see above). The data are presented as median values of these 
means per group (n= 7 to 15 rats). Group differences were calculated with a two-tailed 
Mann-Whitney U test. An interaction was considered to be significant if the effect of the 
combination of compounds was significantly higher or lower than the effect of each drug 
alone. The lowest dose that produced significant effects compared to controls is defined as 
the threshold dose for prolonging hindlimb or forelimb retraction time. The highest 
ineffective dose tested is defined as the sub-threshold dose. All doses above the threshold 
dose are defined as supra-threshold doses. The drugs used were SCH 39166 (kindly 
donated by Schering Co., USA), raclopride (kindly donated by Astra Lakemedel, 
Sweden) and haloperidol (Janssen, Belgium). Because SCH 39166 is poorly soluble, it 
was dissolved in a drop of acetic acid. When two drugs were combined, they were 
dissolved separately and then mixed. 
Results 
Effects of haloperidol, SCH 39166 and raclopride alone 
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Haloperidol 
••conti· (modian valu·) 
FRT HRT 
H нэо ОТ о t «g/io C D о a · ag/h« 
•VJ о в »g/hg ^З 1 Q •·/!« C D 3 О ««/M 
Fig 1 The effects of different doses of halopendol in the p a * test 
Differences between controls and drug treated groups were tested 
with a two tailed Mann Whune\ b test · Ρ < 0 05 " P u t i d i 
" * P < 0 0 O I 
SCH 39166 
• •cond ì (modian valu«) 
FRT 
МИТ 
•Ш ИЗО ЬШ 0 08 мд/кд CD 0 1 · · / * · 
• • 0 38 яд/ho в Э 0 a »д/hg I I ЮвоЛЩ 
Fig 2 The effects of different doses of S C H 19166 in the paw test 
Differences between controls and drug-treated groups were tested 
with i two tailed M a n n Whitney U test * P < 0 0 5 " · P < 0 0 l 
· " Ρ <00Ol 
Raclopride 
••eond· {median v»lu«) 
FHT HRT 
• • M20 СШ 0 1 t-д/к« C D 0 » «f/hg 
• • 0 · мд/Ь« Ξ 1 0 ид/hg C D 2 0 ng/htj 
Fig 3 The effects of different doses of raclopride in the paw test 
Differences between controls and drug treated groups were tested 
with a two tailed Mann Whitne> U test * Ρ < 0 0 ^ * * Ρ < (J 01 
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Administration of distilled water gave the following control values (median): HRT = 1.8 
s; FRT = 1.0 s. Haloperidol (0.1-2.0 mg/kg) increased the HRT and FRT at the same 
dose. The ratio for the threshold dose for FRT over HRT was 1 (fig. 1). SCH 39166 
(0.1-1.0 mg/kg) and raclopride (0.25-2.0 mg/kg) increased the HRT and FRT. The dose 
required to increase the HRT was lower than that needed to increase the FRT for both 
compounds. The ratio of the threshold dose for prolonging forelimb retraction time to that 
for prolonging hindlimb retraction time was comparable for SCH 39166 and raclopride 
(ratio of 5 and 4, respectively; fig. 2 and 3). 
Combined administration of D¡ and D2 antagonists 
TABLE ι 
The effects of single and combined administration of SCH 19166 and halopendol on FRT and HRT in the paw test FRT and HRT are given as 
median values of a group SCH = SCH 19166, Hal = halopendol combination = SCH 39166 and halopendol Lombined 
(Sub (threshold 
doses 
for HRT 
(Sub-llhreshold 
doses 
for FRT 
Dose (mg/kg) 
SCH 
0 05 
0 05 
0 1 
0 1 
0 25 
0 25 
05 
05 
Hal 
(1 1 
0 25 
0 1 
0 25 
0 1 
0 2S 
0 1 
1 25 
FRT(s) 
SCH 
1 0 
1 0 
1 0 
ι η 
1 0 
1 0 
7 3 ' 
7 3 ' 
Hal 
1 0 
72 
1 0 
72 
1 0 
72 ' 
1 0 
7 2 ' 
Combination 
1 0 
1 0 
10 
1 2 
Ч 1 1 , 
1 1 1 ' 
5S 
182" 
HRT(s) 
SCH 
27 
27 
7 0 a 
7 0 " 
5 4 ' 
5 4 " 
2 1 3 ' 
2 1 3 ' 
Hal 
1 К 
I H ' 
1 к 
134 ' 
18 
1 4 ' 
i g 
1 3 4 ' 
Combination 
56 
TT ") 
13 I 
16 3 
20 5 >• 
23 2 ' 
169 
22 I 
Ρ < (I 05 (vs controls) " Ρ < 0 OMvs each drug alone) 
Tables 1 and 2 show the effects of combining SCH 39166 with haloperidol or raclopride, 
respectively. Since the (sub-)threshold doses of SCH 39166 and raclopride for prolonging 
forelimb retraction time were higher than the (sub-)threshold doses of these compounds 
for prolonging hindlimb retraction time, studies on the effects of combined administration 
of these compounds on FRT included experiments with doses that were supra-threshold 
for prolonging hindlimb retraction time. This was not the case for haloperidol because 
there was no difference between the (sub-)threshold doses of haloperidol for prolonging 
hindlimb and forelimb retraction time. For the same reason, studies on the effects of the 
combined administration of SCH 39166 and raclopride on FRT included experiments with 
doses that were (sub-)threshold for prolonging hindlimb retraction time and which were 
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lower than the sub-threshold dose for prolonging forelimb retraction time. Again, this was 
not the case for haloperidol. 
TABLE 2 
The effects of single and combined administration of SCH 39166 and raclopride on FRT and HRT in the pa» test FRT and HRT are given as 
median values of a group SCH = SCH 19166 Rado = raclopride combination = SCH 39166 and raclopride combined 
Dose (m 
SCH 
0 05 
0 05 
0 1 
0 1 
0 25 
0 25 
0 5 
0 5 
•g/kg) 
Rado 
0 1 
0 25 
0 1 
0 25 
0 5 
1 0 
0 5 
1 0 
FRT (s) 
SCH 
10 
10 
1 0 
1 0 
10 
10 
7 J ' 
7 3 " 
Rado 
10 
io 
10 
10 
1 2 
1 8 ' 
1 2 
1 8 ' 
Combination 
10 
10 
10 
1 2 
5 3 " 
19 l h 
117 
19 5 ь 
HRT Is) 
SCH 
2 7 
2 7 
7 0 ' 
7 0 a 
5 4 " 
5 4 ' 
21 3 ' 
21 3 " 
Rado 
2S 
4 2 " 
25 
42 ' 
5 7 ' 
15 3 ' 
5 7 ' 
153 ' 
Combination 
56 
4 4 
48 
11 7 
199 
io ab 
23 7 
23 5 
' Ρ < 0 05 (vs controls). ь Ρ < 0 05 (vs each drug alone) 
Effects on HRT 
Combinations of sub-threshold and/or threshold doses for prolonging hindlimb retraction 
time did not significantly affect HRT. 
A sub-threshold dose for prolonging hindlimb retraction time of haloperidol (0.1 mg/kg) 
significantly increased the HRT elicited by 0.25 mg/kg SCH 39166 (supra-threshold dose 
for HRT), but not that elicited by 0.5 mg/kg SCH 39166. 
A threshold dose for prolonging hindlimb retraction time of haloperidol (0.25 mg/kg) 
significantly increased the HRT elicited by 0.25 mg/kg SCH 39166 (supra-threshold dose 
for HRT), and vice versa. When the same dose of haloperidol was combined with 0.5 
mg/kg SCH 39166 (supra-threshold dose for HRT), the HRT was not significantly 
increased. 
A supra-threshold dose for prolonging hindlimb retraction time of SCH 39166 (0.25 
mg/kg) significantly increased the HRT elicited by 1.0 mg/kg raclopride (supra-threshold 
dose for HRT), and vice versa. A combination of 0.25 mg/kg SCH 39166 and 0.5 mg/kg 
raclopride (supra-threshold doses for HRT) did not significantly increase the HRT 
compared with each drug alone, although there was a clear tendency in that direction. A 
higher dose of SCH 39166 (0.5 mg/kg) combined with 0.5 or 1.0 mg/kg raclopride did 
not significantly increase the HRT compared with each drug alone. 
(Sub (threshold 
doses 
for HRT 
(Sub Xhreshold 
doses 
for FRT 
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Effects on FRT 
A sub-threshold dose for prolonging forelimb retraction time of SCH 39166 (0.25 mg/kg) 
combined with 0.1 mg/kg halopendol or 0.5 mg/kg raclopride (sub-threshold doses for 
FRT) produced a FRT which was significantly greater than the control values. In other 
words, combining the ineffective, sub-threshold doses of these compounds resulted in a 
significant effect. Combinations of lower doses of SCH 39166 and haloperidol or 
raclopride did not affect FRT. 
A sub-threshold dose for prolonging forelimb retraction time of SCH 39166 (0.25 mg/kg) 
significantly increased the effect on the FRT elicited by 0.25 haloperidol and 1.0 mg/kg 
raclopride (threshold doses for FRT). The FRT was far greater than the FRT elicited by 
haloperidol or raclopride alone. On the other hand, the combination of 0.1 mg/kg 
haloperidol or 0.5 mg/kg raclopride (sub-threshold doses for FRT) with 0.5 mg/kg SCH 
39166 (threshold dose for FRT) had the same effect as SCH 39166 alone. 
A threshold dose for prolonging forelimb retraction time of SCH 39166 (0.5 mg/kg) 
significantly increased the FRT elicited by 0.25 mg/kg haloperidol or 1.0 mg/kg 
raclopride (threshold doses for FRT), and vice versa. 
Discussion 
The results show first of all that, like haloperidol (Ellenbroek et al., 1987), SCH 39166 
and raclopride also increase the HRT. Given the evidence that an increase in HRT is a 
measure of antipsychotic potential (see Introduction), this would imply that both SCH 
39166 and raclopride possess antipsychotic potential. Raclopride seems to have 
antipsychotic effects, although the clinical studies performed were open studies (Farde et 
al., 1988; Cookson et al., 1989). No clinical studies with SCH 39166 have yet been 
reported. Haloperidol showed the profile of a classical neuroleptic, because the lowest 
dose that was needed to increase the HRT and FRT was similar. This confirms earlier 
findings (Ellenbroek et al., 1987). 
The dose of SCH 39166 or raclopride required to increase the FRT was higher than the 
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dose required to increase the HRT, implying that both drugs showed the profile of an 
atypical neuroleptic. When compared with the profile of clozapine and haloperidol in the 
paw test (Ellenbroek et al., 1987) it is clear that both SCH 39166 and raclopride (ratio 
minimum effective dose for prolonging forelimb retraction time to that prolonging 
hindlimb retraction time was 5 and 4, respectively) are somewhere in between clozapine 
(ratio greater than 5) and classical drugs (ratio of 1). Since an increase in FRT is a 
measure of an increase in extrapyramidal side effects, this implies that both SCH 39166 
and raclopride would be expected to have a lower potential for inducing extrapyramidal 
side effects than haloperidol. Indeed, relatively few extrapyramidal side effects have been 
reported for raclopride in the clinic (Farde et al., 1988; Farde et al., 1989). Although 
there are no clinical data on SCH 39166 yet, preclinical data for monkeys indicate that 
this compound, when administered for a few days, is capable of blocking extrapyramidal 
side effects induced by chronic administration of haloperidol (McHugh and Coffin, 1991). 
When the related compound SCH 23390 is acutely administered in drug-free monkeys, 
extrapyramidal side effects are reported to be present (Ellenbroek et al., 1989; Lawrence 
et al., 1991, Casey, 1992) or absent (Coffin et al., 1989). Interestingly, Casey (1992) 
concluded that SCH 23390 induces much weaker extrapyramidal side effects in monkeys 
than haloperidol and suggested that low doses of SCH 23390 might have an antipsychotic 
effect without inducing extrapyramidal side effects. The present results for SCH 39166 
suggest the same. Again, clinical studies will have to show to what extent SCH 39166 or 
SCH 23390 induce extrapyramidal side effects in humans. 
Combinations of SCH 39166 and haloperidol that were sub-threshold for prolonging 
forelimb retraction time significantly enhanced the FRT (table 1). The data presented in 
3.3.1 and 3.3.2 show that the effects on the FRT were not just additive in nature, but 
synergistic. Furthermore, a sub-threshold dose of SCH 39166 increased the effects of a 
threshold dose of haloperidol on the FRT, but not vice versa. Thus, a sub-threshold dose 
of a D, receptor antagonist enhanced the effects of a D2 receptor antagonist, whereas a 
sub-threshold dose of a D2 receptor antagonist did not enhance the effects of a O¡ receptor 
antagonist. From these interactions it can be deduced that, for FRT, the D2 receptor 
function is more dependent on D, receptor function than vice versa. 
Ellenbroek et al. (1988) found that clozapine blocked the effects of haloperidol on FRT, 
but not on HRT. Since their results for FRT and our results for FRT are opposite, it 
42 
would seem that although both clozapine and SCH 39166 inhibit D, receptors (see 
Introduction), the effects of these drugs on the FRT of halopendol are mediated via 
different mechanisms Possibly the high affinity of clozapine for 5-HT2/lc and/or ACh 
receptors may be responsible for the blockade of the FRT induced by halopendol 
(Ellenbroek and Cools, 1988, Ellenbroek et al , in prep ) 
Interestingly, exactly the same effects on FRT occurred when SCH 39166 was combined 
with raclopnde instead of halopendol This indicates that halopendol and raclopnde may 
share common mechanism(s) as far as this effect is concerned However, halopendol and 
raclopnde had a different FRT/HRT ratio This difference cannot be ascnbed to the 
different effect of these compounds on 5 HT2 receptors (Ellenbroek et al , in prep ) Since 
forehmb ngidity induced by intracerebral administration of halopendol can be blocked by 
an αϊ noradrenergic agonist (Ellenbroek et al , 1988), the different ratios of halopendol 
and raclopnde may be due to a different effect of these compounds on αϊ noradrenergic 
receptors 
As mentioned, sub-threshold and threshold doses of the D, receptor antagonist, SCH 
39166, enhanced the FRT elicited by the D2 receptor antagonists, halopendol and 
raclopnde In contrast, sub threshold and threshold doses of SCH 39166 had no effect 
upon the HRT elicited by the D2 receptor antagonists These data suggest that the D,-D2 
receptor relationship found for HRT differs from that found for FRT This indicates that 
the prolongation of forelimb retraction time and hindlimb retraction time are not mediated 
by the same brain area(s) Studies on the differential involvement of the neostnatum and 
the nucleus accumbens in the control of the musculature in the forehmbs and hindhmbs 
are consistent with this suggestion (Ellenbroek et al , 1988, Cools and Jongen-Relo, 
1991) 
Cooperative effects of combinations of D, and D2 receptor antagonists have often been 
reported, e g for catalepsy (Wanibuchi and Usuda, 1990, Undie and Fnedman, 1988, 
Parashos et al , 1989) Catalepsy in rats is sometimes considered as an animal model of 
extrapyramidal side effects If this consideration is correct, it can be expected that 
combinations of D, and D2 receptor antagonists would have stronger extrapyramidal side 
effects than each antagonist alone The present study provides additional evidence in favor 
of this suggestion SCH 39166 increased the halopendol- and raclopnde-induced FRT 
Since FRT is a measure of extrapyramidal side effects, we predict that D, receptor 
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antagonists will increase the extrapyramidal side effects of D2 receptor antagonists. On the 
other hand, SCH 39166 had no effect upon the haloperidol- and raclopride-induced HRT, 
and vice versa (except at very high doses). Since HRT is a measure of antipsychotic 
potential, we predict that D, receptor antagonists will not influence the antipsychotic 
efficacy of D2 receptor antagonists. At high doses, however, they may enhance 
antipsychotic efficacy, but this will be accompanied by a great increase in extrapyramidal 
side effects. 
The following conclusions can be drawn on the basis of our results. First, HRT can be 
increased by selective blockade of either D, or D2 receptors; the same holds true for 
FRT. Second, selective blockade of D, receptors superimposed on selective blockade of 
D2 receptors increases the FRT elicited by D2 receptor antagonists, but not vice versa. 
Third, neither selective blockade of D, receptors superimposed on selective blockade of 
D2 receptors, nor selective blockade of D2 receptors superimposed on selective blockade 
of D, receptors alters the HRT elicited by D, or D2 receptor antagonists alone (unless 
very high doses are used). 
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Chapter 4 
The role of serotonin receptor subtypes in the behavioural effects of neuroleptic 
drugs. A paw test study in rats 
Abstract 
The present study was designed to evaluate the role of serotonin 5-HT1A and 5-HT2 
receptors in the effects of neuroleptic drugs in the paw test. This behavioural test has 
Deen shown to model both the antipsychotic efficacy as well as the extrapyramidal side 
effect liability of neuroleptic drugs. The results show that whereas the 5-HTIA receptor 
agonist 8-OHDPAT reduced the effects of the classical neuroleptic haloperidol, it 
increased the effects of the atypical neuroleptic clozapine. The 5-HT2 receptor antagonist 
ketanserin as well as the 5-HTlc/5-HT, receptor antagonist ritanserin, on the other hand 
reduced the effects of haloperidol whereas the 5-HTlc/5-HT2 receptor agonist DOI 
reduced the effects of clozapine. The most important finding, however, was that the 
behavioural effects of different (putative) neuroleptics (fluphenazine, SCH 39166, 
remoxipride, prothipendyl, thioridazine and risperidone) were differentially influenced by 
both 8-OHDPAT and DOI, suggesting that there are important differences between the 
neuronal mechanisms underlying the behavioural effects of these neuroleptic drugs, even 
within the subclasses of classical and atypical neuroleptics. 
Introduction 
Many different hypotheses have been put forward to explain the differences between 
classical neuroleptics (antipsychotic drugs which also induce extrapyramidal side effects) 
and atypical neuroleptics (antipsychotic drugs which do not induce these side effects). In 
general these hypotheses can be subdivided into two categories: receptor diversity and 
regional selectivity hypotheses. The receptor diversity hypotheses state that the difference 
between classical and atypical neuroleptics is based on differences in binding affinity for 
specific receptors, whereas the regional selectivity hypotheses state that the differences 
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are due to a differential influence of these drugs on certain brain regions (for review see 
Deutch et al , 1991, Ellenbroek, 1993) Examples of the first group of hypotheses are the 
acetylcholine (Snyder et al , 1974), the dopamine D, receptor (Andersen et al, 1986) and 
the serotonine hypothesis (Meltzer et al , 1989) Examples of the latter group are- the A, 
versus A10 (Chiodo and Bunney, 1983, White and Wang, 1983), the olfactory tubercle 
versus the neostriatum (Altar et al , 1986) and the olfactory tubercle versus the nucleus 
accumbens (Cools et al , 1992) hypotheses A big disadvantage for evaluating these 
hypotheses is the lack of adequate animal models with predictive validity In many of the 
currently used models atypical neuroleptics seem to have little effect (cf Moore and 
Gershon, 1989) Some years ago, we have developed an animal model which 
distinguishes between classical and atypical neuroleptic drugs the paw test (Ellenbroek et 
al , 1987) The paw test measure two variables, the forehmb retraction time (FRT) and 
the hindlimb retraction time (HRT), which model the extrapyramidal side effects and the 
therapeutic effects respectively In a recent review we have shown that the paw test fulfils 
all the criteria for predictive validity (Ellenbroek, 1993) Thus, no false positives or 
negatives have yet been found, although more than 20 neuroleptics and an equal number 
of non-neuroleptics (like diazepam and morphine) have already been tested Moreover, 
the FRT, but not the HRT is sensitive to anticholinergics and develops tolerance upon 
chronic treatment (Ellenbroek and Cools, 1988) Finally there appears to be a nice 
correlation between the minimal effective dose for increasing HRT and average clinical 
doses (like for instance the chlorpromazine index) Thus, the paw test seems suited for 
evaluating the receptor diversity as well as the regional selectivity hypotheses 
Using this test we have recently shown that, although the D, receptor plays an important 
role in the effects of the atypical neuroleptic clozapine, it can not account for the atypical 
profile of clozapine (Ellenbroek et al , 1991) In the present study we have evaluated the 
interaction between serotonergic drugs and neuroleptics Our prime objective was to 
evaluate the hypothesis put forward by Meltzer and his coworkers (Meltzer et al , 1989) 
Using in vitro binding data they suggested that neuroleptics with a 5-HT2/D2 affinity ratio 
in favour of 5-HT2 would be atypical neuroleptics, whereas those with a ratio favouring 
D-, receptors would be classical neuroleptics This hypothesis leads to two simple 
predictions (1) increasing the serotonergic antagonistic tone should change the profile of 
a classical neuroleptic into an atypical one, and (2) decreasing the serotonergic 
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antagonistic tone should change the profile of an atypical neuroleptic into a classical one. 
Besides evaluating the role of 5-HT2 receptors in the effects of classical and atypical 
neuroleptics in the paw test, we have also looked at the 5-HT1A receptor. As with the 5-
HT2 receptor, many studies have shown interactions between this receptor and the 
dopaminergic system (see discussion) Moreover, the selective 5-HT1A agonist 8-
OHDPAT has been claimed to have possible antipsychotic efficacy (Ahlemus, 1989). Yet 
on the other hand, it has been claimed to possess dopamine agonistic properties (Smith 
and Cutts, 1990) and to antagonise the effects of neuroleptic drugs (see discussion). 
The results of the present study show that 5-HT1A and 5-HT2 receptors play a different 
role in the effects of neuroleptics in the paw test However, more importantly, the data 
indicate that the interactions between serotonergic drugs and neuroleptics depend strongly 
on the neuroleptic drug used 
Material and methods 
Animals 
Male Wistar rats, obtained from the Central Animal Laboratory ( C a t h U n i v . of 
Nijmegen) weighing 230-280 g at the time of experiments were used. The animals were 
kept on a 12h light dark cycle, with lights on between 7.00h and 19.00h, with food and 
water ad libitum. Animals were housed in groups of three until the day prior to the 
experiment, when they were housed individually. Animals were used only once. 
Experimental design 
All experiments were performed between 09.00 and 16 00h Animals were injected 
intrapentoneally with a drug or a combination of drugs, after which they were returned to 
their home cage. At 30, 40 and 50 minutes after the injection each animals was submitted 
to the paw test The paw test was performed on a perspex platform measuring 30 χ 30 cm 
with a height of 20 cm The platform contained four holes two of 4 cm diameter for the 
forehmbs and two of 5 cm for the hindlimb (see Ellenbroek et al , 1987), as well as a slit 
for the tail 
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The rat was held behind the forelimbs and gently placed in the box First his hindhmbs 
were placed in the bigger holes and then his forelimbs were lowered into the smaller 
holes Two dependent variables were scored (1) The forelimb retraction time (FRT) 
defined as the minimal time the rat needs to withdraw its first forelimb, (2) The hindhmb 
retraction time (HRT) defined as the mimimal time the rat needs to withdraw its first 
hindhmb Because of the difficulty in determining the exact starting time of each 
experiment, the minimum FRT and HRT were set at 1 second The maximum FRT and 
HRT were set at 30 seconds, after which the rats were taken out of the experimental box 
Four different sets of experiments were performed In the first set of experiments, the 
effects of different doses of the selective 5 ΗΤ1Λ agonist 8-OHDPAT, the non-selective 5 
HTlc/5-HT2 agonist DOI, the non-selective 5 HTlc/5-HT2 antagonist ntansenn and the 
selective 5-HT2 antagonist ketansenn on the effects of the standard classical neuroleptic 
halopendol (0 5 mg/kg ι p) were evaluated This dose was chosen on the basis of earlier 
results (Ellenbroek et al , 1987, Prinssen er al, 1993) In the second set of experiments 
we evaluated the effects of 8 OHDPAT, DOI, ntansenn and ketansenn on the effects of 
the standard atypical neuroleptic clozapine We initially chose a dose of 20 mg/kg ι ρ , 
again based on earlier studies (Ellenbroek et al , 1987) However, in pilot studies we 
found that 8-OHDPAT increased the effects of clozapine on HRT Since the effects of 
this dose of clozapine were already almost maximal (see fig 5), we repeated the 
expenments with a lower dose of clozapine (10 mg/kg) Since the interactions between 
serotonergic drugs and halopendol and clozapine were both quantitatively and 
qualitatively different, we decided to extend our interaction study to a number of other 
classical and (putative) atypical neuroleptics In this set of experiments we usually tested 
only one dose of a neuroleptic and one dose of the serotonergic drug In a number of 
cases (for instance risperidone, prothipendyl and fluphenazine) we also used other doses 
of the serotonergic drugs The doses of the serotonergic drugs were determined on the 
basis of the expenments with clozapine and halopendol Since with only one exception 
(clozapine and 8 OHDPAT, see results) clear dose dependencies were obtained, we chose 
a dose of 1 mg/kg of ketansenn, 8 OHDPAT and DOI The dose of the neuroleptics was 
again based on earlier studies (Ellenbroek et al 1987, Ellenbroek et al, 1992, Prinssen 
et al , 1993) and unpublished data The doses were chosen in order to induce a significant 
increase in HRT (atypical neuroleptics) or in both FRT and HRT (classical neuroleptics) 
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In the case of SCH 39166 which has not been clinically evaluated, we chose a dose which 
increased both FRT and HRT. In the last set of experiments, the effects of the 
serotonergic drugs alone were evaluated. 
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Each rat was tested three times, 30, 40 and 50 minutes after the injection of the drug. 
The final score for each rats was simply the mean of these three scores. Per drug a group 
of 8 rats was used and the median value of the individual rat scores was calculated 
(Ellenbroek et al, 1987). The Mann Whitney U test (Siegel, 1956) was used to evaluate 
the differences between drug conditions. A significance level of ρ < 0.05 (two-tailed) was 
considered significant. 
Seconds 
30 r 
251 
FRT HRT 
0 1 05 1 0 1 05 1 
mg/kg l.p. 
В 
30 
25 
20 
15 
10 
5 
0 
Seconds 
FRT 
! ** ** ** 
τ 
0 05 
Γ 
0 
τ 
1 0 
hr 
5 
HRT 
Τ 
ή 
0 05 
Τ 
rh 1 
0 1 
h 
± 
0 5 
Τ 
1 
mg/kg i.p. 
FIG 3 (A) The effects of the *> HT 1 ( '5 HT, antagonist Mianserin (0 I - t 
mg/kg ι ρ ) on the effects of the classical neuroleptic halopcndol on FRT (left) 
and HRT fright) (П) The effects ol the 5 HT 2 antagonist ketansenn i0 0 5 - I 
mg kg ι ρ ) on the ellecis ol the classical neuroleptic halopendol on TRT (lelt) 
and HRT (right) Represented are median values and the interquartile ranges 
(25 and 75% points) */» < 0 05 **P < 0 01 versus halopendol alone 
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Drugs 
The following neuroleptics were used: clozapine (generous gift of Sandoz, Uden the 
Netherlands), fluphenazine (Schenng, Weesp, the Netherlands), haloperidol (Janssen, 
Beerse, Belgium), prothipendyl (generous gift of Asta Medica AG, Frankfurt, F.R.G.), 
remoxipride (generous gift Astra Lakemedel, Södertalje, Sweden), risperidone (generous 
gift of Janssen, Beerse, Belgium), thioridazine (Wander, Berne, Switzerland) as well as 
the selective D, receptor antagonist SCH 39166 (generous gift of Schering, Bloomfield, 
USA). Furthermore 8-hydroxy-2(di-n-propylamino)tetralin-HCl (8-OHDPAT), l-(2,5-
dimethoxy-4-iodophenyl)-2-aminopropane (DOI), ketansenn-tartrate (all from Research 
Biochemicals Incorporated) and ritanserin (generous gift of Janssen, Beerse, Belgium) 
were used. Clozapine was dissolved in a 0.1 ml of IN HCl, diluted with water and 
brough to pH 4 with NaHC03. Fluphenazine, prothipendyl, remoxipride, 8-OHDPAT, 
DOI, ketansenn and ketanserin were dissolved in water. Haloperidol and thioridazine was 
taken from ampoules and diluted with water. Risperidone was dissolved in 0.1 ml of 
lactic acid and diluted with water. SCH 39166 was dissolved in a drop of pure acetic acid 
and diluted with water. All drugs or combinations of drugs (coadministration) were 
injected intraperitoneally in 1 ml/kg. 
Results 
Serotonergic drugs and the effects of haloperidol 
Figure 1 shows the effects of the selective 5-ΗΤ1Λ agonist 8-OHDPAT on the haloperidol 
induced increase in FRT and HRT. As is evident from this picture, 8-OHDPAT dose 
dependently reduced the effects of haloperidol on both FRT and HRT. Moreover, both 
parameters were influenced by the same doses of 8-OHDPAT. 
Figure 2 shows the effects of the non-selective 5-HTlc/5-HT2 receptor agonist DOI on 
haloperidol. In contrast to the effects of 8-OHDPAT, DOI actually increased the effects 
of haloperidol. Moreover, the effects were only found on HRT and not on FRT. Figure 3 
shows the effects of the non-selective 5-HTlc/5-HT2 antagonist ritansenn (fig. ЗА) and the 
more selective 5-HT2 antagonist ketanserin (fig. 3B) on the effects of haloperidol in the 
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paw test. The data show that both ritanserin and ketanserin dose dependency inhibited the 
haloperidol induced increase in FRT, while not influencing the haloperidol induced 
increase in HRT. 
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Serotonergic drugs and the effects of clozapine 
The effects of 8-OHDPAT on the effects of clozapine are shown in fig 4. As mentioned 
in the materials and methods section a dose of 10 mg/kg clozapine was used, since a dose 
of 20 mg/kg already increased HRT almost to its maximum of 30 s. The effects of 10 
mg/kg clozapine were dose dependently potentiated by 8-OHDPAT. Although the increase 
of FRT seems only small, it should be remembered that the minimum time was set at 1 
second. In the case of clozapine alone, all animals had an FRT of 1 second, whereas of 
the animals treated with clozapine and 1 mg/kg 8-OHDPAT all animals had an FRT 
larger than 1 s. With respect to the effects on HRT, there appeared to be a bell shaped 
dose response curve, with the highest dose of 8-OHDPAT (1 mg/kg) being significantly 
less effective than the dose of 0.5 mg/kg. 
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In contrast to the effects on halopendol, DOI significantly and dose dependently reduced 
the effects of clozapine on HRT (Fig 5a). There were no effects of FRT. However, it 
should be kept in mind that clozapine, by itself, does not increase FRT, so only an 
increase can be observed, and not a reduction. That this effect of DOI is mediated via the 
5-HT2 receptor is shown by the dose dependent reversal of this reduction by ketanserin 
(Fig 5b). 
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on the effects of the atypical neuroleptic clozapine on FRI (left) and HRT (right) 
(B) The interaction between the 5 HT 2 antagonist ketanserin, the 
5 HT l c /5 HT 2 agonist DOI and the atypical neuroleptic clozapine on FRT (left) 
and HRT (right) Represented are median values and the interquartile ranges 
(25 and 75% points) ' P < 0 05 "/> < 0 01 versus clo7apme alone, *P < 
0 05 versus clozapine 20 mg/kg plus DOI 1 mg/kg 
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Figure 6 shows the effects of the antagonists ritanserin and ketansenn on the effects of 
clozapine. Although dose response curves were made, only the highest doses tested are 
represented. The results are in agreement with the effects of haloperidol, showing no 
effects on HRT of either ketansenn and ritanserin. Since clozapine does not induce any 
effects on FRT by itself no reduction could be measured. 
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Serotonergic drugs and the effects of other neuroleptics 
Given the fact that the serotonergic drugs used had such a different effect on the classical 
neuroleptic halopendol and the atypical neuroleptic clozapine, we decided to study the 
effects of these drugs on a number of other neuroleptics. The overall results of these 
experiments are displayed in table 1. 
The results of table 1 show that the selective 5-HT2 antagonist ketanserin was without 
effect on virtually all neuroleptics tested, the only exception being haloperidol, in which it 
significantly reduced the FRT. 
On the other hand, the 5-HT,c/5-HT2 agonist DOI and the 5-ΗΤ1Λ agonist 8-OHDPAT 
had a significant, yet differential effect on many neuroleptics tested. Moreover, this 
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influence was opposite in most situations. Thus whereas 8-OHDPAT reduced the effects 
of four neuroleptics (halopendol, fluphenazine, SCH 39166, and remoxipride), DOI 
enhanced the effects of five (halopendol, fluphenazine, remoxipride, thioridazine and 
risperidone). Likewise, whereas 8-OHDPAT enhanced the effects of clozapine, and 
prothipendyl on HRT, DOI reduced these effects. The only exception to this rule 
appeared to be thioridazine, where 8-OHDPAT and DOI both enhanced the effects on 
HRT. 
T \ H I F 1 Fiïccts of kctansenn (1 0 mg kg) DOI (I mg kg) and 8 OHDPAT (1 mg'kg) on the effects ot neuroleptics in the paw test 
lorelimb retraction time hindlimb retraction lime 
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SCH 39166 (0 5) 
remoxipride (5) 
clozapine (10) 
clozapine (20) 
prothipendyl (10) 
prothipendyl (50) 
thioridazine (30) 
risperidone (1) 
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2 1 
12 8 6 
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1 0 
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1 0 
10 10 
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1 0 
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8 2 
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12 1 
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2 4 
/ 4 7 8 
2 2 
12 88 
1 0 
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5 S 
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23 9 
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WO 20 3 
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3 8 13 8 
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23 8 30 
6 2 
2 8 13 6 
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Values are medians (or 2roups of eight rais numbers in nains indn.dk the interquartile rangi. 
^Numbers in brackets art doses in mg kg ι ρ 
t Significant reduction ol ihc ilici! of thL neuroleptic 
• Significant potentiation ol ihc elicci ol the neuroleptic 
Another characteristic difference between 8-OHDPAT and DOI was that whereas 8-
OHDPAT in general influenced both FRT and HRT (halopendol, clozapine, SCH 39166, 
fluphenazine and remoxipride), DOI usually only influenced HRT (haloperidol, clozapine, 
SCH 39166, thioridazine, prothipendyl and remoxipnde). 
The effetti of serotonergic drugs in the paw test 
In the last set of experiments we have evaluated the effects of the serotonergic drugs in 
DOI 
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the paw test None of the drugs tested had any significant effect on FRT or HRT, in 
doses which significantly influenced the effects of halopendol, clozapine or both The 
median value for FRT was always 1 0 s and the median value for HRT varied from 1 3 
(after 1 mg/kg 8 OHDPAT) to 3 6 (after 1 mg/kg ketansenn) 
Discussion 
The results of the present study show that both the selective 5-HT,A agonist 8-OHDPAT, 
as well as the selective 5-HT2 antagonist ketansenn and the non-selective 5-HTiC/5-HT2 
agonist DOI and antagonist ntansenn are able to influence the effects of neuroleptics in 
the paw test Moreover, the effects depend strongly on the neuroleptic drugs studied (see 
also table 2) Given the fact that the paw test models both the therapeutic potency (HRT) 
and the extrapyramidal side effect liability (FRT) the present results may give more 
insight in the clinical implications of these neuroleptic-serotonine interactions 
The interaction between 8 OHDPAT and neuroleptic drugs 
Although 8-OHDPAT interacts with different neuroleptics in a different way, the primary 
effect seems to be a reduction of the neuroleptic induced increase in FRT and HRT 
(halopendol, fluphenazine, SCH 39166 and remoxipnde, see table 2) This suggests that 
8-OHDPAT may reduce the antipsychotic as well as the extrapyramidal side effects of 
these neuroleptic drugs Although one might speculate that the effects of 8-OHDPAT 
might be due to its well known effects on forlimb movements (see Lucki, 1992), this 
seems unlikely for several reasons First we have never observed any forepaw treading in 
the dose range studied Second although 8 OHDPAT reduces the effects of certain 
neuroleptics, it enhances the effects of others, like clozapine This suggests that the 
effects of 8-OHDPAT are not due to behavioural competition Due to the lack of a 
selective antagonist, it was impossible to unequivocally identify the involvement of the 5-
HT1A receptor in this effect of 8-OHDPAT However, given the fact that 8 OHDPAT is a 
highly selective ligand (Middlemiss and Tncklebank, 1992) with at least a 100 fold 
selectivity towards other receptors, and given the fact that doses as low as 0 5 mg/kg 
induced significant eftects, it seems very likely that these effects were due to the 
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interaction of 8-OHDPAT with the 5-HT1A receptor. The present results are in agreement 
with a large body of literature data, especially regarding catalepsy (Broekkamp et al., 
1988; McMillen et al., 1988; Invernizzi et al., 1988; Hicks, 1990; Wadenberg, 1992). 
Since the neuroleptic induced catalepsy seems to be more related to the induction of 
extrapyramidal side effects (Ellenbroek, 1993), these data agree nicely with the effects of 
8-OHDPAT on the neuroleptic induced increase in FRT, as found in the present study. 
In contrast to the many data showing a reduction of the neuroleptic effect by 8-OHDPAT, 
no studies have, to our knowledge, found a potentiation of the effects of clozapine, 
prothipendyl or thioridazine as was observed in the present study. It has recently been 
shown that at least in human tissue, clozapine and thioridazine in contrast to most other 
neuroleptics have some affinity for the 5-HT1A receptor (Wander et al, 1987; Mason and 
Reynolds, 1992). Whether this can explain the observed differences remains to be 
elucidated. 
TABLE 2 Summary of effects of 8-OHDPAT and DOI on effects of neuroleptics 
foreltmb retraction time hindlimb retraction time 
8 OHDPAT 
prothipendyl* 
thioridazine* 
risperidone* 
DOI 
halopendol 
SCH 39166' 
remojupnde 
clozapine* 
prothipendvl* 
thioridazine' 
clozapine' halopendol 
fluphen 
SCH 39166a 
remoxipnde 
t 
fluphen 
risperidone 
risperidone* 
SCH 39166a 
clozapine3 
proihipendyl' 
tfuondazine3 
\ 
clozapine* 
prothipendvl' 
halopendol 
fluphen 
SCH 39166a 
remoxipnde 
t 
halopendol 
fluphen 
remoxipnde 
thioridazine* 
risperidone* 
0 indicates that the effects of the neuroleptic drugs in uns column are not influenced bv 8 OHDPAT (upper pan of cable ι or DOI (lower pan] ' indicates (hai (he effects of the 
neuroleptics in uns column are significanilv increased bs 8 OHDPAT or DOI I indica(es Lhat the effecis of [he neurolepdts m (his column are decreased bs В OHDPAT or DOI 
'Drugs thai aci as arvpical neuroleptics in the paw test 
The interaction between DOI and ketanserin and neuroleptic drugs 
In contrast to the effects of 8-OHDPAT on neuroleptic drugs, much less is known on the 
interaction between DOI and neuroleptic drugs. Hicks (1990) reported that the haloperidol 
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induced catalepsy was blocked by DOI, a finding which seems to be in conflict with our 
data (see fig 2) Again, we are unaware of any data with respect to the interaction 
between DOI and clozapine in behavioural studies Our data (tables 1 and 2) clearly 
indicate that clozapine (and prothipendyl) differ completely from the other neuroleptics 
Whereas all other neuroleptics were either not affected or potentiated by DOI, the effects 
of clozapine and prothipendyl were dose dependently blocked by this 5-HTlc/5-HT2 
agonist Although it has recently been suggested that clozapine's atypical character might 
be due to Us high affinity for the 5 HT,C receptor (Canton et al, 1990), the effects of DOI 
on clozapine seem to be due to an interaction with the 5-HT2 receptor, given the fact that 
they were reversed by ketansenn (see fig 5b) Interestingly, Ashby and Wang (1990) 
recently reported electrophysiological data comparable to our behavioural data They 
observed that DOI when administered ìontophoretically into the medial prefrontal cortex 
leads to a reduction in firing rate This effect was found to be enhanced by halopendol, 
whereas it was found to be attenuated by clozapine Given the fact that HRT is an animal 
model for the therapeutic effects of neuroleptics drugs (see above) and that the prefrontal 
cortex has been implicated in the therapeutic effects of neuroleptic drugs (Chang et al , 
1986) this indicates that the medial prefrontal cortex may be an important area for the 
effects of neuroleptic drugs on HRT in the paw test Studies are currently underway to 
evaluate this 
The original objective of the present study was to evaluate Meltzer's 5 HT hypothesis As 
explained in the introduction, this hypothesis states that atypical neuroleptics have less 
side effects by virtue of a higher affinity for 5-HT2 receptors as compared to D2 
receptors, which leads to two easily testable predictions (1) increasing the serotonergic 
antagonistic tone (by adding the 5 HT2 antagonist ketansenn) should change a classical 
neuroleptic into an atypical neuroleptic (ι e reduce neuroleptic induced FRT in the paw 
test), (2) reducing the serotonergic antagonistic tone (by adding the 5-HTlc/5-HT2 agonist 
DOI) should change an atypical neuroleptic into a classical neuroleptic (ι e increase the 
neuroleptic induced FRT in the paw test) The data with respect lo halopendol seem to be 
in agreement with prediction 1, since adding ketansenn to halopendol reduces the 
increase in FRT However, the data with respect to fluphenazine do not support this 
prediction, since ketansenn did not affect the fluphenazine induced increase in FRT One 
possible explanation for this may be that fluphenazine already has significant 5-HT2 
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blocking effect of its own (Meltzer and Nash, 1991), and that further increasing this 
antagonistic tone can not reduce the FRT any more. Support for this idea comes from the 
fact that the FRT induced by 1 mg/kg fluphenazine is much lower (4.8 s) than that 
induced by 0.5 mg/kg haloperidol (15.0 s) despite the fact that the two drugs induce 
similar increases in HRT (see table 2). Moreover, higher doses of fluphenazine do not 
further increase FRT (Prinssen and Ellenbroek, unpublished data). Finally, the 5-HT 
agonist DOI increases the effects of fluphenazine on FRT, whereas it has no effect on the 
FRT induced by haloperidol (table 2). 
The data with respect to most of the atypical neuroleptics, however, seem to be in 
disagreement with prediction 2 of Meltzer's hypothesis, since adding DOI to clozapine, 
thioridazine or prothipendyl does not increase the FRT. The only atypical neuroleptic 
drug which fulfils prediction 2 is risperidone (table 2). With respect to the atypical 
neuroleptics clozapine and prothipendyl, the data suggest that 5-HT2 blockade may be 
important for the therapeutic efficacy of clozapine and prothipendyl, given the fact that 
the effects of these drugs on HRT are blocked by DOI. Overall these data indicate that 
the 5-HT receptor hypothesis of Meltzer is only valid in a few cases (haloperidol and 
risperidone), but not in many others (clozapine, thioridazine, prothipendyl). This agrees 
well with the findings of Casey (1989), who reported that four neuroleptics with a 
different 5-HT2/D2 ratio (haloperidol, clopenthixol, tefludazine and setoperone) did not 
differ with in their ability to induce dystonia in Cebus monkeys. 
The differential interaction of neuroleptic drugs with serotonergic drugs 
Probably the most important result of the present study is the finding that neuroleptics 
differ fundamentally in their pharmacological interaction with serotonergic drugs. 
Although differences in the interaction between neuroleptic drugs and other drugs have 
been reported before, these differences were usually only quantitative. Thus, Scheel 
Krüger and Christenssen (1980) reported that the anti stereotypic effects of haloperidol and 
pimozide were much more potently reversed by muscimol than the effects of fluphenazine 
or flupenthixol. Likewise, Chnstensen (1985) found comparable differences in the 
interaction between neuroleptics and scopolamine. Yet these authors never reported 
opposite effects, as was found in the present study (table 2). One very interesting 
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exception is the study by Costal] et al., (1975) who have studied the effects of lesions of 
the raphe nuclei on neuroleptic induced catalepsy. The authors have reported that 
lesioning of the serotonergic cell bodies in either the dorsal raphe, or the medial raphe 
attenuates the haloperidol and the fluphenazine induced catalepsy. These lesions do not 
affect the thioridazine induced catalepsy and they enhance the clozapine induced 
catalepsy. Comparing these data with our own results (especially with respect to the 
effects on FRT) there is a striking parallel to the interactions between neuroleptics and 8-
OHDPAT. Thus 8-OHDPAT reduced the haloperidol and the fluphenazine induced 
increase in FRT, had no effects on thioridazine and potentiated the effects of clozapine 
(table 2). Given the fact that 8-OHDPAT is known to activate primarily presynaptic 5-
HT1A receptors (Lucki, 1992) and the fact that intra raphe application of 8-OHDPAT 
reduces both the release of 5-HT in the terminal areas (Hillegaart et al., 1990) and the 
haloperidol induced catalepsy (Invemizzi et al., 1988) we suggest that the interaction of 
8-OHDPAT with the neuroleptics on FRT (and possibly on HRT, since most interaction 
between 8-OHDPAT and neuroleptics on FRT and HRT are the same) take place at the 
level of the cell bodies. 
Many studies have investigated possible differences between classical and atypical 
neuroleptics drugs. However, in many studies only one classical (haloperidol) and one 
atypical (clozapine) neuroleptic drug are investigated. The present data clearly show that 
in order to get a proper overview of the interaction between neuroleptics and other drugs 
more neuroleptics should be studied. The overall results, as displayed in table 2 show that 
the differences found cannot be explained on the basis of classical versus atypical 
neuroleptics. Thus whereas the effects of the atypical neuroleptics clozapine and 
prothipendyl are reduced by DOI, the effects of the atypical neuroleptics thioridazine and 
risperidone are enhanced by DOI. This seems to indicate that clozapine acts differently 
from most other atypical neuroleptics (although it shares many feature with prothipendyl). 
This is in line with biochemical data (Ángulo et al, 1990), as well as with drug 
discrimination studies (Goas and Boston, 1978; Wiley and Porter, 1992). 
In conclusion, the present study shows that serotonergic drugs (8-OHDPAT, ketanserin, 
ritanserin and DOI) have no effect in the paw test. However, they potently and selectively 
interfere with the effects of classical and atypical neuroleptic drugs. Moreover, the 
interaction with these serotonergic drugs is different for every neuroleptic studied, 
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suggesting subtle pharmacological differences between these neuroleptics. This would 
imply that drugs with a 5-HT2 and a D2 component in their binding profile will have to be 
screened very carefully. At present it seems impossible to predict whether such a drug 
will have extrapyramidal side effects or not. This is illustrated by the new drug 
ocapendone, which has a strong 5-HT2 and D2 blocking component, yet acts as a classical 
neuroleptic in the paw test (Ellenbroek et al, unpublished data) and is certainly not devoid 
of extrapyramidal side effects (Niemegeers et al, 1991). 
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Chapter 5 
The role of noradrenergic receptor subtypes in the behavioural effects of a classical 
and an atypical neuroleptic drug 
51 Peripheral and central adrenoceptor modulation of the behavioural effects of 
clozapine in the paw test 
Abstract 
1 In rats, the atypical neuroleptic clozapine has been found to increase the hindhmb 
retraction time, but not the forelimb retraction time, in the paw test. These parameters 
have predictive validity for the antipsychotic efficacy and extrapyramidal side-effects of 
drugs, respectively The present study analysed to which extent noradrenergic drugs affect 
the behavioural effect of clozapine in the paw test. 
2 The a, agonist ST 587, but not the peripherally working a, agonist methoxamine, 
decreased the effect of clozapine on the hindhmb retraction time The a{ antagonist 
phenoxybenzamine increased this effect of clozapine, and blocked the effect of ST 587 on 
clozapine at low doses Only the combination of phenoxybenzamine with clozapine 
produced an increase in forelimb retraction time. 
3 The a7 agonist Clonidine decreased the effect of clozapine on the hindhmb retraction 
time This effect was neither antagonized by the a2 antagonist rauwolscine nor by the a¡ 
antagonist phenoxybenzamine Rauwolscine or the peripherally working a2 antagonist L-
659,066 did not influence the effect of clozapine on the hindhmb retraction time. The 
forelimb retraction time was not affected by any of the combinations. 
4 In contrast to the ß2 agonist clenbuterol which was ineffective, the peripherally 
working β agonist (-)-isoprenahne increased the effects of clozapine on the hindhmb 
retraction time The β antagonist (-)-propranolol as well as the peripherally working β 
antagonist nadolol decreased this effect of clozapine. Low doses of the peripherally 
working /?, antagonist atenolol as well as low doses of the β2 antagonist ICI-118,551 
decreased the effect of clozapine A low dose of nadolol blocked the effect of (-)-
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ïsoprenaline on clozapine Only the combination of clenbuterol with clozapine produced 
an increase in forelimb retraction time 
5. It is concluded that blockade of central a,-adrenoceptors plays an important role in the 
effect of clozapine on the hindlimb retraction lime. Furthermore, the effect of clozapine 
on the hindlimb retraction time is strongly modulated by peripheral /3,- and/or ß2-
adrenoceptors. Given the predictive validity of the paw test, the presented data suggest 
that the α,-adrenoceptor antagonist properties of clozapine are important for its 
therapeutic effects, but not for its lack of extrapyramidal side-effects 
Introduction 
Many studies point toward- a role for the noradrenergic system in schizophrenia (Maas et 
al., 1993, for review Van kammen et al , 1986). Complementary, there are many studies 
suggesting a role for α-adrenoceptors in the therapeutic effects of neuroleptics (Petersen, 
1981, Marwaha & Aghajaman, 1982, Cohen & Lipinsky, 1986; Baldessanni et al , 
1992), although blockade of dopamine D2 receptors is believed to be crucial (Creese et 
al., 1976; Seeman et al., 1976, Peroutka & Snyder, 1980, however, see Cohen & 
Lipinsky, 1986). However, clozapine is a much weaker antagonist of the dopamine D2 
receptor than most neuroleptics (Andersen, 1988; Farde & Nordstrom, 1992; Richelson & 
Nelson, 1984), while it is effective in patients that are unresponsive to other neuroleptics 
(Kane et al , 1988) Moreover, clozapine is superior to most other neuroleptics with 
respect to lack of extrapyramidal side-effects (Angst et al , 1971) and amelioration of 
negative symptoms (Honigfeld et al , 1987) Together, this implies that clozapine must 
have a working mechanism that is different from that of other neuroleptics One of the 
prominent features of clozapine is its potent a,- as well as ^-adrenoceptor antagonist 
properties (Hall et al., 1986, Richelson & Nelson, 1984), which are even more 
pronounced since clozapine is administered in high doses (Wyatt, 1976) Therefore, the 
present study examined to which extent a,- and a2-adrenoceptors play a role in the effects 
of clozapine. Moreover, since a- and /^-adrenoceptors can interact strongly (e.g Stone et 
al., 1987), the possible modulation of the effects of clozapine by ^-adrenoceptors was 
68 
also studied The animal model used was the so called paw test which models both the 
antipsychotic efficacy and the extrapyramidal side-effects of drugs (Ellenbroek et al , 
1987) With regard to a large number of criteria (such as false positives and false 
negatives, response to chronic treatment, interactions between neuroleptics and 
anticholinergics, etc ), this model has been shown to have predictive validity for both the 
antipsychotic efficacy and the extrapyramidal side-effects of drugs (Ellenbroek et al, 
1987, Ellenbroek & Cools, 1988, Ellenbroek, 1993) 
Materials and methods 
The procedure followed was similar to that descnbed by Pnnssen et al (1993) Male 
Wistar rats (weighing between 220 and 250 grams) were housed individually 24 h before 
the experiment Experiments were performed between 10 00 a m and 4 00 ρ m , and rats 
were used only once On the day of the experiment, the rats received one or two 
intraperitoneal injections In the case of single injections, each rat was injected at t=0 
min In the case of two injections, the first injection (a noradrenergic drug) was given at 
t = -10 min and the second (clozapine) at t=0 mm When a (putative) noradrenergic 
antagonist was combined with its agonist, the two drugs were administered as a cocktail 
at t= 10 The injection volume was always 1 ml/kg, except for phenoxybenzamine 
dissolved in propylene glycol (0 5 ml/kg) All drugs were dissolved in distilled water, 
except for clozapine to which a drop of hydrochloric acid was added (1 N), 
phenoxybenzamine which was dissolved in propylene glycol, and the combination of 
Clonidine or ST 587 and phenoxybenzamine which was dissolved in 50% alcohol Control 
injections consisted of distilled water, since combinations of propylene glycol or 50% 
alcohol with clozapine did not differ from the combination of distilled water with 
clozapine (data not shown) 
Thirty minutes after the last injection the paw test was performed and repeated at 40 and 
50 min In the paw test a rat was placed on a Perspex platform which has four holes The 
rat was placed on the platform by positioning first the hind- and then the forehmbs in the 
holes Two variables were measured in this test, namely the time it takes the animal to 
retract its first hindlimb (hindlimb retraction time, HRT) and the time it takes the animal 
to retract its first forelimb (forelimb retraction time, FRT) with a minimum lime of 1 s 
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and a maximum time of 60 s. Since only robust effects are considered to be important, 
the window (1 to 60 s) was chosen so that both significant decreases and significant 
increases could be easily detected. The individual score was calculated for each animal as 
the mean of the three trials. The data are presented as the median value of these means 
per group (n = 6-15 rats) together with the corresponding 25 and 75 percentiles. Group 
differences were calculated with a two-tailed Mann-Whitney U-test. 
The following drugs were used (for sake of clarity, peripherally working drugs are 
defined as drugs that do not readily pass the blood-brain barrier): the atypical neuroleptic 
clozapine (Sandoz, The Netherlands), the a, agonist ST 587 (Boehringer Ingelheim, 
FRG), the peripherally working a, agonist methoxamine HCl (Wellcome, USA), the a, 
antagonist phenoxybenzamine HCl (SK&F, USA), the a2 agonist Clonidine HCl 
(Boehringer Ingelheim, The Netherlands), the a2 antagonist rauwolscine HCl (Carl Roth, 
FRG), the peripherally working a2 antagonist L 659,066 (Merck, USA), the ß2 agonist 
clenbuterol HCl (Sigma, The Netherlands), the peripherally working β agonist (-)-
isoprenaline HCl (Sigma, USA), the β antagonist (-)-propranolol HCl (RBI, USA), the 
peripherally working β antagonist nadolol (Sigma, St. Louis), the peripherally working /3, 
antagonist (+/-)-atenolol (RBI, USA) and the β2 antagonist ICI-118,551 (Zeneca, USA). 
Results 
Effects of noradrenergic drugs alone 
The purpose of this study was to analyse the interaction of noradrenergic drugs with 
clozapine. To avoid the use of doses of noradrenergic drugs that were effective by itself, 
all noradrenergic drugs used in interaction with clozapine, were also tested alone in high 
doses. In case of strong behavioural effects of a noradrenergic drug, a sub-threshold dose 
was used in the interaction study with clozapine. ST 587 (1 mg kg1), phenoxybenzamine 
(10 mg kg1), rauwolscine (5 mg kg1), L 659,066 (5 mg kg1), (-)-isoprenahne (5 mg kg 
'), (-)-propranolol (10 mg kg1), nadolol (10 mg kg"1), atenolol (1 mg kg1) and ICI-
118,551 (1 mg kg') did not significantly influence HRT or FRT compared with controls 
(distilled water, median values: HRT 1.1 sec; FRT: 1.0 sec). Methoxamine (10 mg kg1) 
and clenbuterol (10 mg kg') induced small, but significant increases in HRT (median 
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value of HRT: 2.9 and 4.3 sec, respectively). Since higher doses of Clonidine induced 
strong effects on the HRT [(Clonidine (0.3 mg kg1) induced a HRT of 22.0 sec (median 
value)], the highest dose used in this study was limited to 0.1 mg kg1, a dose that was 
without significant effects. 
ST5B7 
Clozapine 20 
Phenoxybenzamine 
Clozapine 15 
Figur« I The effect of ST 5S7 and phenoxybenzamine on Ihe hind-
limb retraction time (HRT) induced by clozapine The doses used (in 
mg kg ') are shown in the figure Median values and percentiles (25 
and 75%) of the HRT are shown */><005 * · / > < 0 υ 1 
| 30 Ι ι 
Clonidine 
Clozapine 20 
Rauwolscme 
Clozapine 15 
Figure 2 The effect of Clonidine and rauwolscme on the hindlimb 
rctrdLtion time (HRT) induced b> clozapine The dose;» used (in 
mg kg ') are shown in the figure Median values and percentiles (25 
and 7S%) of the HRT are shown **/><() 01 
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In line with earlier findings, clozapine (15-20 mg kg1) significantly increased the HRT 
(P<001 , Fig 1), but not the FRT (data not shown) compared with controls (distilled 
water, see above) 
Effects of a,-selective drugs on clozapine 
ST 587 (0 25-1 mg kg ') decreased the effect of clozapine (20 mg kg ') on the HRT (Fig 
1) higher doses produced stronger effects On the other hand, the peripherally working 
a, agonist methoxamine (10 mg kg1) combined with clozapine (20 mg kg1) did not 
influence the HRT (median value 56 6 sec) compared with clozapine alone (median 
value 60 0 sec, Fig 1) Phenoxybenzamine increased the effect of clozapine (15 mg kg1) 
on the HRT (Fig 1) the lowest dose which was significantly effective, already produced 
a maximal increase (60 0 sec) The effect of ST 587 on clozapine could by antagonized 
be phenoxybenzamine (1 mg kg ', Fig 3), in a dose that itself did not affect clozapine (15 
mg kg1, Fig 1) 
The FRT was not affected by any of the combinations, apart from the combination of 
phenoxybenzamine (10 mg kg') and clozapine (15 mg kg1) that produced a small, but 
significant effect (P<0 05) on the FRT (median value 6 2 sec) compared with clozapine 
alone (median value 1 0 sec) 
Effects of a2-selecnve drugs on clozapine 
Clonidine (0 03 0 1 mg kg ') significantly decreased the effect of clozapine (20 mg kg') 
on the HRT (Fig 2) higher doses could not be tested since they produced strong effects 
by itself (see above) Rauwolscine (1 5 mg kg ', Fig 2), as well as L 659,066 (5 mg kg ', 
HRT, median value 35 8), did not influence the effect of clozapine (15 mg kg1) on the 
HRT The inhibitory effect of Clonidine (0 1 mg kg ') on clozapine (20 mg kg ') could not 
be antagonized by relatively high doses (see Discussion section) of rauwolscine (1 mg 
kg [) or phenoxybenzamine (1 mg kg1, Fig 3) 
The FRT was not affected by any of the combinations 
Effects of ß-selective drugs on clozapine 
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Figure 3 All groups received 20 mg kg ' clozapine The lelt p.iri ol 
ihc figure shows thai ihe inhibition of clozapine b\ ST 5K7 is 
antagonized by phenox>benzamme The right pari of the figure 
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(PBZ) The doses used (in mg kg ') are shown in the figure Median 
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used (in nig kg ') are shown in ihe hgure Median \alucs and 
pcrecnliles (25 and Ti0,) of Ihe HRT are shown , / > < 0 u 5 
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Clenbuterol (1-10 mg kg') did not influence the effect of clozapine on the HRT (15 mg 
kg'; Fig. 4). In contrast, the peripherally working β agonist (-)-isoprenaline (1-5 mg kg"1) 
increased the effects of clozapine (15 mg kg') on the HRT (Fig. 5): the lowest dose 
which was significantly effective, already produced maximal effects (60.0 sec). (-)-
Propranolol (1-10 mg kg'), nadolol (1-10 mg kg"1), atenolol (0.1-1 mg kg"1) and ΙΟ­
Ι 18,551 (0.1-1 mg kg') decreased the effect of clozapine (20 mg kg') on the HRT (Figs. 
Γ + -
1 5 10 
Clenbuterol 
Clozapine l b 
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4-6). The effect of (-)-isoprenaline (5 mg kg1) on clozapine (15 mg kg'1) was blocked by 
a dose of nadolol (1 mg kg') that itself had no effect (Fig. 5). 
The FRT was not affected, apart from the combination of clenbuterol (10 mg kg') and 
clozapine (15 mg kg1), which produced a significant increase in the FRT (median value: 
15.7 sec) compared with clozapine alone (median value: 1.0 sec). 
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Figure 5 The effect of ( - Hsoprenjline and or nadolol on the limd-
limb rclraction time (HRT) induced by clozapine The doses used (HI 
mg kg ') arc shown in the figure Median \alues and pen.eiuiles (2^ 
diid 75°o) of the HRT are shown " / * < . ( ) i l l + /»<() 05. compared 
with the combination ol ( - )-isoprcn,iline (5 mg kg ') and clozapine 
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Figure 6 All groups received 20 nig k g - 1 clozapine The elicci ol 
atenolol and ICI-118.551 on the hindlimb retraction lime (HRT I 
induced by clozapine is shown The doses used (in mp kg ') are 
shown in the figure Median values and percentiles (25 and 75%) of 
the HRT are shown *F<005. '·Ρ<0<)\ 
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The role of a ¡-adrenoceptors in the effects of clozapine 
In line with earlier findings, clozapine (15-20 mg kg1) enhanced the hindlimb retraction 
time (HRT) in the paw test. The a, agonist ST 587 decreased this effect of clozapine. The 
effect of ST 587 appeared to be α,-adrenoceptor-specific: 1) ST 587 is highly selective 
for a,- over a2-adrenoceptor stimulation (De Jonge et al., 1981); 2) the effect of ST 587 
could be attenuated by a dose of the a, antagonist phenoxybenzamine that itself did not 
affect clozapine; 3) when combined with clozapine, higher doses of phenoxybenzamine 
produced effects opposite to those of ST 587. 
A high dose (cf. Liebau et ai, 1989) of the peripherally working a, agonist methoxamine 
did not alter the effect of clozapine on the HRT. Even when a possible effect of 
methoxamine was obscured by the ceiling effect of clozapine, it can be excluded that 
peripheral α,-adrenoceptors significantly contribute to the effects of ST 587, since the 
effective dose of ST 587 (0.5 mg kg ') was 20 times smaller than the ineffective dose of 
methoxamine (10 mg kg1). Thus, the attenuation of the effects of clozapine by a,-
adrenoceptor stimulation did not seem to involve peripheral α,-adrenoceptors. Therefore, 
it is concluded that central α,-adrenoceptor stimulation decreased the effects of clozapine 
on the HRT in the paw test. These data together with the fact that clozapine potently 
antagonizes ^-adrenoceptors (Hall et al., 1986; Menon et al., 1988) strongly suggest that 
blockade of central α,-adrenoceptors significantly contribute to the HRT elicited by 
clozapine. Since the HRT is a parameter with predictive validity for the antipsychotic 
efficacy of drugs (Ellenbroek et ai, 1987, Ellenbroek & Cools, 1988; Ellenbroek, 1993), 
the present study implies that inhibition of central α,-adrenoceptors is important for the 
antipsychotic effects of clozapine. On the other hand, a high dose of phenoxybenzamine 
alone (10 mg kg ') did not increase the HRT, suggesting that blockade of α,-
adrenoceptors alone is not enough to produce such an effect. Indeed, recent studies have 
shown that the serotonin 5-HT2 receptor antagonist properties (Ellenbroek et al., 1994) as 
well as the dopamine D, receptor antagonist properties, but not the dopamine D2 receptor 
antagonist properties of clozapine (Ellenbroek et al, 1991) also play a role in the effects 
of clozapine on the HRT. At this moment we are studying to which extent combined 
antagonism of serotonin 5-HT2, dopamine D, and noradrenaline a, receptors may produce 
a clozapine-like profile in the paw test. 
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As previously reported (Ellenbroek et al , 1987), unlike classical neuroleptics, clozapine 
did not induce an increase in the forelimb retraction time (FRT) When combined with 
clozapine, ST 587 did not induce an increase in FRT, indicating that the a, antagonist 
properties of clozapine do not play a role in its lack of FRT Since the FRT is a 
parameter with predicitive validity for extrapyramidal side effects (Ellenbroek et al , 
1987, Ellenbroek & Cools, 1988), the present data indicate that the a, antagonist 
properties of clozapine do not play a role in its lack of extrapyramidal side-effects 
Moreover, phenoxybenzamine in combination with clozapine, did induce an increase in 
FRT, suggesting that additional blockade of ^-adrenoceptors on top of clozapine, may 
increase, but not decrease, extrapyramidal side effects (cf Chiodo & Bunney, 1985) 
The role ofa2-adrenoceptors m the effects of clozapine 
As mentioned, clozapine enhanced the HRT in the paw test The higher dose of Clonidine 
(0 1 mg kg ') decreased this effect of clozapine This effect of Clonidine could not be 
blocked by a relatively high dose of rauwolscine (cf Timmermans et al , 1981), 
suggesting that a2-adrenoceptor stimulation does not affect clozapine with respect to the 
HRT This is underlined by the finding that both rauwolscine and L 659,066 did not 
modulate the effect of clozapine on the HRT Since the HRT is a parameter with 
predictive validity for the antipsychotic efficacy of drugs (see above), the present study 
implies that inhibition of ^-adrenoceptors does not contribute to the antipsychotic effects 
of clozapine 
Since Clonidine has a,-adrenoceptor properties as well (Liebau et al , 1989), the role of 
these adrenoceptors was evaluated as well However, a dose of phenoxybenzamine (1 mg 
kg ') that strongly attenuated the effect of ST 587, did not attenuate the effect of Clonidine 
on clozapine This suggests that the effects of Clonidine on clozapine are neither due to its 
a,-adrenoceptor properties However, until more is known about the pharmacology of the 
many different a,- and a2-adrenoceptor subtypes that have recently been identified 
(Bylund et al , 1988, Johnson & Minneman, 1986, Morrow & Creese, 1986), a role for 
these receptor subtypes cannot be fully excluded Moreover, the effect of Clonidine may 
involve an interaction between α
Γ
 and a2 adrenoceptor (sub)types Alternatively, other 
receptors for which Clonidine has a high affinity may be involved, e g imidazoline 
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receptors (Moldenngs et al , 1993) 
As mentioned clozapine did not induce an effect on the FRT The combination of 
Clonidine with clozapine neither induced an increase in FRT, indicating that the or2 
antagonist properties of clozapine do not play a role in its lack of effect on FRT Since 
the FRT is a parameter with predicitive validity for extrapyramidal side-effects (see 
above), the present data indicate that the a2 antagonist properties of clozapine do not play 
a role in its lack of extrapyramidal side-effects 
The role of ^-adrenoceptors in the effects of clozapine 
The peripherally working β agonist (-) isoprenaline increased the effect of clozapine on 
the HRT, which could be attenuated by an ineffective dose of the peripherally working β 
antagonist nadolol (1 mg kg') Moreover, when given alone, higher doses of nadolol 
decreased the effects of clozapine Together, these data imply that peripheral /3-
adrenoceptors modulate the effect of clozapine on the HRT The decrease of the effect of 
clozapine on the HRT by /3-adrenoceptor blockade seems to be mediated via /3,- as well as 
^-adrenoceptors, since atenolol and ICI-118,551 were both effective in doses that are 
receptor-specific (Bilsky et al, 1983) The significant effect of a low dose of atenolol 
(0 1 mg kg ') furthermore underlines the involvement of peripheral receptors The β2 
agonist clenbuterol had no effect on clozapine, in contrast with (-)-isoprenaline This was 
especially surprising since selective β2 adrenoceptor blockade did affect clozapine (see 
above) These data may indicate that stimulation of ^-adrenoceptors, as opposed to non­
selective β adrenoceptor stimulation, is not sufficient to enhance the effect of clozapine on 
the HRT However, one has to be careful since clenbuterol seems to possess /3, antagonist 
properties as well (Ordway et al , 1987) Since a ft antagonist (atenolol) decreased the 
clozapine-induced HRT, it cannot be excluded that the lack of effect of clenbuterol is due 
to its ability to interact with both /3,- and ft-adrenoceptors in an opposite manner 
As mentioned, clozapine did not induce an increase on the FRT Neither did the 
combination of any of the penperally working drugs with clozapine produce an effect on 
the FRT Interestingly, clenbuterol, that readily passes the blood brain bamer, did induce 
an increase in FRT, when combined with clozapine, suggesting that central ft-
adrenoceptors may be involved in this increase in FRT 
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Since clozapine has a very low affinity for /3-adrenoceptors (Hall et al, 1986), it becomes 
difficult to ascribe the effects of peripheral /3-adrenergic agents on the clozapine-induced 
increase of HRT to clozapine's ability to interact with ^-adrenoceptors. While the precise 
mechanisms of action by which peripheral /3-adrenoceptors might modulate the effects of 
clozapine are unknown, we can exclude the following ones. First, the effects of the β 
ligands do not seem to be mediated by a change in the pharmacokinetics of clozapine. 
For, propranolol has been shown to increase, and not to decrease, the plasma 
concentration of neuroleptics (the classical neuroleptic chlorpromazine and the atypical 
neuroleptic thioridazine; clozapine was not studied), increasing thereby their therapeutic 
efficacy (Peet et ai, 1980; Silver et al., 1986). Indeed, (-)-propranolol has been found to 
increase, but not to decrease, the effects of haloperidol on the HRT (unpublished 
observations). Second, the effect of the β ligands could not be ascribed to a direct 
influence on the extrafusai fibers in the hindhmb muscles, influencing thereby the 
contractability of these muscles, despite of the fact that these muscle fibers contain /32-
adrenoceptors (Buckenmeyer et al., 1990): for, both /3,- and ^-adrenoceptors were found 
to be involved in the effects studied. Moreover, (-)-propranolol increased the effects on 
haloperidol on the HRT (see above), while it decreased the effects of clozapine (Fig. 4): 
such effects seem imcompatible with a direct action on muscle fibers. Futher research 
about the mechanisms of action by which peripheral /3-adrenoceptors modulate the effects 
of clozapine is necessary. 
Summary 
The present study shows that central a,-adrenoceptor stimulation decreases the effects of 
clozapine on the hindlimb retraction time (HRT), a parameter with predictive validity for 
antipsychotic efficacy of drugs. As discussed, these data imply that blockade of central 
^[-adrenoceptors by clozapine are important for the antipsychotic effects of clozapine. 
The present study also shows that blockade of (3,- and/or /^-adrenoceptors decreased the 
effect of clozapine on the HRT, an effect that seemed to be mediated by peripheral 
receptors. The forelimb retraction time (FRT), a parameter with predictive validity for 
extrapyramidal side-effects, on which clozapine has no effect, was not increased when 
clozapine was combined with a
x
 agonists. Therefore, these data imply that a{-
adrenoceptors do not play a role in clozapine's lack of extrapyramidal side-effects. 
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5 2 Adrenoceptor modulation of the behavioural effects of Haloperidol in the paw test 
Abstract 
1 In the paw test, the classical neuroleptic halopendol increases both the hindlimb 
retraction time (HRT) and the forelimb retraction time (FRT) of rats These parameters 
model the therapeutic effects and the extrapyramidal side effects of neuroleptics, 
respectively The present study analysed to what extent drugs acting on adrenoceptors 
affect the behavioural effects of halopendol in the paw test. 
2 The a,-adrenoceptor agonist ST 587 decreased the effect of halopendol on the HRT and 
the FRT Methoxamine, a peripherally working α,-agonist, decreased the FRT, but not 
the HRT The a,-antagonist phenoxybenzamine enhanced the effect of halopendol on the 
HRT, but not the FRT 
3 The a2-agonist Clonidine enhanced the effect of halopendol on the HRT and the FRT. 
Rauwolscine, an a2-antagonist, decreased the effect of halopendol on the HRT, but not 
the FRT The peripherally working a2- antagonist L-659,066 did not influence the effects 
of halopendol 
4 Clenbuterol, a /32-agonist, decreased the effects of halopendol on the FRT, but not the 
HRT The peripherally working 0-agonist (-)-isoprenahne did not influence the effects of 
halopendol The 0-antagonist (-)-propranolol enhanced the effect of halopendol on both 
the HRT and FRT, while the peripherally working /3-antagonist nadolol did not influence 
the effects of halopendol 
5 It is concluded that agents interacting selectively with central a, adrenoceptors as well 
as agents interacting selectively with central (^-adrenoceptors affect the halopendol-
ïnduced HRT, albeit in an opposite manner Agents interacting with central jS-
adrenoceptors affect the halopendol-induced FRT, and possibly the HRT Agents 
interacting only with peripheral a,-adrenoceptors may also affect the halopendol-induced 
FRT 
Introduction 
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The role of adrenoceptors in the pharmacotherapy of schizophrenia is still unclear 
Recently, using an animal model for neuroleptic drugs, the so called paw test, we have 
found evidence that the a, adrenoceptor antagonist property of the atypical neuroleptic 
clozapine is important, although not sufficient, for its effects on the parameter modelling 
antipsychotic efficacy (Pnnssen et al , 1994) In the present study, we wanted to analyse 
the modulatory effect of drugs acting on adrenoceptors on the behavioural effects of 
halopendol, a classical neuroleptic Although halopendol is thought to produce its effects 
via blockade of dopamine D2 receptors (Ellenbroek et al , 1991), dopamine systems are 
known to strongly interact with noradrenergic systems (Antelman & Caggiula, 1977) 
Indeed, studies on catalepsy, an animal model for extrapyramidal side effects, have shown 
strong modulation of the effects of halopendol by drugs acting on adrenoceptors (Honma 
& Fukushima, 1977, Pycock, 1977, Pichler & Kobinger, 1985, Yntema & Korf, 1987) 
Clinically, the /3-antagonist propranolol seems to enhance the therapeutic effects of 
neuroleptics (Berlant, 1987), while both propranolol and the a2 agonist Clonidine 
ameliorate neuroleptic-induced akathisia (Fleischhacker et al , 1990) 
In the present study, therefore, we analysed the effect of drugs acting on adrenoceptors 
on the classical neuroleptic halopendol The animal model used, the paw test, is well-
validated and models both the antipsychotic potential (the hindlimb retraction time) and 
extrapyramidal side-effects (the forehmb retraction time) of drugs (Ellenbroek et al , 
1987, Ellenbroek & Cools, 1988, Ellenbroek, 1993) Repeated testing with halopendol is 
found to increase its effects in several procedures (Hillegaart et al , 1987, Iwata et al, 
1989, Barnes et al , 1990) Since we were interested whether the paw test is similarly 
susceptible to repeated testing, it was decided to extent the number of intra-individual 
tests as compared to our normal paradigm (cf Ellenbroek et al, 1987, Pnnssen et at , 
1994) 
Materials and methods 
The procedure followed was similar to that descnbed in Pnnssen et al (1993) Male 
Wistar rats (weighing between 220 and 250 grams) were housed individually 24 h before 
the expenment Experiments were performed between 10 h 00 m and 16 h 00 m, and rats 
were used only once On the day of the expenment, the rats received one or two 
84 
intraperitoneal injections In the case of single injections, each rat was injected at t=0 
min In the case of two injections, the first injection (an adrenoceptor (ant)agonist) was 
given at t=-10 min and the second (halopendol) at t=0 min The injection volume was 1 
ml kg ' All drugs were dissolved in distilled water, except from phenoxybenzamine 
which was dissolved in 50% alcohol Control injections consisted of distilled water, since 
combinations of 50% alcohol and halopendol did not differ from the combination of 
distilled water and halopendol (data not shown) 
Thirty minutes after the last injection the paw test was performed and repeated every ten 
minutes until t = 80 min In the paw test a rat is placed on a Perspex platform which has 
four holes The rat is placed on the platform by positioning first the hind- and then the 
forehmbs in the holes Two variables were measured in this test, namely the time it takes 
the animal to retract its first hindlimb (hindlimb retraction time, HRT) and the time it 
takes the animal to retract its first forehmb (forehmb retraction time, FRT) with a 
minimum time of 1 s and a maximum time of 60 s The individual score was calculated 
for each animal as the mean of the first three tnals (Tl) and of the second three tnals 
(T2) The data are presented as the median value of these means per group (л = 6-12 
rats) per time block together with the corresponding 25 and 75 percentiles, since the data 
showed no normal distribution These means were transformed to ranks and statistically 
analyzed, using the SAS statistical package First, for the H20-halopendol groups only, a 
paired t-test with variable time was performed on the separate groups Second, drug 
effects were analysed with a repeated nonparametnc analysis of vanance (ANOVA) with 
factors time and drug In case of a significant effect on the factor drug and/or on the 
interaction between drug and time, a two tailed t-test was performed at each time block 
(post hoc analysis) 
The following drugs were used (for sake of clanty, penpherally working drugs are 
defined as drugs that do not readily pass the blood-brain barner) the classical neuroleptic 
halopendol (Janssen, Belgium), the a, agonist, ST 587 (Boehnnger Ingelheim, FRG), 
the peripherally working a, agonist, methoxamine HCl (Wellcome, USA), the a,-
antagonist, phenoxybenzamine HCl (SK&F, USA), the a2-agonist, Clonidine HCl 
(Boehnnger Ingelheim, The Netherlands), the a, antagonist, rauwolscine HCl (Carl Roth, 
FRG), the penpherally working a2-antagonist, L 659,066 (Merck, USA), the j82-agonist, 
clenbuterol HCl (Sigma, The Netherlands), the peripherally working 0-agomst, (-)-
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isoprenaline HCl (Sigma, USA), the /3-antagonist, (-)-propranolol HCl (RBI, USA) and 
the peripherally working ^-antagonist, nadolol (Sigma, St Louis) 
Results 
Effects of drugs acting on adrenoceptors 
The purpose of this study was to analyse the effects of drugs acting on adrenoceptors on 
halopendol To avoid the use of doses of drugs that were effective on their own, all drugs 
used, were also tested alone in high doses In case of strong behavioural effects of such a 
drug, a sub-threshold dose was used in the study with halopendol ST 587 (1 mg kg1), 
methoxamine (10 mg kg'), phenoxybenzamine (10 mg kg1), rauwolscine (5 mg kg1), L 
659,066 (5 mg kg1), (-)-isoprenahne (5 mg kg1), (-)-propranolol (10 mg kg1) and nadolol 
(10 mg kg ') did not significantly influence HRT or FRT compared with controls (distilled 
water Tl, median values HRT 1 1 s, FRT 1 0 s, T2, median values HRT 1 5 s, FRT 
1 0 s) Clenbuterol (10 mg kg ') induced a small, but significant increase in HRT (median 
values HRT Tl 4 3 s, T2 2 8 s) compared with controls (P<0 05) Since higher doses 
of Clonidine induced strong effects on the HRT [Clonidine (0 3 mg kg1), median values 
HRT Tl 22 0 s, T2 18 4 s], the highest dose used in this study was limited to 0 1 mg 
kg ', a dose that was without significant effects 
Effects of halopendol alone 
When comparing the Tl and T2 values of the H20-halopendol groups on the HRT (Fig 
1) and the FRT (Fig 2), an apparent increase in time can be seen Indeed, the paired t 
test showed a significant difference between Tl and T2 on the HRT of the H2O-0 1 mg 
kg1 halopendol group (P<0 01), but only a trend towards a difference in this respect in 
the HjO-O 5 mg kg ' halopendol group (P=0 06) With respect to the FRT, the paired t-
test showed a highly significant difference between Tl and T2 of the H2O-0 5 mg kg' 
halopendol group (P<0 001) 
The lowest dose of halopendol (0 1 mg kg ') induced a small, but significant increase in 
HRT (F(l,13)=7 0, /><0 05), but not FRT compared with controls (distilled water, see 
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Figure 1. The effects of drugs acting on adrenoceptors on the halopendol-induced HRT (maximum value 60 
s). Shown are the median values and the corresponding 25 and 75 percentiles of the first time block (left of 
two bars) and the second time block (right of two bars). Doses are shown in the figure in mg kg'. + 
denotes significant effect at one of the time blocks compared with controls (H,0 group, data not shown). * 
denotes significant effect at one of the time blocks compared with the correspondent H;0-halopendol group. 
(A) Role of α,-adrenoceptor specific drugs All groups left of the vertical bar received 0.5 mg kg'1 
halopendol, the other groups received 0.1 mg kg ' halopendol (B) Role of a2-adrenoceptor specific drugs. 
All groups left of the vertical bar received 0.1 mg kg' halopendol, the other groups received 0.5 mg kg' 
halopendol. (C) Role of /J-adrenoceptor specific drugs All groups left of the vertical bar received 0.5 mg 
kg ' halopendol, the other groups received 0.1 mg kg ' halopendol. Abbreviations: clenb = clenbuterol, hal 
= halopendol, isopren = (-)-isoprenahne, methox = methoxamme, propranolol = (-)-propranolol. 
above and Fig. 1). Post-hoc analysis showed a significant increase at T2 only. 
When compared to controls (distilled water; see above) halopendol (0.5 mg kg"1) 
significantly increased the HRT (F(l,16) = 60.4, P<0.001) and the FRT (F( 1,16) =50.2, 
P<0.001). For the HRT, a significant increase was found for both Tl and T2. With 
respect to the FRT, a significant interaction between the factors time and drug was found 
(F(l,16)=9.86, P<0.01). Post-hoc analysis showed a significant increase at both Tl and 
T2. 
Effects of a ¡specific drugs on halopendol 
ST 587, in a dose of 10 mg kg"1, but not 5 mg kg'1, decreased the effect of haloperidol 
(0.5 mg kg1) on the HRT (F(l,22)=8.5, P<0.001). Post-hoc analysis showed a 
significant decrease at both Tl and T2 (Fig. 1A). On the other hand, the peripherally 
working a¡ agonist methoxamme (10 mg kg"1) did not influence the effect of haloperidol 
(0.5 mg kg'1) on the HRT. Phenoxybenzamine, in a dose of 10 mg kg', but not 1 mg kg 
', increased the effect of haloperidol (0.1 mg kg') on the HRT (F(l,16) = 10.9, P<0.0\). 
Post-hoc analysis showed a significant increase at both Tl and T2 (Fig. 1A). 
ST 587, in a dose of 10 mg kg'1, but not 5 mg kg ', showed a trend towards a decrease of 
the effect of haloperidol (0.5 mg kg1) on the FRT (F(l,22) = 3.4, P=0.08). Post-hoc 
analysis showed a significant decrease in T2 only (Fig. 2A). Methoxamine (10 mg kg"1) 
decreased the effect of haloperidol (0.5 mg kg1) on the FRT (F(l,21)=6.5, Ж0.05). 
Moreover, a significant interaction between the factors time and drug was found as well 
(/"(1,21) = 11.3, P<0.0\). Post-hoc analysis showed a significant decrease in T2 only 
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(Fig 2A). Phenoxybenzamine (10 mg kg1) did not affect the halopendol (0.5 mg kg1)-
ìnduced FRT. 
Effects of a2-speafic drugs on halopendol 
Clonidine, in a dose of 0.1 mg kg1, but not 0.03 mg kg1, increased the effect of 
halopendol (0.1 mg kg1) on the HRT (F(l,18)=9.5, F<0 01). Moreover, a significant 
interaction between the factors time and drug was found as well (F(l,18)=6.5, P<0.02). 
Post-hoc analysis showed a significant increase in Tl only (Fig. IB). Rauwolscine, in a 
dose of 5 mg kg ·, but not 1 mg kg ', decreased the effects of halopendol (0.5 mg kg ') on 
the HRT (F(l,19)=4 7, P<0 05) Post-hoc analysis showed a significant decrease in Tl 
only (Fig IB). L-659,066 did not affect the halopendol (0.5 mg kg ')-induced HRT. 
Clonidine, in a dose of 0 1 mg kg1, but not 0 03 mg kg1, increased the effect of 
halopendol (0.5 mg kg1) on the FRT (F(l,21)=5.7, F<0 05). Post-hoc analysis showed 
a significant increase at Tl only (Fig 2B) The combination of 0.1 mg kg ' Clonidine and 
0.1 mg kg1 halopendol did not induce a significant increase in FRT (data not shown). 
Rauwolscine (5 mg kg ') and L-659,066 (5 mg kg ') did not affect the halopendol (0.5 mg 
kg ')-induced FRT 
Effects of ß-speafic drugs on halopendol 
Clenbuterol (5 mg kg1) and (-)-isoprenaline (10 mg kg1) did not affect the halopendol 
(0.5 mg kg ^-induced HRT. (-)-Propranolol, in a dose of 10 mg kg1, but not 1 mg kg"1, 
increased the effect of halopendol (0.1 mg kg1) on the HRT (F(l,18) = 15.0, P<0.001). 
Post-hoc analysis showed a significant effect at both Tl and T2 (Fig. 1С) Nadolol (100 
mg kg ') did not affect the halopendol (0 1 mg kg ')-induced HRT. 
Clenbuterol, in a dose of 5 mg kg ', but not 1 mg kg ', decreased the effect of halopendol 
(0 5 mg kg1) on the FRT (F(l,22) = 5.0, P<0.05). Post-hoc analysis showed a significant 
effect at T2 only (Fig 2C). (-)-Isoprenalme (10 mg kg ') did not affect the halopendol 
(0 5 mg kg ^-induced FRT. (-)-Propranolol, in a dose of 10 mg kg1, but not 5 mg kg"1, 
increased the effect of halopendol (0.5 mg kg1) on the FRT (F(l,22)=9.0, Ж0.01) 
Post-hoc analysis showed a significant increase at both Tl and T2 (Fig 2C). The 
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Figure 2. The effects of drags acting on adrenoceptors on the halopendol (0.5 mg kg')-induced FRT 
(maximum value 60 s). Shown are the median values and the corresponding 25 and 75 percentiles of the 
first time block (left of two bars) and the second lime block (right of two bars). Doses are shown in the 
figure in mg kg'. + denotes significant effect at one of the time blocks compared with controls (H20 
group, data not shown) * denotes significant effect at one of the time blocks compared with the H20-
halopendol group. (A) Role of a,-adrenoceptor specific drugs. (B) Role of a;-adrenoceptor specific drugs. 
(C) Role of ^-adrenoceptor specific drugs. Abbreviations: hal = halopendol, isopren = (-)-isoprenahne, 
methox = methoxamine, phenox = phenoxybenzamine, propranolol = (-)-propranolol. 
combination of 10 mg kg1 (-)-propranolol and 0.1 mg kg1 haloperidol did not induce a 
significant increase in FRT (data not shown). Nadolol (100 mg kg1) did not affect the 
haloperidol (0.5 mg kg ')-induced FRT. 
Discussion 
Haloperidol alone 
In the present study, 0.1 mg kg1 haloperidol induced an increase in HRT, but not FRT. 
Earlier studies have shown that 0.1 mg kg ' haloperidol was ineffective for both HRT and 
FRT (Ellenbroek et al., 1987; Pnnssen et al., 1993). The inclusion of the extra time 
block (T2) in the present study explains this difference, since the significant effect was 
only seen in this time block. As was expected (see Introduction section), the HRT and the 
FRT showed a significant increase in time after repeated testing. These data are in line 
with studies on repeated testing of conditioned avoidance response (Hillegaart et al., 
1987) that, like the HRT, models antipsychotic efficacy of drugs, and with studies on 
catalepsy (Hillegaart et al, 1987; Iwata et ai, 1989; Barnes et ai, 1990) that, like FRT, 
models extrapyramidal side-effects of drugs. 
a
r
specific drugs on haloperidol 
The a,-agonist St 587, but not the peripherally working α,-agonist methoxamine 
decreased the effects of haloperidol on the HRT, indicating a role for central, but not 
penpheral, a,-adrenoceptors in this effect. A role for α,-adrenoceptors is underscored by 
the finding that the a,-antagonist phenoxybenzamine enhances the effects of haloperidol 
on the HRT. Therefore, it is concluded that agents interacting selectively with central o¡,-
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adrenoceptors modulate the halopendol-induced HRT, as has been found for clozapine 
(Pnnssen et al , 1994) However, in comparison with clozapine, the role for the a,-
adrenoceptor blockade in the effects on HRT appears to be relatively small, since the dose 
of St 587 needed to decrease the halopendol-induced HRT was 20 times higher than that 
needed to decrease the effects of clozapine (Pnnssen et al, 1994) Indeed, the in vivo 
occupation of α,-adrenoceptors after administration of behaviourally active doses of 
halopendol is relatively low compared with clozapine (Leysen et al , 1993) Given the 
predictive validity of the paw test (see Introduction) this would imply that a,-adrenoceptor 
blockade will not significantly alter the antipsychotic effects of halopendol On the other 
hand, the a, antagonist phenoxybenzamine strongly enhanced the halopendol-induced 
HRT, but not FRT Given the validity of the paw test, this would imply that a,-
antagonists can enhance the antipsychotic effects of halopendol without altenng its 
extrapyramidal side-effects in patients 
With respect to the FRT, a role for a, adrenoceptors is less clear St 587 showed only a 
trend towards a decrease, whereas phenoxybenzamine had no effect at all on the 
halopendol-induced FRT However, the penpherally working α,-agonist methoxamine 
strongly decreased the effects of halopendol, indicating that peripheral mechanisms may 
modulate the halopendol induced increase in FRT (cf Yntema & Korf, 1987) So, it is 
not yet possible to predict to what extent a, agonists such as St 587 attenuate the 
extrapyramidal side effects of halopendol in patients 
a2-speafic drugs on halopendol 
Clonidine enhanced the halopendol-induced HRT Rauwolscine, but not the peripherally 
working a2-antagonist L 659,066, decreased the halopendol-induced HRT Taken 
together, this strongly suggests that central a2- adrenoceptors are involved in these 
effects These results are in contrast with those found with clozapine, where Clonidine 
attenuated the clozapine-induced HRT via an non-a2-adrenoceptor specific effect (Pnnssen 
et al , 1994) In clinical studies, the interaction between drugs acting on (^-adrenoceptors 
and halopendol is not yet studied 
With respect to the FRT, Clonidine enhanced the halopendol-induced FRT, while 
rauwolscine and L 659,066 were ineffective Therefore the receptor-specificity of this 
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effect has to be questioned. So, it is not yet possible to predict to what extent a2-agonists 
may enhance the extrapyramidal side-effects of haloperidol in patients. 
ß-specific drugs on haloperidol 
In contrast to the clozapine-induced HRT (Prinssen et al., 1994), the haloperidol-induced 
HRT is not affected by peripherally working drugs acting on /3-adrenoceptors, 
underscoring again the differences between these neuroleptics. On the other hand, (-)-
propranolol enhanced the effect of haloperidol on the HRT. However, the /3-adrenoceptor 
specificity of this effect needs to be questioned, since the /32-agonist clenbuterol that 
readily passes the blood-brain barrier, was without effect on the haloperidol-induced HRT 
[although this might also be explained by its differential effects on /3,. and ß2-
adrenoceptors (Ordway et al., 1987; cf. Prinssen et al., 1994)]. Moreover, propranolol 
has inhibitory effects on dopamine synthesis (Tuross and Patrick, 1986) and enhances the 
plasma concentration of neuroleptics (Peet et al., 1980; Silver et al., 1986). Irrespective 
of the mechanism by which propranolol enhanced the effects of haloperidol on the HRT, 
this finding is in line with the clinical findings that propranolol enhances the antipsychotic 
effects of neuroleptics (Berlant, 1987). 
With respect to the FRT, clenbuterol, but not (-)-isoprenaline, decreased, while (-)-
propranolol, but not nadolol, increased the haloperidol-induced FRT, suggesting that 
central /3-adrenoceptors are involved in this effect. The present study shows that (-)-
propranolol enhanced the haloperidol-induced FRT, while Honma & Fukushima (1977) 
have shown that an identical dose of (±)-propranolol does not enhance the haloperidol-
induced catalepsy. However, this may simply reflect potency differences between ( + )-
propranolol and (-)-propranolol, since a two-fold lower dose of (-)-propranolol in the 
present study was without effect. So, these data allow the prediction that (-)-propranolol 
also enhances the extrapyramidal side-effects of haloperidol in patients. 
General discussion 
The present study suggests that the haloperidol-induced HRT is modulated by central ar 
and (^-adrenoceptors, though in an opposite manner. On the other hand, (-)-propranolol 
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may well affect the halopendol-induced HRT aspecifically (see above) Although the level 
at which these interactions take place are unknown, it is of interest to consider the 
dopamine system as a target site for the effects of ( ) propranolol and the drugs acting on 
a, and a2"
adrenoceptors First, although halopendol has affinity for several receptors 
(Leysen, 1984), its effects in the paw test seem to be caused by D2 receptor blockade 
(Ellenbroek et a! , 1991), while antagonism of serotonin 5 HT2 receptors, dopamine D, 
receptors or a,-adrenoceptors by halopendol seems unimportant (Ellenbroek et al , 1991, 
Ellenbroek et al, 1994, this study) Second, a,- and ^-adrenoceptors modulate the 
dopamine system in an opposite manner, at the level of the ventral tegmental area and the 
substantia nigra pars compacta (Grenhoff & Svensson, 1988, 1989, 1993), areas that 
contain dopaminergic cells projecting to the ventral and dorsal striatum, respectively 
These striatal areas have been shown to be crucial in the effects of halopendol in the paw 
test (Ellenbroek & Cools, 1991) Third, propranolol, via a non /^-adrenoceptor specific 
effect, decreases the synthesis of dopamine in the dorsal striatum (Tuross & Patrick, 
1986), and may thereby modulate the effects of halopendol Therefore, the effects of the 
drugs acting on adrenoceptors on halopendol may be explained by their ability to 
influence the dopaminergic activity 
With respect to the FRT, other mechanisms must play a role as well, since the effect of at 
least methoxamine seem to be peripherally located On the other hand, agents interacting 
selectively with central (/3-)adrenoceptors also affect the halopendol-induced FRT 
Indeed, peripheral (Yntema & Korf, 1987) and central (Pycock, 1977, Asm et al , 1982) 
adrenergic systems have been found to play a role in halopendol-induced catalepsy, 
another model for extrapyramidal side-effects 
Finally, both halopendol and clozapine were strongly modulated by drugs acting 
selectively on adrenoceptors However, as can be easily seen in Table 1, the modulation 
of these two neuroleptics was completely different Only the drugs acting selectively on 
α,-adrenoceptors affect halopendol and clozapine in the same direction However, even 
here, the minimal dose of ST 587 needed to decrease the HRT showed a 20 fold 
difference (see above) Taken together, this suggests that the working mechanisms of 
halopendol and clozapine in the paw test, differ fundamentally 
In sum, it is concluded that agents interacting selectively with central α,-adrenoceptors as 
well as agents interacting selectively with central a2 adrenoceptors affect the halopendol-
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Table 1. A summary of the modulation by noradrenergic drugs of 
the effects of haloperidol (section 5.2) and clozapine (secti-
on 5.1) in the paw test. t/i: a significant increase/decrease 
compared to neuroleptic alone; - no significant effect 
HRT FRT 
HAL CLOZ HAL CLOZ 
ST 587 i i i -
Methoxamine - - I -
Phenoxybenzamine î t - t 
Clonidine t i τ -
Rauwolscine i - - -
L-659,066 - - - -
Clenbuterol - - i t 
(-)-Isoprenaline - t - -
(-)-Propranolol î i τ -
Nadolol - i - -
induced HRT, albeit in an opposite manner. Agents interacting selectively with central β-
adrenoceptors seem to affect the haloperidol-induced FRT, but not HRT. Agents 
interacting with peripheral αϊ-adrenoceptors may also affect the haloperidol-induced FRT. 
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Chapter б 
Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies 
the atypical profile of clozapine 
Abstract 
Previous studies have shown that a!-adrenoceptors, dopamine D,-hke and 5-HT2A 
receptors play an important role in the effects of the atypical neuroleptic, clozapine, on 
the parameter modelling antipsychotic efficacy in the paw test Therefore, it became of 
interest to investigate whether antagonism of all these receptors together would give rise 
to effects characteristic of clozapine The effects of the combined administration of the 
a,-adrenoceptor antagonist phenoxybenzamine, the dopamine D, receptor antagonist, SCH 
39166 (4-(4-chloro-3-methoxyphenyl)-l,2-dihydronaphthalene), and the 5-HT2A receptor 
antagonist, ketansenn, were therefore measured in the paw test The present data show 
that all three drugs together, but not simply combinations of two out of three, produced a 
profile similar to that of clozapine a significant increase in the parameter modelling 
antipsychotic efficacy and no change m the parameter modelling extrapyramidal side-
effects 
Introduction 
Clozapine is unique among neuroleptics since it is the only antipsychotic drug that 
ameliorates both positive and negative symptoms, lacks extrapyramidal side-effects, and is 
effective in "neuroleptic-resistant" patients (for review see Baldessanni and Frankenburg, 
1991) A major drawback of clozapine is its severe side-effect on white blood cells in 
humans Therefore, many studies have been devoted to unravelling the working 
mechanism of clozapine in the hope that it offers a rationale for the design of a new class 
of atypical neuroleptics The search for the working mechanism of clozapine is 
complicated by the fact that clozapine affects a greaty variety of receptors Clozapine has 
high affinity for α,-adrenoceptors, dopamine D„, 5-HT2A and 5-HT2C) muscarinic 
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acetylcholine and histamine H, receptors, moderate affinity for ^-adrenoceptors, 
dopamine D l ; D2 and D5 receptors and for 5-HT3 receptors, and a low affinity (yet 
relatively high compared with other neuroleptics) for the 5-HT1A receptor (Van Toi et al , 
1991, Bolden et al., 1992; for reviews see Baldessanni and Frankenburg, 1991, Coward, 
1992). Indeed, many studies have already shown that the ability of clozapine to 
antagonize simultaneously two (or more) distinct types of receptors may underlie the 
absence of extrapyramidal side-effects of this drug. In this respect the co-occurrence of 
dopamine D2 receptor blockade and blockade of acetylcholine (Snyder et al., 1974), 
dopamine D, (Gerlach and Hansen, 1992) or 5-HT2A (e g. Meltzer, 1992) receptors has to 
be mentioned Occasionally, it has been suggested that such simultaneously occurring 
effects may also give nse to the therapeutic effects of clozapine (cf. Gerlach, 1991, 
Meltzer, 1992) Recently, a validated animal model for antipsychotic effects as well as 
extrapyramidal side-effects, namely the paw test (for review see Ellenbroek, 1993), has 
been used to study systematically to what extent clozapine antagonism of a particular 
receptor subtype contributes to the effects of clozapine in this test. These studies have 
shown that stimulation of a, adrenoceptor, dopamine D,-hke and 5-ΗΤ2Λ receptors (but 
not of a2 adrenoceptors, dopamine D2-like, muscarinic acetylcholine and 5-ΗΤ1Λ 
receptors) attenuates the effects of clozapine on the parameter modelling antipsychotic 
efficacy in the paw test (Ellenbroek, 1988, Ellenbroek et al, 1991, 1994; Pnnssen et al., 
1994) This implies that these three receptors may be important for the therapeutic effects 
of clozapine Since clozapine does not affect the parameter modelling extrapyramidal side-
effects, but only the parameter modelling the antipsychotic effects, we hypothetized that 
the combined antagonism of a, adrenoceptors, dopamine D,-like and 5-HT2A receptors is 
sufficient for eliciting the neuroleptic profile characteristic of clozapine In the present 
study, we tested this hypothesis by analyzing the effects of combinations of appropriate 
doses of the a
:
 adrenoceptor antagonist, phenoxybenzamine, the dopamine D, receptor 
antagonist, SCH 39166, and the 5-HT2A receptor antagonist, ketansenn, in the paw test. 
Materials and methods 
The methods used were similar to those described by Pnnssen et al (1993). Depending 
on the experiment, one or two intraperitoneal injections were given to male Wistar rats 
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(200-300 g), the rats were used only once Phenoxybenzamine (hydrochloride, SK&F, 
Philadelphia) was dissolved in propylene glycol (0 5 ml/kg) and injected separately at t=-
10 min SCH 39166 (4-(4-chloro-3-methoxyphenyl)-l,2-dihydronaphthalene), kindly 
donated by Schenng Co , USA), ketansenn (tartrate; RBI, Natick, USA) or their 
combination (administered as a mix) were dissolved in distilled water (1 ml/kg) and 
administered at t = 0 min Whereas the paw test is normally performed at t=30 min and 
repeated every ten min up to t=50 min, this was extended in the present study uo to 
t = 80 min because of the clear time effects that were noticed during the experiments In 
the paw test a rat was placed on a platform with four holes, first positioning the 
hindlimbs, then the forelimbs in the holes The time it takes the animal to retract one 
hindlimb (hindlimb retraction time) and the time it takes the animal to retract one 
forelimb (forehmb retraction time) was measured with a minimum of 1 s and a maximum 
of 60 s Since only strong effects are considered to be important, the range (1 to 60 s) 
was chosen so that significant increases could be easily detected The individual score was 
calculated for each animal as the mean of the first three trials (Tl) and of the second 
three trials (T2) These means were transformed to ranks and statistically analyzed, using 
the SAS statistical package Drug effects were analyzed with a repeated nonparametnc 
analysis of variance (ANOVA) with factors time and drug In the case of a significant 
effect on the factor drug or on the interaction between drug and time, a t-test was 
performed for each time block (post-hoc analysis) The data are presented as the median 
value (P50) of the means per group (N = 6-12 rats) per time block together with the 
standard error of the median (P75-P25/1.34VN) 
Results 
Phenoxybenzamine (10 mg/kg) and ketansenn (1 mg/kg) alone were not significantly 
different from controls (H20 group) with respect to the hindlimb retraction time (Fig 2) 
and forelimb retraction time (data not shown) On the other hand, in line with results of 
an earlier study (Prinssen et al , 1993), SCH 39166 (0 1 mg/kg) had a significant effect 
(F(l,12) = 19 1, P<001) on the hindlimb retraction time (Fig 1), but not on the forelimb 
retraction time (data not shown), compared with the controls (Fig 2). The combinations 
of two drugs did not elicit additive or synergistic effects on the hindlimb retraction time 
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Figure 1. The effects of SCH 39166 (0.1 mg/kg) alone as well as all possible combinations of 
phenoxybenzamine (10 mg/kg), ketanserin (1 mg/kg) and SCH 39166 (0.1 mg/kg) on the hindlimb 
retraction time. The median values and the standard error of the median are shown. +, P<0.05 compared 
with controls (H20 group, cf. Fig. 2); *, Ρ <0.05 compared with SCH 39166 alone and all combinations of 
two drugs. 
(Fig. 1). Combining all three drugs produced a strong increase in hindlimb retraction 
time, but not in forelimb retraction time, that was significantly different from the effect of 
0.1 mg/kg SCH 39166 alone (F(l, 13) = 10.3, P<0.01; Fig. 1). Moreover, this effect of 
the mix of the three drugs on the hindlimb retraction time was significantly different from 
the effects of the combination of phenoxybenzamine and ketanserin (F(l,12)=20.3, 
Ρ < 0.001), the combination of phenoxybenzamine and SCH 39166 (F(l ,12) = 10.6, 
P<0.01) and the combination of ketanserin and SCH 39166 (F(l,13) = 12.3, P<0.01; 
Fig. 1). For all these comparisons, post-hoc analysis showed a significant increase at T2 
only. The necessary control experiment, in which propylene glycol was administered ten 
min before the combination of ketanserin and SCH 39166, produced effects similar to 
those of the combination of ketanserin and SCH 39166 alone (data not shown). 
In a second experiment, the same ineffective doses of phenoxybenzamine and ketanserin 
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Figure 2. The effects of phenoxybenzanune (10 mg/kg), ketanserin (1 mg/kg), SCH 39166 (0.05 mg/kg) 
and their combination on the hindhmb retraction time. The median values and the standard error of the 
median are shown. *. Ρ < 0.05 compare*] with all drugs alone 
were combined with an ineffective dose of SCH 39166 (0.05 mg/kg; Prinssen et al., 
1993). The mix of the three drugs produced a highly significant effect on the hindlimb 
retraction time (Fig. 2), but not on the forelimb retraction time (data not shown), 
compared to phenoxybenzamine alone (F(l,ll)=28.3, P<0.001), ketanserin alone 
(F(l,13)=26.6, P<0.001) and SCH 39166 alone (F(l,12)=24.8, P<0.001). Post-hoc 
analysis showed that this applied to both Tl and T2. 
Discussion 
The results showed that the combined administration of phenoxybenzamine, SCH 39166 
and ketanserin had synergistic effects on the hindlimb retraction time, but not on the 
forelimb retraction time. It can be excluded that the present data simply reflect a 
pharmacokinetic increase in the concentration of SCH 39166 in the biophase caused by 
phenoxybenzamine and ketanserin. Namely, higher doses of SCH 39166 that further 
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increase the hindhmb retraction time (0 5 mg/kg), affect the forehmb retraction time as 
well (Pnnssen et al., 1993), while the combination of phenxybenzamine, SCH 39166 and 
ketanserin produced an increase in hindhmb retraction time without any change in 
forehmb retraction time. Therefore, pharmacokinetic effects on SCH 39166 itself cannot 
explain the interaction between the drugs This is underscored by the fact that, combined 
with identical doses of phenoxybenzamine and ketansenn, the higher dose of SCH 39166 
(0.1 mg/kg) did not lead to greater effects compared to the combination with 0.05 mg/kg 
SCH 39166 (Figs. 1 and 2). The same held true when 0.25 mg/kg SCH 39166 was 
combined with identical doses of phenoxybenzamine and ketansenn (hindhmb retraction 
time, median value Tl* 12 6 s; T2: 35.6 s). Apparently, the effects described depend on 
a delicate balance between the degree, to which each single receptor type is antagonized 
Thus, combined antagonism of α,-adrenoceptors, dopamine D,-hke and 5-HT2A receptors 
elicited effects in the paw test similar to that of the atypical neuroleptic, clozapine: strong 
effects on the hindhmb retraction time and no effects on the forehmb retraction time. This 
is exactly what was predicted on basis of the afore-mentioned studies on clozapine. 
Therefore, the present data indirectly validate our hypothesis about the working 
mechanism of clozapine, namely that it produces its effects on the parameter modelling 
antipsychotic efficacy by antagonizing a, adrenoceptors, dopamine D,-like and 5-HT2A 
receptors simultaneously. This possibility is supported by the fact that the doses of the 
drugs used were chosen so that the occupation of the receptor under study was 
comparable to that with a highly effective dose of clozapine (20 mg/kg), taking into 
account the binding data reported Moreover, since the combination of the three drugs 
was devoid of effects on forehmb retraction time, the present data may also explain the 
lack of extrapyramidal side-effects of clozapine. Finally, the proposed working 
mechanism of clozapine that involves combined antagonism of three receptors 
simultaneously, gives an explanation for the effect of clozapine in "neuroleptic-resistant" 
patients (see Introduction), since it is completely different from the working mechanism 
proposed for classical neuroleptics (namely blockade of dopamine D2 receptors) Studies 
using other animal models are required to further (m)validatc the proposed working 
mechanism of clozapine 
In any event, since the paw test has predictive validity for antipsychotic efficacy and the 
extrapyramidal side-effects of drugs (for review, see Ellenbroek, 1993), the present data 
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predict that the combination of phenoxybenzamine, SCH 39166 and ketanserin in doses 
that are themselves ineffective, has antipsychotic effects without inducing extrapyramidal 
side-effects. The present data may provide a rationale for the design of a new class of 
atypical neuroleptics. 
In summary, combining a, adrenoceptor, dopamine D, and З-НТ^ receptor antagonists, 
but not any two of these, had synergistic effects on the hindlimb retraction time 
(modelling antipsychotic efficacy), but not on the forelimb retraction time (modelling 
extrapyramidal side-effects) in the paw test. 
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Chapter 7 
Role of striatal dopamine D2 receptors in the paw test, an animal model for the 
therapeutic efficacy and extrapyramidal side-effects of neuroleptic drugs 
Abstract 
The effect of administration of the D2 antagonist sulpiride in three striatal areas (dorsal 
striatum, DS; nucleus accumbens, ACC; olfactory tubercle; ОТ) was studied in the so-
called paw test. In the paw test two parameters are measured: the hindlimb retraction time 
(HRT) and the forelimb retraction time (FRT) that model the therapeutic efficacy and the 
extrapyramidal side-effects of neuroleptics, respectively. Sulpiride significantly enhanced 
the HRT in each of the three structures. Identical doses of sulpiride administered in the 
three structures produced similar effects. The FRT was enhanced after administration of 
sulpiride in the DS and in the ACC. The minimal effective dose was lower for the DS. 
Administration of sulpiride in the ОТ did not affect the FRT. The effects on the FRT 
were relatively tardy (strong effects 4 hours or more following administration of 
sulpiride), especially in comparison to the rapid effect on FRT following systemic 
administration of classical neuroleptics. To analyze this tardiness, two additional 
experiments were performed: first, the inter-trial time was changed so that it was identical 
to that used in systemic studies; second, sulpiride was administered simultaneously in the 
DS and the ACC. Neither experiment produced an earlier effect on the FRT. The present 
data provide additional evidence for the theory that regional selectivity of drugs 
determines their propensity to induce extrapyramidal side-effects. 
Introduction 
A large number of studies have shown that classical and atypical neuroleptics can be 
discerned with respect to their regional selectivity. Thus, chronic administration of 
atypical neuroleptics attenuates spontaneous firing in dopamine AIO, but not A9 cells, 
while classical neuroleptics affect both AIO and A9 cells4,23. Atypical neuroleptics 
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selectively block locomotor activity induced by dopamine in the nucleus accumbens 
(ACC) as compared to locomotor activity induced by dopamine in the dorsal striatum7 
(DS) These in vivo behavioural and electrophysiological findings are supported by 
pharmacological studies showing that atypical neuroleptics affect spiperone binding in the 
ACC and/or ОТ stronger than in the DS, while the reverse is true for classical 
neuroleptics11617, but see 1B21 Taken together, most studies suggest that drugs that 
selectively block the striatal AIO system (ACC and ОТ) have a low propensity to induce 
EPS (viz atypical neuroleptics) 
On the other hand, regional selectivity of neuroleptics is also found within the AIO 
system classical neuroleptics block locomotor activity elicited from the ACC stronger 
than that elicited from the ОТ, while the reverse is true for atypical neuroleptics56 The 
latter studies suggest that neuroleptics not only show selectivity for the dopamine A9 
system vs the dopamine AIO systems, but show selectivity within the AIO system as 
well To further characterize the role of the DS, the ACC and the ОТ, the present study 
further analyses the role of these structures in the paw test, an animal model with 
predictive validity for both the antipsychotic potential (the hindlimb retraction time) and 
the extrapyramidal side effects (the forelimb retraction time) of drugs' , 0 " The effects of 
intra-cerebral administration of sulpiride, a D2 selective antagonist and neuroleptic, are 
determined 
The results show that sulpiride affects the hindlimb retraction time after administration in 
all three areas, whereas the forelimb retraction time is especially affected after 
administration of sulpiride into the DS However, the effects of sulpiride on the forelimb 
retraction time were tardy, in comparison with systemic administration of neuroleptics" 
To analyze this tardiness, two additional experiments were performed first, the inter-tnal 
time was changed so that it was identical to that used in systemic studies", second, 
sulpiride was administered simultaneously in the DS and the ACC, two areas involved in 
the effects of sulpiride upon the forelimb retraction time However, the results show that 
these additional experiments did not change the tardiness of the effect on the FRT. 
Materials and methods 
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Naive, male Wistar rats (n = 7-12 animals per group, Central Animal Laboratory, 
Nijmegen) were used Rats weighing between 180 220 g were anaesthetized with sodium 
pentobarbital (Narcovet, 60 mg/kg, IP) and placed in a stereotaxic apparatus Guide 
cannulas (outer diameter 0 65 mm, inner diameter 0 30 mm) were bilaterally implanted 
into the DS (ant 9 4, vert 1 0, lat 2 5), the ACC (ant 9 8, vert 2 7, lat 1 2) and the 
ОТ (ant 8 8, vert 1 1 , lat 2 2)14 Cannulas (5 mm length) directed at the ACC were 
angled 10 degrees laterally, while cannulas directed at the DS (4 mm length) and ОТ (6 
mm length) were not angled Cannulas were fixed onto the skull with dental cement 
(Durelon, ESPE, carboxylate cement) aided by the attachment of two screws After 
surgery the rats were housed individually in the original stockroom and allowed recovery 
from operation for at least one week Rats were kept on a 12 h day/night cycle with lights 
on at 7 00 am Food and water were available ad libitum At the day of the experiment, 
rats received bilateral injections of dl sulpiride (Sigma, dissolved in distilled water and a 
drop of acetic acid after which the pH was adjusted to 6-7) in the DS, the ACC or the ОТ 
at t=0 mm Injections were given by means of a 5 μ\ syringe with a 0 25 mm needle that 
extended into the brain tissue below the tip of the permanent embedded cannula (0 5 mm 
for DS, 1 0 mm for ACC, 1 5 mm for ОТ) The volume was 0 5 μΐ injected over a 10 s 
period, and the needle was left in situ for another 10 s to minimise diffusion along the 
needle tract The, the inner cannula was re-inserted Earlier studies have shown that this 
procedure leads to highly localized injections20 In an additional experiment, every animal 
received four intra-cerebral injections first, bilateral injections in the ACC (at t=0, 
cannulas implanted at ant 9 8 mm, vert 0 0 mm, lat 1 0 mm, no lateral angle), 
immediately followed by bilateral injections in the DS (cannulas implanted at ant 9 4, 
vert 0 0 mm, lat 2 5, vertical angle 10 degrees) The paw test was performed at t=30 
and repeated at t= 60, 90, 120, 180, 240, 300 and 360 min for each rat (in one 
additional experiment, the inter-trial time was limited to 10 min, so that the paw test was 
performed at t= 30, 40, 50, 60, 70, 80, 90 and 100 min) Testing occurred between 9 00 
and 17 00 hr Animals were only used for a single experiment In the paw test a rat was 
placed on a Perspex platform, measuring 30 by 30 cm with a height of 20 cm and having 
tour holes, two holes of 5 cm diameter for the hindlimbs and two holes of 4 cm for the 
forehmbs11 The rat was placed on the platform by positioning first the hind- and then the 
forelimbs in the holes Two variables were measured in this test, namely the time it takes 
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the animal to retract its first hindlimb (hindlimb retraction time; HRT) and the time it 
takes the animal to retract its first forelimb (forelimb retraction time; FRT) with a 
minimum time of 1 s and a maximum time of 30 s. Since only robust effects are 
considered to be important, the window (1 to 30 s) was chosen so that significant 
increases and significant decreases could be easily detected. The data are presented as the 
median value of the scores per group (n = 7-11 rats) together with the standard error of 
the median, since the data showed no normal distribution. The individual scores were 
transformed to ranks and statistically analyzed, using the SAS statistical package. Drug 
effects were analyzed with a repeated nonparametric analysis of variance (ANOVA) with 
factors drug and time. Since we are only interested in drug effects, a significant effect on 
the factor time will not be mentioned. For dose-dependent effects, identical statistical 
analysis was performed, but now with factors dose and time. Finally, in the last 
experiment, a repeated nonparametric ANOVA was performed on the rank-transformed 
data with factors interval (duration) and (number of) trials (see Results section). After the 
experiments rats were sacrificed, and brains were dissected. Brain sections were 
microscopically analyzed. Only data from subjects with injections made into the desired 
sites (Fig. 1) were further analyzed. 
) 
/ 
Fig. 1. The areas in which the injection places were located for the dorsal striatum (A), the nucleus 
accumbens (B) and the olfactory tubercle (C) according to the atlas of Paxinos and Watson (1986). 
Results 
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Effects of intra-striaral administration of sulpiride on the HRT 
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Fig. 2. The effect of local application of sulpiride in three striatal areas on the hindlimb retraction time 
(HRT) Every animal was repeatedly tested in the paw test at the time points shown. Median values and the 
standard error of the median of the HRT are given Closed circles: controls; open circles: 25 ng sulpiride 
groups., open squares 100 ng sulpiride groups A = dorsal striatum, В = nucleus accumbens, C = 
olfactory tubercle 
In the DS, 25 ng sulpiride significantly enhanced the HRT (F1 1 7=37.5, P<0.001; Fig. 
I l l 
2) A higher dose of sulpiride (100 ng) produced significant greater effects than the dose 
of 25 ng (F, , 8=9.8, P<0.01, Fig 2). This dose of 100 ng induced an optimum effect 
since a higher dose of sulpiride (400 ng) was significantly smaller compared with 100 ng 
in the DS (F,
 17 = 7.6, P<0.05; data not shown). In the ACC, 25 ng sulpiride significantly 
enhanced the HRT (F,
 1 4 = 179.0, Ρ<0.001; Fig. 2). A higher dose of sulpiride (100 ng) 
produced significant greater effects than the dose of 25 ng (F, „ = 10 7, P<0.01; Fig. 2). 
Further enhancing the dose to 400 ng did not produce effects different from those of 100 
ng (data not shown). In the ОТ, 25 ng sulpiride significantly enhanced the HRT 
( F 1 M = 6 2, P<0.05; Fig 2). A higher dose of sulpiride (100 ng) produced significant 
greater effects than the dose of 25 ng (F,
 1 5=13 2, P < 0 01, Fig 2). Further enhancing 
the dose to 400 ng did not produce effects different from those of 100 ng (data not 
shown) 
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Fig 3 The effect of local application of sulpiride in two striatal areas on the forelimb retraction time 
(FRT) Every animal was repeatedly tested in the paw test at the time points shown Median values and the 
standard error of the median of the FRT are given Closed circles controls, open circles 100 ng sulpiride 
groups, open squares 400 ng sulpiride groups A - dorsal striatum, В = nucleus accumbens 
Sulpiride (200 ng) administration in both the DS and the ACC did not differ from 
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sulpiride administration (200 ng) in the DS alone, viz. the 'control' group that produced 
the strongest effects (Fig. 4A). The effects of 200 ng sulpiride in the last trial in our 
normal paradigm (testing at 30, 60, 90,...,360 min) were not different from the effects in 
the last trial in the paradigm with the short inter-trial interval of 10 min (testing at 30, 40, 
..,100 min) both for the DS and the ACC (data not shown). 
F R T . 
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Fig 4 The effect of local co-administration of sulpiride (200 ng) in the dorsal striatum (DS) and the 
nucleus accumbens (ACC) on the hindlimb retraction time (HRT) and forehmb retraction time (FRT). Every 
animal was repeatedly tested in the paw lesi at the time points shown. Median values and the standard error 
of the median are given Closed circles: sulpiride in ACC, distilled water in DS; Open circles: sulpiride in 
DS, distilled water in ACC; Open squares sulpiride in DS and ACC. 
Effects of intra-smatal administration of sulpiride on the FRT 
The lowest dose of sulpiride tested (25 ng) did not affect the FRT in any of the three 
areas (data not shown). Higher doses of sulpiride (100-400 ng) produced significant 
effects after administration in the DS (100 ng: F, „ = 65.3, P<0.001; 400 ng: F,
 17=50.7, 
Ρ < 0.001; Fig. 3). In the ACC, sulpiride in a dose of 100 ng did not affect the FRT (Fig. 
3). Further enhancing the dose of sulpiride in the ACC to 400 ng produced a significant 
effect compared with controls (F,
 1 6=9.2, Ρ<0.01; Fig. 3). In the ОТ, 100 or 400 ng of 
sulpiride induced no significant effects (data not shown). Sulpiride (200 ng) administration 
in both the DS and the ACC did not differ from sulpiride administration in the DS alone, 
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viz. the 'control' group that produced the strongest effects (Fig. 4B). 
In contrast to what was expected (see Introduction), the effects of 200 ng sulpiride in the 
last trial in our normal paradigm (testing at 30, 60, 90,...,360 min) were significantly 
higher than the effects in the last trial of in the paradigm with the short inter-tnal interval 
of 10 min (testing at 30, 40, .., 100 min; Fig. 5): an interaction between interval and 
tnals was found for both for the DS (F79B=5.66, P<0.001) and the ACC (F791=3.75, 
P<0 01, Fig. 5) 
FRT. FRT. 
Fig 5 The effect of different inler-lnal intervals following local application of sulpiride (200 ng) in the 
dorsal striatum (A) and the nucleus accumbens (B) on the forelimb retraction time (FRT) Every animal was 
repeatedly tested in the paw test at either 30, 60, 90, 120, 180, 240, 300 and 360 nun (closed circles) or at 
30, 40, 50, 60, 70, 80, 90 and 100 min (open circles) Median values and the standard error of the median 
are given 
Discussion 
Effects of intra-stnatal administration of sulpiride on the HRT 
Systemic administration of both classical and atypical neuroleptics produces strong effects 
on the HRT in the paw test" The present study examined (a.o.) to what extent 
administration of the D2 antagonist sulpiride in distinct striatal areas could mimic such an 
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effect The present data show that administration of sulpiride into the DS, the ACC and 
the ОТ all produced strong effects on the HRT, that were largely comparable from a 
quantitative point of view. Thus, blockade of D2 receptors in all three striatal areas may 
be responsible for the effects observed after systemic administration of D2 antagonists. 
The effects of sulpiride administered in these areas are considered to be specific for the 
area studied, since sulpiride diffuses hardly following intra-cerebral administration2·15. On 
the other hand, one study found evidence that (-)-sulpinde can diffuse from the DS to the 
ACC22 However, it has to be noted that the dose of sulpiride used in this latter study (40 
^g) was at least 100-fold higher than the highest dose used in the earlier-mentioned 
studies as well as in the present study22 
Effects of intra striatal administration of sulpiride on the FRT 
Systemic administration of classical, but not atypical, neuroleptics produces strong effects 
on the FRT in the paw test11 The present study examined to what extent intra-stnatal 
administration of a D2 antagonist could mimic such an effect The present data show that 
administration of sulpiride into the DS and to a lesser extent into the ACC produced 
effects on the FRT Thus, striatal D2 receptors, especially in the DS, but also in the 
ACC, may be responsible for the effects in the paw test following systemic administration 
of D2 antagonists However, unlike the effects seen after systemic administration of D2 
antagonists, sulpiride administered in the DS or ACC produced its effects on the FRT 
only after several hours of repeated testing. Similar tardy effects of sulpiride were 
reported on catalepsy12, which is like the FRT an animal model for extrapyramidal side-
effects The tardy eflect on the FRT was not due to the large inter-tnal interval (30 or 60 
min) that was used in the present study, a control experiment using the 10 min inter-tnal 
interval that produces strong effects on FRT following systemic injections of classical 
neuroleptics", did not produce a faster increase in FRT (Fig 6B) In fact, the 10 mm 
interval produced significantly smaller effects compared with our normal paradigm (30, 
60 , 360 min testing), showing that the strong increase in FRT found in the present 
study, is not a direct consequence of repeated testing. Alternatively, it is theoretically 
possible that this tardy effect was due to diffusion of sulpiride to the DS and/or the ACC. 
In the present study, however, simultaneous administration of sulpiride in both the DS 
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and the ACC produced effects with similar tardiness (Fig 5) Therefore, it is unlikely 
that the tardy effects of sulpiride were due to the slow diffusion of sulpiride to these two 
structures The most logical explanation is that the very slow diffusion of sulpiride in the 
distinct areas itself and, thus, the amount of D2 receptors blocked within these areas 
caused this tardy effect Indeed, extrapyramidal side-effects, for which the FRT is a 
model (see below), are known to require the blockade of about 80% of D2 receptors13 
Given the predictive validity of the paw test showing that the HRT is a model for the 
therapeutic efficacy of neuroleptics and that the FRT is a model for the extrapyramidal 
side effects of neuroleptics (see Introduction), the present study may contribute to our 
understanding of the role of regional selectivity in the EPS profile of neuroleptics The 
fact that sulpiride administered in the DS, the ACC and the ОТ is equipotent in enhancing 
the HRT strongly suggests that all three regions equipotently contribute to the 
antipsychotic efficacy of neuroleptics On the other hand, the finding that sulpiride 
administered in the DS is more potent than sulpiride administered in the ACC in 
enhancing the FRT strongly suggests that neuroleptics with selectivity for the A9 system 
over the AIO system have a relatively high propensity to induce EPS, and that the reverse 
holds true for neuroleptics with selectivity for the AIO system (see Introduction) 
Moreover, since sulpiride administered in the ОТ is still less potent in inducing an 
increase in FRT than sulpiride administered in the ACC, these data also explain why 
neuroleptics with selectivity for the ОТ over the ACC have a lower propensity to induce 
EPS than neuroleptics with selectivity for the ACC over the ОТ56 Finally, it should be 
noted that extra-stnatal areas may also play an important role in the therapeutic effects or 
side-effects of neuroleptics, such as the hippocampus3 and the prefrontal cortex8 
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Part 3: Dopamine receptor stimulation in the nucleus accumbens of rats: in search of 
an animal model for tardive dyskinesia in man 
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Chapter 8 
Jaw muscle activity, the nucleus accumbens and dopaminergic agonists: a new 
approach 
Abstract 
A method was developed to analyse electromyographic (EMG) signals in terms of power, 
viz a measure for overall muscle activity, and number of seconds marked by distinct 
frequency ranges With the help of this method the effects of intra-accumbens 
administration of distilled water, the Dl receptor agonist SKF 38393 (SKF: 5 μg), the D2 
receptor agonist LY 171555 (LY 10 ^g) and their combination upon the EMG signals of 
the masseter and the digastric muscle were analysed in freely moving rats Only the 
combined treatment affected the power the noted increase was limited to the digastnc 
muscle The time/frequency analysis was limited to frequency ranges 3-4 Hz (class A), 4-
5 and 5-6 Hz (class B) and 6 7, 7-8, , 12-13 and 13-14 Hz (class C) Apart from a 
small effect of SKF alone and of SKF in combination with LY on class В of the masseter 
muscle, neither SKF nor LY affected class A or В SKF and LY increased and decreased 
respectively class С in both muscles The data suggest that SKF and LY elicited both 
opposite and synergistic effects The method is a new tool to analyse EMG signals in 
freely moving rats 
Introduction 
Animal studies on oral behaviour in the rat suffer from great obscunty concerning the 
assessment of oral behaviours (12) As a result of the great variety of methods used it is 
difficult to quantitatively, or even qualitatively, compare the outcome of the available 
studies Still, there are some experimental designs providing more objective and detailed 
measures, such as the designs in which variations in the distance between two fluorescent 
points on the upper and lower jaw ol a rat are quantified (5,9) These designs provide 
highly detailed information on the amplitude and the frequency of the jaw movements. 
Although these experimental designs are highly efficient, they also have disadvantages. In 
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the so-called tube test jaw movements are measured in animals that are placed in a tube 
(5). This tube restricts the animals' freedom and, accordingly, creates a stressful situation 
for the animal. In another experimental design (9) the animals are spinally transected, 
inhibiting thereby the display of any non-oral behaviour. Apart from these attempts to 
quantify oral behaviour in restrained rats, there is only a single study with freely moving 
rats (2). In that study the EMG signal of the masseter muscle was used as a dependant 
variable. However, no attempt was made to analyse these EMG signals other than 
visually. Given the need to have an objective and quantitative method for analysing oral 
behaviour in freely moving animals, it was decided to develop a new method for 
quantifying EMG signals of jaw muscles in freely moving rats. This newly developed 
method allows a quantitative analysis of EMG signals by determining both the power of 
the EMG signal (as a measure for the overall activity) and the number of seconds marked 
by distinct frequency ranges of the EMG signal. In the present study this method was 
used to analyse the effects of intra-accumbens administration of distilled water, the Dl 
receptor agonist SKF 38393 (SKF), the D2 receptor agonist LY 171555 (LY) and their 
combination upon the EMG signals recorded from the masseter (the principal jaw closing 
muscle) and the digastric muscle (the principal jaw opening muscle) in freely moving rats. 
Several studies indicate a role for the nucleus accumbens in the generation of oral 
behaviour: intra-accumbens administration of dopaminergic agonists increases oral 
behaviour (1,3,7). In spinally transected rats intra-accumbens administration of Dl or D2 
agonists induces a small increase in rhythmic jaw movements. When given together, these 
agonists induce an excessive amount of rhythmic jaw movements (9). 
In the present study we re-investigated the effects of intra-accumbens injections of SKF, 
LY and their combination in freely moving rats. First, the oral behaviour was analysed in 
terms of changes in the EMG signals recorded from the masseter and the digastric 
muscles; the outcome of this analysis is presented in this report. Second, the behavioural 
effects were analysed in terms of changes in oral and general motor behaviour (7); the 
detailed outcome of this analysis will be presented elsewhere (Koene et al., in prep.). In a 
final study we will report to which degree the EMG data correlate with the behavioural 
data (Pnnssen et al., in prep.). 
Material and Methods 
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Animals 
Male Wistar rats were used (Central Animal Laboratory, Nijmegen). They were 
individually housed, under a 12-h light-dark cycle (lights on 8 a.m.), with food and water 
ad libitum available. 
Surgery 
Rats (n=29) weighing between 175 and 190 grams were anaesthetized with sodium 
pentobarbital (Narcovet, 60 mg/kg i.p.) and placed in a stereotaxic apparatus. Guide 
cannulae (outer diameter: 0.65 mm; inner diameter: 0.30 mm) were bilaterally implanted 
into the nucleus accumbens (ant. 9.8, vert. 2.7, lat. 1.2, lateral angle 11 degrees) 
according to (8). The cannulae and a five pinned plug connected with five biomed wires 
(Cooner Wire, AS 632-4SS) were attached to the skull with dental acrylic cement 
(Durelon, ESPE). Four of the five biomed electrodes were subcutaneously led to the jaw 
muscles. After the insulation was removed from the end of the wires (± 4 mm), two 
electrodes were unilaterally placed in the anterior superficial part of the right masseter 
muscle; two other electrodes were unilaterally placed in the anterior part of the right 
digastric muscle. The distance between the two electrode ends within one muscle was 
about 5 mm. Contraction of the specific muscle following electrical stimulation of the 
electrodes (Grass S48 stimulator) was used to verify the correct placement of the 
electrodes. The fifth wire was placed subcutaneously in the neck and served as a 
grounding electrode. 
Experimental procedure 
After recovery of at least one week, non-habituated rats were intracerebrally injected just 
before the experiment. Bilateral injections were given by means of a 5 μ] Hamilton 
syringe (needle diameter: 0 35 mm; needle length: 12 mm; 7 mm below the skull). The 
volume was 0.5 μ\ per site injected over a period of 10 seconds. Following the injection 
the needle was left in its place for another 10 seconds to minimise diffusion along the 
needle track Subsequently, the plug on the rat's head was connected with the recording 
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device, and the rat was placed in a plexiglass observation cage (25x25x35 cm) The 
recording device consisted of a Hewlett Packard 3960 instrumentation recorder. The 
EMG signals were transmitted by electric wires coupled to a swivel in order to create full 
freedom of movement. The EMG signals were filtered (50 Hz) and, subsequently, 
amplified. Since the amplitude of the EMG signal reached its highest value during 
grooming, the amplitude seen dunng grooming was maximally amplified and set at 100% 
per muscle. The experiment lasted exactly 60 min. In addition to the recording of the 
EMG signals, the behaviour of the rats was registered with the help of an operationally 
defined ethogram The behavioural data will be presented elsewhere in detail (Koene et 
al , in prep ) After the experiment the rats were sacrificed with an overdose of 
pentobarbital (150 mg/kg ι ρ ), and the brains were dissected Subsequently, the brains 
were cut on a cryotome, and the sections were microscopically analysed. Only data from 
animals with correct injection sites are included in this report 
Analysis of the EMG signals 
EMG signals were high-pass filtered (80 Hz) to remove movement artifacts from the 
EMG signal and fed to the computer The signals of the masseter and digastric muscles 
were analysed independently, but in the same manner The data were analysed with the 
help of a software program (written in Turbo Pascal on an IBM-compatible computer) 
developed especially for this purpose by one of the authors (D.H.). The signals were 
divided in parts of one second, rectified and smoothed (see respectively Figure 1A, IB 
and 1С) Subsequently, the data were subjected to a fast-founer transformation (FFT) per 
block of 1 second This analysis offered two parameters (see Figure ID) a) the power 
per second being the area under the curve of the EMG signal per second; and b) the 
frequency distribution curve per second The power values of all recorded seconds (3600) 
were summed per rat and served as a measure for the overall muscle activity (dependent 
variable no. 1). Besides this the power was also used as a criterium for the assignment of 
a frequency to a second (see below) A dominant frequency range was determined per 
second in the following manner First, frequencies below 3 Hz were excluded because 
visual analysis of the actual recordings revealed that jaw muscle contractions with a 
frequency lower than 3 Hz were highly unusual in this study Due to the relative lack of 
124 
FR 
Э- 1 
4- 5 
5- 6 
6- 7 
7- a 
a- 9 
9-10 
10-11 
11-12 
1?-13 
13-11 
14-15 
15-16 
16-17 
17-1Θ 
18-19 
19-50 
»FDC 
5 69 
4 55 
Э 29 
5 76 
17 59 
18 го 
6 35 
5.05 
5 3β 
3 54 
3 35 
Э 96 
4 49 
4 51 
г 68 
1 17 
1 56 
В 10 íc 
Frequency 
FIG I. Mosl imponant steps in Ihe analysis of EMG signals. For de-
scription of the method, see the Method Section. EMG signals were 
high-pass Altered (80 Hz) and divided in pans of I s (Л). Subsequently, 
the signal was reclined and smoothed (B and С respectively). Next, the 
data were subjected to a FFT per block of I s This analysis offered two 
parameters (D): I ) the power per second as an absolute value (viz., the 
area under the curve of the EMG signal per second) and as a percentage 
of the highest power found in the entire observation period and 2) the 
frequency distribution curve per second. Then, the proportional contri­
bution of the area between two consecutive frequencies under the fre­
quency distribution curve (3-20 Hz) was calculated (E), of which the 
largest was called the dominant frequency range. FR. frequency range; 
%FDC proportional contribution of the area under the frequency dis­
tribution curve 
these frequencies, the influence of artifacts resulting from the FFT becomes exceptionally 
high in these lower frequency ranges. Such artifacts occur for instance when a second 
contains a high frequency signal which starts after 0.5 second; in such a case the results 
of the FFT will include, besides the high frequency peak, also an artificial 2 Hz peak. 
The latter was considered to be another reason for excluding frequencies below 3 Hz in 
the present study. Second, frequencies above 20 Hz were also excluded because their 
contribution was found to be negligibly small in the present series of experiments. In fact, 
post-hoc analysis revealed that even the frequencies 15-20 Hz were absent in the present 
experiments. Subsequently, the proportional contribution of the area between two 
consecutive frequencies under the frequency distribution curve (3 to 20 Hz) was 
calculated per second (see Figure IE). The proportionally greatest area under the curve 
between two consecutive frequencies was labelled as the dominant frequency range. In 
125 
order to assign a frequency range to a second, two conditions had to be fulfilled. (A). 
The dominant frequency range had to be a salient feature of the second under study. For 
that reason, the proportional contribution of the dominant frequency range per second had 
to surmount a minimum percentage (14%) of the total area under the frequency 
distribution curve (3 to 20 Hz) of that second. (B). The EMG activity per se had to be a 
salient feature of the second under study. For that reason all seconds were compared as 
far as it concerns their power: the power of the second under study had to surmount a 
minimum percentage (25%) of the highest power found per second throughout the 
observation period. Only when both restrictions were fulfilled, was a frequency range 
assigned to the second under study; otherwise the second was not taken into account. 
Drug-induced effects upon frequency ranges were quantified in terms of total number of 
seconds marked by a particular frequency range. The latter served as additional, 
dependent variable in this report. 
Drugs 
±SKF 38393 hydrochloride (SKF; Research Biochemicals Inc. USA) and LY 171555 
(LY; kindly donated by Eli Lilly and co.) were dissolved in distilled water. Drugs were 
injected bilaterally in a dose of 5 μg (SKF; n=7), 10 μg (LY; n = 8) and a combined 
injection of 5 μg SKF + 10 μ% LY (SKF + LY; η =7). These doses were purposely 
chosen because they have been found to elicit oral behaviour in at least one design, in 
which they were locally administered into the nucleus accumbens of rats (9). Control 
injections consisted of distilled water (n = 7). 
Statistical analysis 
Data were square root transformed and analysed in a multivariate analysis of variance 
(MANOVA) with two factors, each at two levels (Dl-factor: H20 and SKF; D2-factor: 
H20 and LY). In this analysis the Dl-factor reflects the overall effect seen in the SKF-
versus the control-group and in the SKF + LY- versus the LY-group. Likewise, the D2-
factor reflects the overall effect seen in the LY- versus the control-group and in the 
SKF + LY- versus the SKF-group. The interaction between the Dl- and the D2-factor only 
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FIG 2 Main characteristics of three different EMG signals (1 s) as de-
termined by analysis The high-pass filtered, rectified, and smoothed 
EMG signal was subjected to a FFT per block of 1 s This analysis offered 
two parameters 1) the power per second as an absolute value and as a 
percentage of the highest power lound in the entire observation period 
and 2) the frequency distribution curve per second Subsequently, the 
proportional contribution of the area between two consecutive frequencies 
under the frequency distribution curve (3-20 Hz) was calculated, of which 
the largest was called the dominant frequency range A frequency range 
is assigned to the upper second (A), whereas no frequency ranges were 
assigned to the second in the middle panel (B, %FDC < 14%) and the 
second in the lower panel (C, power < 25%) See also the Results Section 
For abbreviations, see Fig 1 
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reaches a significant value when the effect of the combined administration of SKF and LY 
is synergistic The Duncan multiple range post-hoc test (c*<0 05) was performed to 
determine significant differences between individual groups (H20, SKF, LY and 
SKF+LY) 
Results 
Methodological aspects 
Figure 2 illustrates how the dependent variables were derived from the EMG signals Per 
second selected, the frequency distribution curve as well as the proportional contribution 
of the area under the frequency distribution curve between two consecutive frequencies 
are shown Furthermore, the power value is given in absolute terms and as a percentage 
of the highest power found per second in the entire observation period In the upper 
fragment a frequency range was assigned to the second shown (Figure 2A) In the lower 
two fragments no frequency range was assigned, because either the area of the dominant 
frequency range did not surmount the minimum percentage (14%) of the total area under 
the frequency distribution curve of that second (Figure 2B, 13%) or the power found in 
the second under study did not surmount the minimum percentage (25%) of the highest 
power found per second in the entire observation period (Figure 2C, 12%) 
Effects of intra-actumbens administration of SKF and LY 
SKF alone and/or combined with LY (Dl-factor) as well as LY alone and/or combined 
with SKF (D2-factor) were found to have a clearcut overall effect upon the variables 
studied In fact, the MANOVA showed that there was a highly significant overall effect 
of the Dl-factor (F(12,14) = 10 48, p<0 0001) and the D2-factor (F(12,14)=13 94, 
p<0 0001), but not of the interaction between these factors (F(12,14)=0 68, p=0 79) 
The effects of the various treatments on the power are given in Table 1 ANOVA analysis 
with respect to the power as dependent variable showed that there was only a significant 
interaction between the Dl- and the D2 factor as far as it concerns the digastric muscle 
(Table 1), indicating that SKF and LY acted synergislically Post-hoc analysis showed 
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T A B L E 1 
EMG ANÁLISIS Oh TWO JAW MUSCLES 
Interaction Between 
Variable D Tactor D : Factor D, and D ; Factors 
Masseter muscle 
Power 
Class A 
С lass В 
ClassC 
Digastric muscle 
Power 
Class A 
Class В 
Class С 
Results of the analysis of the ГМО signals of the masseler and the 
digastric muscle after administration of distilled water SKF LV. or 
SKF ' LS. in the nucleus accumbens Besides the power the number of 
seconds grouped per class ol Irequenev ranges are shown (see the Results 
section) class A = frequenta range 1 4 Hz class В = frequence ranges 
4 s and 5-6 Hz class С = Irequenev ranges 6-7 7-8 12-13 
and 13-14H? Significant increases · ;>< 0 05 t / i < 0 01 J i x O O O l 
Significant decrease !} ¡ι < 0 001 
that the power of the SKF + LY-group was significantly greater than that seen m the LY 
group Concerning the analysis of the drug-induced effects upon distinct frequency 
ranges, it was found that the effects could easily be described with the help of three main 
classes of frequency ranges, in which the distinct frequency ranges were similarly 
affected. For that reason, the analysis was limited to the following classes: class A = 
frequency range 3-4 Hz, class В = frequency ranges 4-5 and 5-6 Hz; class С = 
frequency ranges 6-7, 7-8, ., 12-13 and 13-14 Hz The seconds marked by frequency 
ranges > 13-14 Hz could not be grouped into one or more classes, since they simply did 
not occur. The effects of the various treatments upon the classes Α-C are also shown in 
Table 1. This table shows that class A was not influenced by the Dl- or D2-factor. The 
Dl-factor, however, affected class В in the masseter muscle as shown in Table 1, the 
variable in question was significantly increased. Still, the post-hoc analysis showed that 
there were no significant differences between the four groups (Figure 3), indicating that 
SKF alone had only a minor effect In contrast, the Dl- and D2-factors significantly 
affected class С in both the masseter and the digastric muscle The interaction between 
the Dl- and the D2 factor, however, was not significant in any of the muscles, excluding 
thereby the presence of a synergistic action between both factors. Anyhow, post-hoc 
analysis showed that class С was significantly increased in the SKF-group, and 
X § 
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FIG 3 Effects of bilateral injections ol distilled water ^ Mg SKF 10μ§1Λ and 5 ßg SKF + 10 μ§ LY into the nucleus accumbens upon power and 
frequency range classes А С Data were summed over the hour and square root transformed Significant group differences were determined with the 
Duncan multiple-range posthoc lest *p < 0 05 Bars denote SFM 
significantly decreased in the LY-group, when compared to the control-group. Moreover, 
the effect in the SKF-group was significantly greater than that seen in the SKF + LY-
group, which itself did not differ from the control-group (Figure 3) 
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Discussion 
Methodological aspects 
The method that is presented here provides an objective and automated way to 
quantitatively analyse EMG signals in freely moving animals With this EMG analysis it 
is possible to differentiate between power and frequencies, viz two important 
characteristics of EMG signals Furthermore, distinct frequency ranges can be separately 
studied The value of these dependent variables is illustrated by the results of an 
experiment in which the effects of intra accumbens administration of SKF and LY on two 
jaw muscles were studied Before discussing the outcome of this experiment it is 
necessary to evaluate the pros and cons of the method used First, the method allows one 
to study unrestrained animals which can display any behaviour In this respect the method 
is superior to the available tube-test and the spinally transected rat-test (see Introduction) 
Second, the method allows one to analyse EMG signals in an objective manner 
Accordingly, the method does not suffer from the drawbacks characteristic of a visual 
analysis of EMG signals personal bias and/or subjective measurements are no longer 
influencing the outcome of the study Still, the present method has its limitations too 
First, it does not solve the problem of variability resulting from the placement of 
electrodes This placement, common to all EMG studies, remains an obvious source of 
variability In the present study, however, we tried to minimise this variability by 
correcting differences in placement of individual electrodes through adjustement of the 
amplification of the EMG signal in the beginning of the experiment The amplification of 
the signal was set at 100% for each muscle during grooming, a behaviour which was 
found to induce the highest amplitude in both jaw muscles Even when this technique is 
insufficient to reduce possible differences between individual rats, there is no reason to 
assume that such differences were non randomly divided across the various groups 
Second, the method itself is not free of decisions to be taken by the investigator For 
instance, it had to be decided when a frequency range should be assigned to a second In 
the present study this was done under strictly defined conditions, viz the dominant 
frequency range had to surmount a minimum percentage (14%) of the total area under the 
frequency distribution curve of that second, and the power of that second had to surmount 
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a minimum percentage (25%) of the highest power per second found in the entire 
observation period (see Material and Methods) The selection of these minima required a 
decision of the investigator In the present study this selection was made on the basis of a 
comparison of the results of the EMG analysis and the occurrence of behavioural effects 
Subsequent comparison of relevant and irrelevant parts of the recordings was used to 
define the above-mentioned minima Another decision to be taken by the investigator dealt 
with the frequencies to be studied As explained in the Material and Methods section, one 
of the entena was the incidence of a frequency throughout the entire observation period 
(frequencies <3 Hz and >20 Hz rarely occurred and were therefore excluded) In 
studies on effects of chronic administration of neuroleptics, for instance, frequencies of 
jaw movements below 3 Hz are known to increase (6) Accordingly, such studies should 
include the analysis of these lower frequencies Third, assessment of the dependent 
vanable "number of seconds marked by a distinct frequency range" implies that the 
subsequent analysis only deals with a subset of seconds, but not with the whole 
observation period The latter among others explains why measurements of power and 
number of seconds marked by distinct frequency ranges highlights different aspects of the 
EMG signals studied Fourth, the presently chosen lower limit of the power as a criterion 
for the assignment of a frequency range to a second (see above) implies that changes in 
tonic EMG signals could not be detected in terms of changes in the seconds marked by 
frequency ranges Given these limitations and knowing the impact of the decisions to be 
taken, the method can easily be assessed in a variety of EMG studies on the condition that 
the decisions are taken in view of the goal of the study to be performed 
Intra-accumbens administration ofSKF and LY 
The most significant effects of SKF and LY were seen in the analysis of class С in both 
muscles Intra accumbens administration of SKF increased class C, whereas íntra-
accumbens administration of LY decreased it Thus, the number of frequency ranges 
between 6 and 14 Hz were increased by SKF and decreased by LY in the masseter and 
digastric muscles These data suggest that at least the information directing these 
frequencies in both muscles can be funneled via a common pathway The data do not 
exclude the possibility that the Dl and D2 receptors directing this information are even 
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located on the same neuron Anyhow, Dl receptor stimulation results in effects 
diametrically opposite to those elicited by D2 receptor stimulation. As far as we know, 
this is the first behavioural study that reports opposite effects of a Dl and a D2 receptor 
agonist within the nucleus accumbens. These results are in line with the outcome of an 
electrophysiological study in which intracellular recordings of nucleus accumbens slices 
were used to illustrate opposite effects of a Dl and a D2 agonist (11). 
In contrast, simultaneous administration of SKF and LY increased the power of the 
digastnc, but not the masseter, muscle in a synergistic manner. As shown in Table 1, a 
significant interaction between the Dl- and D2 factor was found in this case. Still, the 
overall MANOVA did not reach significance in this respect. Despite of this, the power of 
the digastric muscle in the combined SKF+LY-group was larger than that in the other 
three groups, reaching a significant difference with the LY-group (Figure 3). These 
findings together suggest that SKF and LY act synergistic only as far as it concerns the 
power of the digastnc muscle These data reveal two relevant features. First, they show 
that the information directing the overall activity of the masseter muscle cannot be 
funneled via the pathway that funnels the overall activity of the digastnc muscle. Second, 
the present data suggest that the Dl and D2 receptors within the nucleus accumbens act 
synergistic only in the case of the overall activity of the digastnc muscle. In this context 
it is interesting to note that such a synergistic effect on the amplitude of the EMG signal 
of the digastric muscle also occurs after systemic administration of SKF and LY (10). 
Synergistic effects of Dl and D2 receptor stimulation in the nucleus accumbens are found 
in several other studies with respect to rhythmic jaw movements (9), locomotor activity 
(4) and extra-cellular recordings of nucleus accumbens slices (13). 
Besides this single synergistic effect, simultaneous Dl and D2 receptor stimulation in the 
nucleus accumbens induced only additive effects in the present study (see Results). 
In sum, the method presented here provides an objective and automated way to 
quantatively analyse EMG signals in freely moving rats. Given this method it is now 
possible to describe oro-facial movements such as vacuous chewing, tremor, etc. in terms 
of the mentioned EMG-parameters As already known, intra-accumbens administration of 
SKF, LY and their combination are able to elicit oral movements in a drug-specific 
manner (7) Once the behavioural effects can be descnbed in terms of EMG-changes 
(Pnnssen et al , in prep ), it becomes also possible to establish whether the effects elicited 
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by SKF and LY in this study have to be considered as normal behaviours of which just 
the frequency and/or duration are affected, or as abnormal, dyskinetic behaviours which 
are absent, or nearly absent, in untreated animals. In other words, the present method is 
believed to lay a firm foundation for studies on the nature and occurence of oral 
movements in animal models of oro-facial dyskinesia in man. 
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Chapter 9 
Involvement of the nucleus accumbens in oral behaviour in the freely moving rat 
Abstract 
The role of the nucleus accumbens in oral behaviour was examined by intra-accumbens 
injections of a single dose of a selective dopamine D, receptor agonist (SKF 38393: 5 
μ§/5ΐ(ίε), a selective dopamine D2 receptor agonist (quinpirole: 10 μg/slde), and their 
combination in freely moving rats. Principal factor analysis revealed four factors to be 
involved in the scored behaviours, two of which concerned oral behaviour· a Chew 
factor, comprising the behaviours chew, tongue protrusion, yawn and lick, and a Groom 
factor, with high factor loadings of tremor and groom The two remaining factors were 
the Circle factor comprising circle, walk and rear, and the Sniff factor comprising sniff, 
yawn and rear Two-way ANOVA (D, class with H20 and SKF 38393 level; D2 class 
with H20 and quinpirole level) of the factor scores revealed that SKF 38393 and 
quinpirole had similar or opposite effects which were additive or antagonistic, depending 
on which behaviour was studied. 
This study demonstrates that (a) the nucleus accumbens plays a major role in the oral 
behaviour of freely moving rats, and (b) an integrated study of all oral behavioural 
elements is necessary to describe the effects of drugs on oral behaviour. 
Introduction 
The result of behavioural studies suggest that dopamine D, and D2 receptors are involved 
in various oral activities in the rat Oral behaviour can be elicited by dopamine D, 
receptor agonists and dopamine D2 receptor antagonists (Rosengarten et al., 1983), 
although the dopamine D, receptor-mediated effect is not always found (Murray and 
Waddington, 1989) The number of dopamine D2 receptors has been found to be 
negatively correlated with the number of repeated jaw movements (Rosengarten et al., 
1986). However, the function of dopamine D2 receptor agonists in oral behaviour remains 
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obscure Dopamine D2 receptor agonists alone have been reported to inhibit (Ellison et 
al , 1987), not to influence (Amt et al , 1987) and to elicit oral movements (Moody and 
Spear, 1989, Johansson et al , 1987, Collins et al , 1991), they can also induce yawning -
behaviour (Longoni et al , 1987) The dose of the drug injected is important in this 
respect A low dose of the dopamine D2 receptor agonist quinpirole has been found to 
suppress all activity In contrast, a high dose of quinpirole has been found to elicit 
sniffing and head movements, but to suppress oral movements Extremely high doses of 
the dopamine D, receptor agonist SKF 38393 have been found to increase general activity 
(Molloy and Waddington, 1985), whereas intermediate doses have been found to induce 
grooming selectively (Molloy and Waddington, 1984) Dopamine D, and D2 receptors 
have been suggested to mediate opposite effects on vacuous chewing (Rosengarten, et al 
1983, Murray and Waddington, 1989, Johansson et al , 1987) Dopamine D, and D2 
receptors are also known to act cooperatively in grooming and in a variety of other motor 
behaviours (Arnt et al , 1987, Braun and Chase, 1986, Robertson and Robertson, 1987, 
Murray and Waddington, 1989) Apparently, the balance between dopamine D, and D2 
receptors seems to determine the behavioural outcome (Rosengarten et al , 1988) The 
above-mentioned studies reveal that differences in the terminology and the definition of 
oral behaviour make comparisons difficult (see also Waddington, 1990) The site for these 
dopaminergic actions may be the striatum, more specifically the ventrolateral striatum and 
the nucleus accumbens Pharmacological activation of the dopaminergic ventrolateral 
striatum elicits oral behaviour in rats (Kelley et al , 1988, Koshikawa et al , 1989, Delfs 
and Kelley, 1990) A dopaminergic striatal subregion is also involved in oral behaviour in 
cats (Spooren et al , 1990) In ketamine anaesthetised rats with a spinal CI transection 
Koshikawa et al (1990) have found that combined administration of the dopamine D, 
receptor agonist SKF 38393 ^g/side injected bilaterally) and the dopamine D2 receptor 
agonist quinpirole (10 ^g/side) into the nucleus accumbens increases rhythmic jaw 
movements The goal of the present study was to investigate whether the nucleus 
accumbens also plays a major role in oral behaviour in freely moving rats The dopamine 
D, receptor agonist SKF 38393 and the dopamine D2 receptor agonist quinpirole were 
administered into the nucleus accumbens of freely moving rats, either alone or in 
combination The doses 5 μ% SKF 38393 and 10 μg quinpirole - were selected on basis 
of the study of Koshikawa et al (1990) It was decided to perform an integrated study by 
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measuring oral behaviour and gross motor behaviour and by recording muscle movements 
with the aid of EMG. The EMG results are published elsewhere (Prinssen et al., 1992). 
Materials and methods 
Subjects 
Naive, male Wistar rats (n=34, Central Animal Laboratory, Nijmegen) were used. 
Before operation they weighed between 175 and 190 grams. Rats were individually 
housed and kept on a 12-h day/night cycle with lights on at 8.00 a.m. and off at 8.00 
p.m. Food and water were available ad libitum. 
Surgery 
Animals were anaesthetised with sodium pentobarbital (Narcovet, 60 mg/kg i.p.). 
Stereotaxic implantation of guide cannulae into the nucleus accumbens (König and Klippel 
(1963): anterior 9.8, vertical 2.7, lateral 1.2) was done according to previously described 
procedures (Prinssen et al., 1992) via guide cannulae (5 mm length, 0.65 mm outer 
diameter, 0.30 mm inner diameter) 5 mm above the skull. The cannulae were angled 11 
degrees from the mid sagittal plane to avoid the ventricular system and to leave space for 
an EMG connector. Cannulae were fixed to the skull with dental cement (Durelon, ESPE; 
carboxylate cement) and two screws. Electrodes were placed in the musculus masseter 
and digastricus after the skin over the cheek and lower mandible had been opened (for 
details see Prinssen et al., 1992). The 5-pole EMG connector was attached to the skull 
with dental cement. 
Apparatus 
Rats were observed in a 25 cm χ 25 cm χ 35 cm cage of Plexiglas. A mirror (angled at 
45 degrees) was mounted beneath the cage to allow the precise recording of behaviour, 
especially of oral movements. Behaviour was registered on a protocol panel with 16 
channels. The EMG signals (via a swivel, pre-amplifier, 50 Hz filter) and the behavioural 
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responses were recorded on an instrumentation recorder (Hewlett Packard 3960, 3968A 
with Agfa Professional РЕМ 639 tape) 
Procedure 
After surgery the rats were housed individually in the original stockroom and allowed to 
recover from operation for at least one week Non-habituated, drug-naive rats were 
observed immediately after injection Bilateral injections were given by means of a 5 μ\ 
Hamilton syringe with a 0 25 mm needle that extended into the brain tissue 2 mm below 
the tip of the permanently embedded cannula The injection volume was 0 5 μ\ per side 
injected over a 10 s penod, and the needle was left in situ for another 10 s to minimise 
diffusion along the needle tract After the cord had been connected to the swivel the 
subjects were placed in the middle of the observation cage, and recording started 
immediately The injection sites were identified histologically, and only data from 
subjects with injections made into the desired sites were analysed further Testing lasted 
60 minutes per animal and took place between 9 00 and 17 00 hr 
Behavioural observations 
For observation of behaviour the following ethogram of behavioural elements was 
defined (1) tremor (rhythmic movements rapid oscillations of cheek and/or lower jaw), 
(2) chew (movement of the lower jaw vertical and/or lateral in a single or repeated 
fashion with or without an object between the teeth), (3) tongue protrusion (not aimed at 
an object), (4) yawn (wide opening of the lower jaw with bare teeth), (5) lick (repeated 
tongue protrusion aimed at an object), (6) groom (face washing, licking the fur and 
scratching), (7) walk (diverse locomotion), (8) sniff (exploratory behaviour with moving 
vibnssae), (9) rear (standing upon hind paws freely and/or against a wall), (10) circle 
(turning in one direction during locomotion) and (11) immobility (absence of any 
displacement of three or four paws) Rapid chains of identical elements of behaviour 
(bouts) were scored as single occurrences, this was especially true for tremor and chew 
which occurred too rapidly to record single movements Durations [tremor, chew, lick, 
groom, walk, sniff, rear, immobility] or frequencies [tongue protrusion, yawn, circle] are 
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analysed and presented. 
Drugs 
+ SKF 38393 hydrochloride (Research Biochemicals Inc. USA) and quinpirole (Eli Lilly 
and co.) were dissolved in distilled water. Drugs were injected bilaterally in an amount of 
5 μg I 0.5 μΐ SKF 38393 and 10 μg I 0.5 μ\ quinpirole. Four groups were formed: one 
group receiving control injections of distilled water, one group receiving SKF 38393, one 
group receiving quinpirole and one group receiving the combination of SKF 38393 and 
quinpirole. 
Statistical analysis 
For analysis, data for the duration or frequency of the 11 behavioural elements, recorded 
over lh, were transformed logarithmically (duration) or by taking the square root 
(frequency). Principal factor analysis with varimax rotation was done to reveal the factor 
structure underlying the variables (procedure Factor of SAS, 1991). This was done also 
on the partial correlations, with the correlations being controlled for the influence of the 
D, and the D2 class. Factor scores of extracted factors were analysed in a two way 
analysis of variance with between-subject classes D, and D2. Main effects found in this 
analysis indicate that SKF 38393 and/or quinpirole have effects in the four groups. An in­
teraction between the D, and the D2 class indicates that the combination of SKF 38393 
and quinpirole has synergistic or antagonistic effects; the absence of an interaction 
indicates that the main effects are additive. Duncan post-hoc tests were done to determine 
differences among the four groups. 
Results 
General results 
The behavioural elements observed were tremor, chew, tongue protrusion, yawn, lick, 
groom, walk, sniff, rear, circle and immobility. The effects of H20, SKF 38393, 
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quinpirole and SKF 38393 + quinpirole on these behavioural elements are shown in 
figure 1 The total sum of the means per group per hour was set at 100% to facilitate 
comparison between the effects of the different drugs SKF 38393 seemed to increase 
tremor, while quinpirole seemed to decrease tremor and groom, but increased yawn, walk 
and circle were increased after administration of SKF 38393 + quinpirole 
trefrcr crew Юпдде ,awi ct д о т " * a * s« rt rear с le runod у 
Fig 1 Behavioural profile The relative differences between the I I О group (open irei) SKI 1X491 group (wide striped area) quinpu ík t ioup 
(netted area) and SKF 48101 + quinpirole group (striped area) ire shown The ihsolule πκ in lri.qut.nty pir houi (tongue proliu ι n \jwii 
circle) or duration in seconds (tremor chew lick groom walk smll re ir and immohihH) ol the beha\i tur il dements in. u u n in the iluinils 
Principal factor analysis of behaviour 
Different oral behaviours can appear in sequences (Spooren et al , 1990) and hence are 
correlated to each other To investigate this possibility, principal factor analysis was done 
with the 11 behavioural elements selected in this study Four factors were found that 
explained 76% of the variance (table 1) To control for correlations directly caused by the 
drugs and thus rule out the influence of the D, and the D2 class, a second principal factor 
analysis was done on the partial correlations between the variables, controlling for the D, 
and D2 class (partial principal factor analysis SAS) [results are presented between 
brackets in table 1] Again, four orthogonal factors were found to explain 70% of the 
variance The factors were similar to those found in the uncorrected analysis Further 
analyses were based on the factor scores of the uncorrected principal factor analysis The 
first factor found explained 28% of the variance and had significant loadings of chew, 
tongue protrusion, yawn and lick The second factor, which explained 19% of the 
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lABLL· 1 
I actor loadings of the rotated factor p a t u m aft<_r principal I at tor analvMS with \anma\ rotation ol behavioural elements of 44 rats treated with 
Η , Ο SKF 3X393, quinpirole and SKF 38193+ quinpirole 
Hetween parentheses the rotated factor pattern of the partial correlation malnx is shown controlled for the LMeet ol the independent variables 
D, and D
:
 Explained rc shows the percent variance explained by the factor cumulative cc is the summation of explained \ananct over the 
l.ictors starting with factor 1 
Factor 
1 2 3 4 
I rcmor 
С hew 
Tongue prolrusion 
Yawn 
Lick 
Groom 
Walk 
Sniff 
Rear 
Circle 
Immobility 
eigenvalue 
Txplained c'c 
Cumulative °/c 
1 .ibel 
0 08 
0 87» 
0 84 * 
0 7 1 ' 
0 6 3 ' 
- 0 0 4 
0 22 
0 00 
0 10 
поз 
0 08 
ι π 
28 
28 
Chew 
(0 24) 
(0 88)» 
(0 77)D 
(0 81)» 
(0 62) " 
( - 0 03) 
(0 13) 
( - 0 02) 
( - 0 03) 
( - 0 08) 
(0 08) 
(271) 
(25) 
(25) 
- 0 01 
0 12 
0 22 
0 03 
- 0 09 
- 0 16 
0 84 -
- 0 12 
0 67 1 
0 86» 
- 0 50 " 
2 11 
1" 
48 
Circle 
(0 19) 
(001) 
(0 17) 
(0 04) 
( - 0 37) 
( - 0 1 1 ) 
(OHO)·1 
( - 0 52)» 
(0 29) 
(0 81)» 
( - 0 10) 
(2 02) 
(18) 
(43) 
- 0 19 
0 12 
- 0 13 
- 0 1 7 
0 52» 
- 0 05 
- 0 18 
0 87» 
0 4 4 ' 
003 
- 0 76 » 
1 67 
15 
63 
Sniff 
(0 17) 
(0 00) 
(0 14) 
(0 13) 
( - 0 33) 
( - 0 02) 
(0 04) 
( - 0 66)» 
( - 0 6 5 ) » 
( - 0 1 7 ) 
(0 8 7 ) ' 
(1 70) 
(15) 
(58) 
0 82» 
0 11 
0 12 
- 0 5 1 ' 
- 0 09 
0 86 ' 
- 0 06 
- 0 15 
0 03 
- O H 
0 09 
1 48 
14 
76 
Groom 
(0 55)» 
(0 11) 
(0 10) 
( - 0 08) 
( - 0 04) 
(0 92)» 
(0 13) 
( - 0 16) 
(0 39) 
(-(109) 
(0 23) 
(1 28) 
(12) 
(70) 
Significarli fauor loading (P < 0 01) 
variance, comprised walk, rear and circle, and had a negative loading of immobility. The 
third factor explained 15% of the variance and had significant loadings of sniff, lick and 
rear, and a negative loading of immobility. The fourth factor explained 14% of the 
variance and had significant loadings of tremor and groom and a negative loading of 
yawn. The factors were labelled according to the behaviour with the highest loading: 1) 
Chew, 2) Circle, 3) Sniff, 4) Groom. The mean factor scores for these four factors are 
shown in figure 2. Analysis of variance of the factor scores showed a significant 
interaction effect of the D, and D2 class on the Chew factor (F(l,30) = 10.31, P=0.003). 
Duncan post-hoc analysis showed that the Chew factor scores of the SKF 38393 and 
quinpirole group were significantly higher than those of the H20 group (fig. 2; Ρ <0.05), 
while the scores of the SKF 38393 + quinpirole group were significantly lower than 
those of the quinpirole group (fig. 2; Ρ<0.05). The scores of the Circle factor showed 
significant effects of the D, class (F(l,30)=9.16, P=0.005) and the D2 class 
(F(l,30)=9.34, P=0.005). Duncan post-hoc test shows that the scores of the SKF 38393 
+ quinpirole group were significantly higher than those of the three other groups (fig. 2; 
Ρ<0.05). On the Sniff factor a significant effect of the D, class was found 
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(F(l,30)=4.56, P=0.041). However, Duncan post-hoc analysis showed no significant 
differences between groups. Both the D, class (F(l,30)=5.60, P=0.025) and the D2 class 
(F(l,30) = 18.70, P=0.000) had a significant effect on the Groom factor. Duncan post-hoc 
analysis showed that the Groom factor scores of the SKF 38393 group were significantly 
higher than those of the quinpirole and SKF 38393 + quinpirole groups (fig. 2; 
Ρ < 0.05), and that the scores of the H20 group were significantly higher than those of the 
quinpirole group (fig. 2; Ρ< 0.05). 
Спел L r c e S u l jrt r 
I ador 
Fig 2 Mean factor scores on the four factors chew circle sniff 
and groom Group identification H
:
0 group (open area) SKF 
38391 group (wide striped area) quinpirole group (netted area) and 
SKF 18194 + quinpirole group (striped area) S F M s are given 
Significant differences with respect to the H ; 0 group arc shown in 
the figure (*P<()0*>) See text for all significant differences he 
tween groups 
Discussion 
Methodology 
Oral behaviour can be registered accurately in fixed (Ellison et al., 1987) or fixed and 
anaesthetised (Koshikawa et al., 1990) rats. The results obtained are different from those 
found with freely moving animals (Johansson et al., 1987). In this study we investigated 
the effects of local administration of a dopamine DL receptor agonist (SKF 38393) and a 
dopamine D2 receptor agonist (quinpirole) in the nucleus accumbens on oral behaviour of 
freely moving rats in a new environment. Although we were primarily interested in oral 
behaviour, we also recorded the effects on more general motor behaviour to detect a 
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possible interaction with oral behaviour. Scoring the behaviour of a freely moving animal 
in a restricted environment was facilitated by placing a mirror under the cage to see jaw 
movements from underneath and by using an ethogram together with EMG, the results of 
which are presented elsewhere (Prinssen et al., 1992). Principal factor analysis of the oral 
behaviour revealed important relations between the different behavioural elements. 
Accounting for these relations by means of factor scores provided information about the 
complexity of oral behaviour and highlighted the risk of concentrating on only one 
behavioural element. The most important finding is that the behavioural elements chew 
and tremor loaded on separate factors. In many studies only one of these behaviours was 
studied or both were combined (see Waddington, 1990) on the assumption that there is a 
direct relation between the two behaviours. The results of this study show that chew and 
tremor must be interpreted separately. Although combined administration of SKF 38393 
and quinpirole did not increase oral behaviour (cf. Koshikawa et al., 1990), it is possible 
that an effect was not seen because of the increase in the behavioural elements circle and 
rear. This increase in activity could have hampered the observation of oral behaviour. 
However, the EMG registrations did not reveal an increase in rhythmic oral muscle 
discharges when SKF 38393 and quinpirole were administered in combination (Prinssen et 
al., 1992). It is therefore likely that oral behaviour did not occur during the circle and re-
ar activity. 
Nucleus accumbens 
The results obtained after intra-accumbens injections unambiguously show the invol-
vement of the nucleus accumbens in oral behaviour. The dopamine D! receptor agonist 
SKF 38393 and the dopamine D2 receptor agonist quinpirole had antagonistic effects on 
the Chew factor. SKF 38393 and quinpirole both significantly increased Chew factor 
scores, but SKF 38393 and quinpirole antagonised each other when administered together 
(cf. Uchimura et al., 1990). These data are not in agreement with the results of 
Koshikawa et al. (1990) who showed that rhythmic jaw movements were increased 
significantly by the combination of SKF 38393 and quinpirole. However, the latter 
authors found that their synergistic effects occurred only after a latency of about 60 
minutes. Because we analysed the initial 60 minutes, we may have overlooked this effect. 
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Still, it cannot be excluded that differences in the experimental set-up (spinalised and 
anaesthetised rats vs. freely moving rats) underlie this discrepancy. SKF 38393 and 
quinpirole had opposite effects on the Groom factor. Whereas SKF 38393 increased 
Groom factor scores, quinpirole decreased Groom factor scores. The increase in 
grooming behaviour after SKF 38393 administration is in agreement with reports in the 
literature (Molloy and Waddington, 1984, 1985; Murray and Waddington, 1989). SKF 
38393 and quinpirole had additive effects in the same direction on the Circle factor, i.e. 
both increased the occurrence of the behaviours that loaded positively on this factor. Use 
of principal factor analysis revealed the presence of four separate principal factors, two of 
which consist of oral behaviour. The first factor, i.e. the Chew factor represents related 
behaviours, viz. chew, tongue protrusion, yawn and lick, that load on the same factor. In 
contrast, the second factor, i.e. the Groom factor, represents tremor and groom, in which 
tremor appears to have a common basis with groom. The effects of SKF 38393 and 
quinpirole on the Chew factor were antagonistic and were opposite on the Groom factor. 
Thus administration of these dopamine D, and D2 receptor agonists into the nucleus 
accumbens results in a complex pattern of oral behaviour (chew, tongue protrusion, yawn 
and tremor). Since only a single dose of each drug was tested, it is evident that the 
above-mentioned effects of SKF 38393, quinpirole and their combination are insufficient 
for drawing conclusions about the interaction between the dopamine D, and D2 receptor 
systems in the nucleus accumbens. Both dose-response studies and studies analysing 
receptor specificity are required. The present study clearly demonstrated that SKF 38393 
and quinpirole have similar or opposite effects which are additive or antagonistic 
depending on the behaviour studied and that the nucleus accumbens plays a major role in 
the oral behaviour of freely moving rats. The results also show that an integrated study of 
all oral behavioural elements is necessary to describe the effects of drugs on oral 
behaviour. 
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Chapter 10 
Evidence for a role of the shell of the nucleus accumbens ¡n oral behaviour of freely 
moving rats 
Abstract 
Behavioural effects of intra accumbens administration of the dopamine DA, receptor 
agonist (3,4-dihydroxyphenylimino) 2-imidazoline (DPI) were studied in freely moving 
rats Three distinct areas were examined core, shell and 'shore', viz the border region 
of the core and shell DPI (5 ¿ig) administered into the shell, but not areas ventral to the 
shell, increased chewing, tongue protrusion, sniffing and grooming, it also induced 
abnormal oral behaviour, viz large amplitude chewing A similar dose of DPI 
administered into the core did not affect any (pen-)oral behaviour, except sniffing 
Because of methodological constraints the receptor-specificity of the DPI effects was 
studied in rats with cannulas directed at the shore DPI (5 0-10 0 ^g) administered into 
the shore increased dose dependently oral behaviour, however, the dose effect curve 
varied per distinct type of oral behaviour The dopamine DA, receptor antagonist 
ergometrine attenuated the effect of DPI on tremor, chewing and sniffing frequencies 
Taken together, the data show that the effects of DPI were DA, receptor specific It is 
concluded that stimulation of dopamine DA, receptors in the shell modulates and induces 
(pen )oral behaviours in freely moving rats 
Introduction 
The idea that the nucleus accumbens is a homogeneous structure is disappearing During 
the last 10 years differences have been found between core and shell with respect to 
anatomy (Zaborsky er al , 1985, Voorn er al , 1989, Heimer er al , 1991, Berendse et 
al , 1992, 7ahm and Brog, 1992, and others), receptor density (Bardo and Hammer, 
1991), pharmacology (Deutch and Cameron, 1992) and electrophysiology (Pennartz, 
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1992). Still, with respect to behaviour of freely moving rats no studies on differences 
between core and shell have been performed. Therefore, the aim of this study was to 
analyse the role of different parts of the nucleus accumbens in modulating behaviour. 
The nucleus accumbens modulates oral behaviour in rats (Bordi et al., 1989; Cools 1990; 
Koshikawa et al., 1990, 1991; Prinssen et al., 1992; Koene et al., 1993). It has been 
found that intra-accumbens administration of the dopamine DA¡ receptor agonist DPI 
increases oral behaviour in rats (Cools, 1990). In cats, the same drug (DPI) has been 
found to induce abnormal, oral movements, viz. oro-facial dyskinesias, when 
administered into a striatal sub-area, the r-CRM (Cools et al., 1976; Spooren et al., 
1991). Accordingly, DPI was considered to be a valid tool to study the putative, 
differential involvement of the core and shell of the nucleus accumbens in oral behaviour 
of freely moving rats. In the present investigation the behavioural effects of DPI-
injections into the core were compared with those elicited by DPI-injecions into the shell. 
The outcome of this study shows that administration of DPI (5 ^g) into the shell, but not 
the core, increased and induced oral behaviours. However, since it was difficult to hit the 
shell correctly, the 'shore', viz. the border region of the core and shell was chosen as the 
target area for studying the specificity of the DPI-induced effects. First, a dose-effect 
curve was made. Second, DPI was combined with the dopamine DA; antagonist 
ergometrine (Struyker Boudier et al., 1975; Cools et ai, 1976). 
Materials and methods 
Subjects 
Naive, male Wistar rats (n = 7-16 animals per group; Central Animal Laboratory, 
Nijmegen) were used. Before operation they weighed between 180 and 220 grams. Rats 
were individually housed and kept on a 12-h day/night cycle with lights on at 7.00 am. 
Food and water were available ad libitum. Animals were used only once. 
Surgery 
Animals were anesthetized with sodium pentobarbital (Narcovet, 60 mg/kg. i.p.). Guide 
cannulas (0.65 mm outer diameter, 0.3 inner diameter), were stereotactically implanted 
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into the core (anterior 10 0 mm; lateral 1 3 mm), the shell (ant. 9 8 mm; lat. 0.5 mm) or 
the border region of the core and shell (the 'shore', ant 9 8 mm; lat 1.2 mm). Cannulas 
(5 mm length) directed at the core and shore were angled 10 degrees, and cannulas (6 
mm length) directed at the shell were angled 15 degrees from the mid sagittal plane to 
avoid the ventricular system and to leave space for an EMG connector. Cannulas were 
fixed onto the skull with dental cement (Durelon, ESPE; carboxylate cement) aided by the 
attachment of two screws Electrodes were placed in the masseter and digastric muscles 
(for details see Pnnssen et al., 1992) The 5-pole EMG-connector was attached to the 
skull with dental cement 
Apparatus 
Observations were done in a cage of Plexiglas (25 cm χ 25 cm χ 35 cm). A mirror 
(angled 45 degrees) was mounted beneath the cage allowing the precise recording of 
behaviour, especially of oral movements Behaviour was registered using a protocol panel 
with 16 channels. The behavioural protocols (and the EMG signals) were directly read 
into a computer and analyzed by a computer program which calculated the frequency and 
duration of every scored behaviour Since a reliable method allowing the calculation of 
the correlation of the EMG-data and the behavioural data was not yet available, it was 
decided to present the EMG-data that require a completely different analysis, in a separate 
paper (Pnnssen et al , in prep ). 
Procedure 
After surgery the rats were housed individually in the original stockroom and allowed 
recovery from operation for at least one week. After the recovery period, rats were 
handled on three subsequent days and tested on the fourth day The handling and test 
procedures included a habituation time of 45 mm. The rats were handled for 5 min on 
day 1 On day 2 the rats were handled for 5 min and the inner cannulas were taken out 
and put back again On the third day the rats were handled for 5 min, a sham injection 
was given, and the rats were connected to the EMG and placed in the experimental box 
for 10 min On the test day the following paradigm was assessed (see Fig 1) The rats 
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were plact 1 at l = -10 min in the observation box and connected with the EMG device, 
which its 'f did not affect the behavioural freedom of the animals (Koene et αι., 1993). 
Subsequently, intra-cerebral injections were bilaterally given at t=-3 min. Recording of 
baseline activity started at t=0 mm and lasted 30 min (pretreatment session), after which 
the rats were placed in the resting cage. The rats were placed in a new observation box at 
t=50 min. Finally, the animals received their last intra-cerebral injection at t=57 min. 
Recording of the drug effects started at t = 60 min and lasted 30 min (experimental 
session). During the habituation, pretreatment and experimental sessions, the 
environmental conditions were kept constant. DPI and its corresponding control (H20) 
was always given at t=57, whereas ergometrine and its corresponding control (H20) was 
given at t = -3, viz. 60 min before the experimental session. In previous experiments 
(Cools, 1978), it has been found that ergometrine given 60 min prior to DPI has its 
strongest antagonistic action. In order to include a control for future studies on the 
efficacy of putative dopamine DA, receptor antagonists that act immediately after 
administration, rats tested in experiment 1 (Fig. 1) received an additional injection of 
distilled water at t=55 min (Fig. 1). Apart from the fact that distilled water injections 
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into the nucleus accumbens are known to be adequate controls (Pijnenburg et al, 1976), 
such additional injections do not produce any tissue damage as long as the number of 
injections is limited to six (Cools, 1986) Injections were given by means of a 5 μ\ 
syringe with a 0 25 mm needle that extended into the brain tissue below the tip of the 
permanent embedded cannula (1 6 mm for core; 2.0 mm for shore; shell injection depth 
was individually calculated by stereotactic measures, normally about 1.7 mm). The 
volume was 0.5 μ\ injected over a 10 s period, and the needle was left in situ for another 
10 s to minimise diffusion along the needle tract After the experiment rats were 
sacrificed, and brains were dissected. Brain sections were stained with cresyl violet and 
microscopically analyzed In principle, only data from subjects with injections made into 
the desired sites were further analyzed on the condition that no histological damage 
around the injection site was found 
About 50% of the injections directed at the shell were misplaced For that reason, these 
groups were supplemented, untili the required number of animals per group (N=7-9) was 
reached Habituation and testing occurred between 9 00 and 17.00 hr 
Behavioural observations 
The following ethogram of behavioural elements was used to record behaviour- (1) chew 
(movement of the lower jaw vertical and/or lateral in a single or repetitive fashion 
without an object between the teeth); (2) gnaw (movement of the lower jaw vertical 
and/or lateral in a single or repetitive fashion with an object (pieces of straw, faeces or 
the box wall) between the teeth), (3) tremor (rapid oscillations of cheek and/or lower 
jaw), (4) tongue protrusion (not aimed at an object), (5) lick (tongue protrusion aimed at 
an object), (6) yawn (wide opening of the lower jaw with bare teeth), (7) sniff 
(exploratory behaviour with moving vibnssae close to an object), (8) groom (face 
washing, licking the fur and scratching) Continuous succession of identical elements of 
behaviour (bouts) were scored as a single event; this held true for all behaviours except 
tongue protrusion and yawn. Duration (except for tongue protrusion and yawn) and 
frequency of all behaviours were analyzed 
Drugs 
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(3,4-dihydroxyphenylimino)-2-imidazoline (DPI, Boehnnger Ingelheim, FRG) ала 
ergometnne maléate (Sigma, USA) were dissolved in distilled water The pH (5-6) and 
osmolality of the resulting solutions are known to remain devoid of any behavioural effect 
(Pijnenburg et al., 1976). The dose of ergometnne was limited to 0.1 /ig, since higher 
doses are known to produce locomotor activity (Cools et ai, 1986). The drug solutions 
were prepared less than 15 min pnor to the injection Drugs were injected bilaterally 
Statistical analysis 
Given the large individual variation in oral bphavn ars, it was decided to calculate the 
drug-induced changes per rat as follows, the scores collected per rat during the 
pretreatment session were subtracted from the scores collected per rat during the 
experimental session Only the resulting data were statistically analyzed. The effects of 
DPI in the core and shell groups (H20 group vs DPI group) were analyzed with 
two-tailed t-tests (P-values <0.05 considered to be significant; experiment 1) The effects 
of different doses of DPI (experiment 2) were analyzed with a one-way analysis of 
variance (ANOVA) with four levels (H20, DPI 5, DPI 7 5 and DPI 10 groups). In case 
of a P-value <0 05, a post-hoc multiple comparison test (Student-Newman-Keuls) was 
performed The data concerning the experiment in which the ability of ergometnne (0.1 
μg) to antagonize the DPI-induced (5 0 /¿g) effects were investigated, were analyzed with 
a two-tailed t-test {(ERG)DPl vs DPI 5 group) The same test was used to determine 
possible effects of ergometnne alone ((ERG)H20 vs H:0 group), a necessary control 
Results 
Histology 
The injection sites of the animals in the core and shell were only accepted as properly 
placed, when both injection places fell entirely in the desired areas according to the atlas 
of Paxinos and Watson (1986) A representative series of these sites is shown in Fig 2. 
Four animals were discarded because of histological damage found around the injection 
site Subjects with misplaced injections were also discarded apart from those with bilateral 
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injections in areas that were adjacent and ventral to the shell, viz the islands of Calleja 
and the olfactory tubercle (see below) 
higuu ' The areas in which the injection pbecs were located for the core (-<) the shore (fl) and the shell (C ) according to the atlas οΓ Paxinos 
.ind Watson (1986) Representative injection sites arc shown 
Data representation 
As mentioned in the section Materials and Methods, the scores collected during the 
pretreatment session showed a large individual variation Accordingly, it was decided to 
correct the scores collected during the experimental session for those collected during the 
pretreatment session by a subtraction procedure per rat The resulting data are shown in 
Figs 4-7 To illustrate the individual variation in the raw data, the scores of the 
behaviour that showed the strongest effect, viz the DPI-induced increase in chewing 
frequency following its administration into the shell or shore (see below), are given in 
Fig 3 This figure presents the raw scores of the pretreatment and experimental sessions 
of four series of experiments shell, H20 (pretreatment session) - 5 μ% DPI (experimental 
session) and its corresponding control H20 H20, shore, H20 (pretreatment session) - 7 5 
μg DPI (experimental session) and its corresponding control H20 H20 The scores 
collected in the experimental sessions were evidently coupled to the scores collected 
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with respect to chewing Irequcncy Correlations between pretreatment 
and experimental scores were significant (see Results) 
during ihe pretreatment session: in both cases a significant correlation was found between 
pretreatment and experimental scores (the lumped DPI groups: Pearson correlation 
coefficient, R=0.66, P<0.01; the lumped H20 groups: Pearson correlation coefficient, 
R=0.65, P<0.01). Moreover, a linear regression equation was sufficient to adequately 
represent the relation of pretreatment and experimental sessions in both cases (DPI data: 
linear regression, R-square =0.42, F-ratio=10.2 ,P<0.01; H20 data: linear regression, 
R-square=0.44, F-ratio = 10.9, P<0.01). These data together with the finding that the 
coefficient of the lines through each of the data-sets have exactly the same coefficient 
(0.68) provided a firm foundation for the reliability of the subtraction procedure assessed 
to evaluate the data. 
Effects of DPI in the core and shell 
Normal, oral behaviour 
Figure 4 shows the effect of DPI (5 μg) in the core and shell on (pen-)oral behaviours. 
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Since the scores in the pretreatment session were subtracted from those in the 
experimental session, some of these parameters were negative (Fig. 4): in the control 
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groups (H20 groups), oral behaviours occurred less during the expérimental session than 
during the pretreatment session With respect to the effects of DPI, Fig 4 shows clearly 
that 5 ßg DPI was highly effective when administered into the shell, and nearly 
ineffective when administered into the core 
DPI administered into the shell significantly increased the frequency of chewing 
(P=0 03), tongue protrusion (P=0 03), sniffing (P=0 04) and grooming (P=0 04) DPI 
administered into the shell increased the duration of chewing (P=0 001) and sniffing 
(P=0 03), but not of grooming (P=0 38) DPI administered into the shell did affect 
neither the frequency nor the duration of gnawing, tremor, yawning and licking (P>0 1 
for every variable) Since the increase in the chewing frequency was the most prominent 
feature of DPI injections in the shell, this variable was also analyzed in subjects with 
injections in areas that were adjacent and ventral to the shell (N=7) The effect of DPI in 
the latter animals was much smaller than that found in animals with injections placed in 
the shell means + SEM, chewing frequency 17 9 ± 14 8 (outside shell) vs 71 60 ± 
24 6 (inside shell) 
Administration of DPI into the core did affect neither the frequency nor the duration of 
any behaviour, apart from an increase in sniffing frequency (P=0 03) 
Abnormal, oral behaviour 
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separately (Fig 5) Administration of DPI (and, rarely, H20 into the shell), but not the 
core, increased the large amplitude chewing frequency (P=0.04) and duration (P=0.01). 
This behaviour was never observed in untreated rats 
Effects of DPI and ergometrine in the shore 
Normal, oral behaviour 
Fig 6 shows the effects of administration of different doses of DPI into the shore on 
(pen-)oral behaviours One-way ANOVA values were significant for the frequency of 
chewing (F(3,29)= 7 93, P<0 001), gnawing (F(3,29)= 5 63, P=0 004), tremor 
(F(3,29)=8 40, P<0 001) and sniffing (F(3,29)= 5 68, P=0 004). With respect to 
chewing frequency a bell shaped curve, with all groups significantly greater than controls, 
was found (Fig 6) The DPI 7 5 group showed the highest peak, which was significantly 
higher than the DPI 5 group (P<0 05) With respect to gnawing frequency a 
dose-dependent increase was observed (with DPI 7 5 and DPI 10 groups significantly 
greater than controls) The increase in tremor frequency showed a bell-shaped curve with 
significant increases in the DPI 5 and DPI 7 5 groups, which disappeared at the highest 
dose tested A similar increase was seen with tongue protrusion frequency, however, none 
of the values reached significance. All DPI groups significantly increased sniffing 
frequency, but not in a dose-dependent manner. DPI did not affect the frequency of 
tongue protrusions, yawning, licking or grooming compared with controls (one-way 
ANOVA, P>0 1 for all variables) 
One way ANOVA values were significant for the duration of chewing (F(3,29)= 7.17, 
P=0 00I), gnawing (F(3,29)= 5 20, P=0 005) and tremor (F(3,29)= 7.98, P<0.001). 
Chewing, gnawing and tremor duration showed dose-effect curves which were similar to 
those of the frequencies of these behaviours DPI did not affect the duration of licking, 
sniffing or grooming compared with controls (P>0.1 for all variables). Although 
ergometrine was administered before the pretreatment session (Fig 1), it did not affect 
any behaviour during the pretreatment session (data not shown). The behaviour during the 
experimental session was neither affected by ergometrine when given alone {(ERG)H20 vs 
H20, Fig 6) Ergometrine significantly decreased the DPI-induced increase in tremor 
frequency (P=0 04), chewing frequency (P=0 01) and sniffing frequency (P=0.03) 
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Ergometnne non-significantly decreased the DPI-induced increase in tremor duration 
(P=0.07) and chewing duration (P=0.09). Since the DPI 5 group did not yet significantly 
increase gnawing, the effect of ergometrine could not be assessed in this case. 
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Abnormal, oral behaviour 
With respect to large amplitude chewing, the analysis of the effect of DPI administration 
into the shore was limited to the % of animals showing this behaviour during chewing in 
the experimental period (Fig. 7). Large amplitude chewing occurred significantly more 
often in the DPI 7.5 and DPI 10 groups than in the control group (Fischer's exact 
probability test; Ρ < 0.001 for each group) and the DPI 5 group (Fischer's exact 
probability test; P=0.05 for each group). Because 5.0 μg DPI did not yet significantly 
increase large amplitude chewing, the effect of ergometrine could not be assessed. 
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Discussion 
General 
The present study analyzed changes in (peri-)oral behaviour that occurred after 
administration of DPI or H20 in different areas of the nucleus accumbens in freely 
moving rats. As discussed below, DPI enhanced and elicited oral behaviours following its 
administration into the shell and shore, but not the core, of the nucleus accumbens. Given 
the large individual variability in individual scores collected during the pretreatment 
sessions it was decided to subtract per rat the scores collected during the experimental 
session from those collected during the experimental sessions. Figure 3 shows that this 
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method adequately accounted for the individual differences found. Apart from the finding 
that the scores of the experimental sessions significantly correlated with those of the 
pretreatment sessions, it was found that the coefficient of the lines fitting the data-set of 
the DPI experiments as well as that of the control experiments was identical. These data 
also prove that the DPI-induced changes were not due to only a subpopulation of animals. 
Figures 4-7 show that distilled water given before the experimental session reduced the 
vast majority of oral behaviours, when compared with the scores collected during the 
pretreatment sessions. Given the fact that the animals were not habituated to the injection 
given before the pretreatment sessions, it is not unlikely that the first injection elicited 
and/or enhanced oral behaviours as a stress-response to the injection. Indeed, the nucleus 
acumbens, especially the shell region, is known to be very sensitive to stressors (Deutch 
and Cameron, 1992). Taking this consideration into account, it can be speculated that the 
observed decrease was due to the weaning of this effect. From this point of view it might 
even be speculated that the DPI-induced increases in oral behaviours which will be 
discussed below in more detail, were due to changes in susceptibility to stress. Although 
this possibility cannot be excluded, it does not explain why DPI elicited abnormal oral 
behaviour, viz. a behaviour that was never seen in untreated rats. In fact, the latter data 
indicate that DPI did not simply reinstate the original situation. The recently reported 
finding that administration of DPI into the shell produces jaw movements in anesthetized 
and spinalized rats (Cools er al., 1993) also indicates that the DPI-induced display of oral 
behaviour is rather independent of stress. In sum, the mechanism underlying the DPI-
effects remains to be investigated. 
DPI-induced effects 
The present study confirms and extends the earlier finding that DPI-administration into 
the nucleus accumbens increases oral behaviour in freely moving rats (Cools, 1990). 
Administration of the dopamine DA, receptor agonist DPI (5 μg) into the shell of the 
nucleus accumbens increased chewing, tongue protrusion, sniffing and grooming, and 
induced abnormal oral movements, viz. large amplitude chewing. Since injections made 
outside, but adjacent to, the shell showed much smaller effects, the effects of DPI in the 
shell are considered to be region-specific. Administration of 5 μg DPI in the core of the 
162 
nucleus accumbens did not affect any (pen-)oral behaviour, except for a small, but 
significant, increase in sniffing frequency (Fig 4) Although it cannot be excluded that 
higher doses of DPI administered in the core might have been effective, the present data 
provide evidence that the shell and core are differentially susceptible to DPI with respect 
to oral behaviour It has to be noted that injections given into the core were centered in 
the region that was recently delineated as the so-called rostral pole of the nucleus 
accumbens (Zahm and Brog, 1992) The question whether administration of DPI into 
more caudal parts of the dorsolateral nucleus accumbens is also ineffective in freely 
moving rats, remains to be investigated However, it is already known that DPI given to 
anesthetized and spinahzed rats enhances jaw movements only, when administered into 
the shell, but not the caudal dorsolateral nucleus accumbens (Cools et al , 1993), viz the 
core according to the nomenclature of Zahm and Brog (1992) These behavioural data 
together with the anatomical, pharmacological and electrophysiological differences 
between the core and the shell as mentioned in the Introduction reveals that the nucleus 
accumbens is indeed a heterogeneous structure in all aspects 
Until now, studies on oro-facial dyskinesias in rats have mainly reported differences in 
frequency or duration of normal behaviours In this study, a behaviour was observed with 
abnormal morphology, viz large amplitude chewing The observation that a small number 
of animals with control injections into the shell also showed this behaviour (Fig 5), is 
considered to be the result of aspecific stimulation of the shell, since it never occurred in 
untreated rats Since DPI-administration into a striatal sub-area of cats is also known to 
elicit abnormal, dyskinetic oral movements (Cools et al , 1976, Spooren et al, 1991), it 
appears justified to conclude that DPI is a valid tool to study oro-facial dyskinesia in cats 
and rats 
Because the percentage of shell-hits was rather low, dose dependency and antagonism of 
the effects of DPI were studied into the 'shore' (the border region of the core and shell) 
DPI (5 0-10 0 μg) administered into the shore increased dose-dependently oral 
behaviours As shown in Figs 6 and 7 the dose-effect curve varied per distinct oral 
behaviour The finding that an increase in tremor required a smaller dose of the dopamine 
DA, receptor agonist DPI than an increase in chewing did, suggests that tremor was more 
susceptible to changes in the dopaminergic activity than chewing Indeed, systemic 
administration of the dopamine Dl receptor agonist SKF 38393 increased tremor at lower 
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doses than those producing an increase in chewing (Collins et al , 1990). 
The dopamine DA, receptor antagonist ergometnne attenuated the effect of DPI on 
chewing, tremor and the frequency of sniffing. The effects of ergometnne on large 
amplitude chewing and gnawing could not be assessed, since the dose of DPI used (5 ¿ig) 
did not yet significantly increase these behaviours. Taken together, the effects of DPI on 
oral behaviour seemed to be mediated via the dopamine DA, receptor, since the effects 
were dose-dependent and could be attenuated with the dopamine DA, antagonist 
ergometnne (cf. Cools et al, 1976; Woodman et al, 1981, Ploeger et al, 1991). 
Since the shore e icompasses the shell and the core and since only the shell is involved in 
oral behaviour (see above), it appears justified to ascribe the shore-effects to stimulation 
of dopamine DA, receptors located in the shell Still, the effects of DPI administered into 
the shore were not fully identical to those elicited by DPI-administration into the shell (cf 
Figs 4 and 6) One explanation might be that the shore region out of the shell is not 
completely devoid of DPI-sensitive receptors additional stimulation of these receptors 
might have altered the effects elicited by stimulation of these receptors within the shell. 
An alternative explanation might be that the shell itself is not homogeneous: for, the 
injections into the shore certainly reached other parts of the shell than the injections into 
the shell 'id (Fig 2) 
It has been postulated that hyperactive dopamine DA, receptors belonging to the 
dopaminergic A8 and AIO neurons play an important role in the pathophysiology of oro-
facial dyskinesia (OFD, Cools, 1980, 1983, Spooren et al, 1991) This postulate is based 
on studies with cats showing that stimulation of mesostriatal, dopamine DA, receptors 
elicits OFD. The present rodent study shows that dopamine DA, receptors in the shell, 
viz an area innervated by dopaminergic A8 and AIO neurons (Gerfen et al., 1987; 
Deutch et al , 1988), are also involved in the display of abnormal, oral behaviours, 
providing additional evidence in favour of the postulate mentioned above. In view of these 
findings it is tempting to speculate that DPI administered into the shell of rats is an 
animal model for OFD in man In this context it is relevant to note that both the shell 
itself, as well as structures such as the dopaminergic AIO cell group and the basolateral 
amygdala which innervate the shell, are sensitive to stressors (see above; Sarter and 
Markowitsch, 1985, Imperato et al , 1991, Deutch and Cameron, 1992) for, OFD in 
man is known to be worsened by stress (Klawans et al, 1980) Future studies are 
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required to test the validity of this animal model of OFD (cf. Waddington, 1990). 
In conclusion, DPI in the shell of the nucleus accumbens increases the incidence of 
different oral behaviours and induces abnormal, oral behaviour, viz. large amplitude 
chewing, via stimulation of dopamine DA, receptors. 
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Chapter 11 
«/-Sulpiride inhibits oral behaviour elicited from the nucleus accumbens of freely 
moving rats 
Abstract 
The present study analyzed the effect of intra-accumbens administration of the 
stereoisomers of sulpiride upon (3,4- dihydroxyphenyhmino)-2-imidazoline (DPI)-induced 
oro-facial behaviour DPI (5 ^g) administered into the nucleus accumbens increased the 
frequency of chewing, gnawing, tremor, tongue protrusion and sniffing, and it induced 
large amplitude chewing /-Sulpiride (2-50 ng) had no effect on DPI-induced (5 /zg) oro-
facial behaviours with the exception of sniffing frequency which was significantly 
decreased ¿-Sulpiride (10-50 ng) significantly antagonized the DPI-induced increase in 
chewing and sniffing (duration), and had a biphasic effect on tremor duration with 
potentiation (10 ng) followed by attenuation (50 ng) Moreover, ¿-sulpiride strongly 
attenuated the effects of DPI on large amplitude chewing, gnawing and tongue 
protrusions When administered alone, /- or ¿-sulpiride did not affect oro-facial 
behaviours 
It is concluded that ¿-sulpiride inhibits DPI-induced oral behaviours It is suggested that 
¿-sulpiride may be effective in the pharmacotherapy of oro-facial dyskinesias in man 
Introduction 
The nucleus accumbens modulates oro-facial behaviour in rats (3, 5, 17, 19, 20, 21) 
More specifically, intra-accumbens administration of (3,4- dihydroxyphenyhmino)-2-
lmidazoline (DPI), that is considered to be a dopamine DA, receptor agonist (6, 7), 
increases several oro-facial behaviours in rats (22). This effect is subregion-specific, since 
DPI affects oral behaviour when administered into the shell but not the core or the rostral 
pole of the nucleus accumbens, moreover, DPI-injections into sites adjacent to this 
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nucleus remain ineffective (8, 22, unpublished observations). The shell being the region 
in which DPI induces oral behaviours is especially important, since the dopaminergic 
activity in the shell, but not the core, of the nucleus accumbens in rats is sensitive to 
stressors (10) Sensitivity to stressors is also a characteristic of oro-facial dyskinesias in 
man (16) Moreover, intra-accumbens administration of DPI induces dyskinetic-like oral 
behaviour (large amplitude chewing, 22), this in contrast with administration of dopamine 
Di and D2 agonists (17) Therefore, DPI-induced oro-facial behaviour in rats has been 
suggested to be an interesting animal model of oro-facial dyskinesias in man (22) 
Since the pharmacotherapeutic treatment of OFD in man is a major problem (14, 15), it 
became of interest to find drugs that attenuate the DPI-induced oral behaviours A 
possible candidate for such a drug is sulpiride It has been found that sulpiride shares its 
high affinity for the so-called mesolimbic I sulpiride binding site (7 nM) in the nucleus 
accumbens with that of DPI [2-5 nM] (9, Csemansky, personal communication) 
Interestingly, in contrast to its affinity for dopamine D2 receptors, the affinity of sulpiride 
to the / sulpiride binding site is not stereospecific [/-sulpiride 7 nM, d sulpiride 9 nM] 
(9) Therefore, the effects of intra accumbens administration of different doses of /- and 
¿/-sulpiride on DPI-induced oro facial behaviour were analyzed in the present study 
Given the possibility that the sulpiride stereoisomers might increase or decrease the 
effects of DPI, a relatively low dose of DPI was chosen [5 μg] (22) Since the effects of 
DPI-injections into the border region of the core and shell [the so-called 'shore' (22)], 
which is easy to hit correctly, are largely comparable to DPI injections into the shell, 
which is difficult to hit (22), it was decided to use 'shore' injections in the present study 
Materials and methods 
Subjects 
Naive, male Wistar rats (Central Animal Laboratory, Nijmegen) were used Before 
operation they weighed between 180 and 220 grams Rats were individually housed and 
kept on a 12-h day/night cycle with lights on at 7 00 am Food and water were available 
ad libitum Animals were used only once 
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Surgery 
Animals were anaesthetized with sodium pentobarbital (Narcovet, 60 mg/kg. i.p.)· Guide 
cannulas (0 65 mm outer diameter, 0.3 inner diameter), were stereotactically implanted 
into the nucleus accumbens, viz the border region of the core and shell (ant. 9.8 mm; lat. 
1 2 mm). Cannulas (5 mm length) were angled 10 degrees from the midsagittal plane to 
avoid the ventricular system and to leave space for an electromyographic (EMG) 
connector Cannulas were fixed onto the skull with dental cement (Durelon, ESPE; 
carboxylate cement) aided by the attachment of two screws. Electrodes were placed in the 
masseler and digastric muscles (for details see 21) The 5-pole EMG-connector was 
attached to the skull with dental cement. 
Apparatus 
During the experiments rats were placed in a cage of Plexiglas (25 cm χ 25 cm χ 35 cm). 
A mirror (angled 45 degrees) was mounted beneath the cage allowing the precise 
recording of behaviour, especially of oro-facial movements. Behaviour was registered 
using a protocol panel with 16 channels The behavioural protocols (and the EMG 
signals) were directly read into a computer and analyzed by a computer program which 
calculated the frequency and duration of every scored behaviour. Results of the EMG-
analysis will be presented elsewhere. 
Procedure 
The procedure is described elsewhere in detail (22) After surgery the rats were housed 
individually in the original stockroom and allowed recovery from operation for at least 
one week After the recovery period, the rats were handled on three subsequent days and 
tested on the fourth day (between 9 00 and 17 00 hr.) The handling and test procedures 
were preceded by a habituation time of 45 min. On the third day, a sham injection was 
given, and the rats were connected with the EMG device, which itself did not affect the 
behavioural freedom of the animals (17), and placed in the experimental box for 10 mm. 
On the test day, intra-cerebral injections with distilled water were bilaterally given at t = -
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3 min. Registration of baseline activity started al t=0 min and lasted 30 min 
(pretreatment session). The animals were given a second injection at t=55 min of l-
sulpiride, ¿-sulpiride or distilled water. Finally, all animals received their last intra-
cerebral injection of DPI or its control (distilled water) at t=57 min. Registration of the 
drug effects started at t=60 min and lasted 30 min (experimental session). The injections 
were given by means of a 5 μ\ Hamilton syringe with a 0.25 mm needle that extended 2 
mm into the brain tissue below the tip of the permanent embedded cannula. The volume 
was 0.5 μ\ per side injected over a 10 s period, and the needle was left in situ for another 
10 s lo minimize diffusion along the needle tract. Then, the cannula was closed by re­
inserting the inner cannula. After the experiment the rats were sacrificed, and the brains 
were dissected. Brain sections were stained with cresyl violet and microscopically 
analyzed. Only data from subjects with injections made into the desired sites (about 90 % 
of total) were further analyzed. All groups consisted of 6-9 animals after excluding rats 
with misplaced injections (N = 11). 
Behavioural observations 
The ethogram of behavioural elements was identical to that described earlier (22): (1) 
chew (movement of the lower jaw vertical and/or lateral in a single or repetitive fashion 
without an object between the teeth); (2) abnormal chewing being large amplitude 
chewing (wide opening and closing of the lower jaw in a brisk repetitive fashion); (3) 
gnaw (movement of the lower jaw vertical and/or lateral in a single or repetitive fashion 
with an object (pieces of straw, faeces or the box wall) between the teeth), (4) tremor 
(rapid oscillations of cheek and/or lower jaw), (5) tongue protrusion (not aimed at an 
object), (6) lick (tongue protrusion aimed at an object), (7) yawn (wide opening of the 
lower jaw with bare teeth), (8) sniff (exploratory behaviour with moving vibrissae close 
to an object). Continuous succession of identical elements of behaviour (bouts) were 
scored as a single event. Duration (except for tongue protrusion and yawn) and frequency 
of all behaviours were analyzed. 
Drugs 
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(3,4-DihydroxyphenyIimino)-2-imidazoline (DPI, Boehnnger Ingelheim, FRG) was 
dissolved in water The stereoisomers of sulpiride (RBI, Nathick, USA) were dissolved in 
distilled water and a drop of acetic acid after which the pH was adjusted to 6-7 Drugs 
were injected bilaterally 
Statistical analysis 
Like in our previous study (22) the scores collected per rat during the pretreatment 
session were subtracted from the scores collected per rat during the experimental session 
to control for the individual variation in oro-facial behaviours Only the resulting data 
were statistically analyzed The effects of different doses of /- or ¿-sulpiride upon the 
DPI-induced oro facial behaviours were analyzed with a one-way analysis of variance 
(ANOVA) with four levels (DPI and 2, 10 and 50 ng of /-sulpiride, DPI and 10, 25 and 
50 ng of ¿-sulpiride), followed by the post-hoc Student-Newman-Keuls test, where 
appropriate 
Possible significant effects of / sulpiride alone (10 and 50 ng) were determined with two-
tailed t-tests The same holds true for the effects of ¿-sulpiride alone (10 and 50 ng) 
Results 
Effects of DPI on oro-facial behaviours 
Since the scores in the pretreatment session were subtracted from those in the 
experimental session (see Materials and methods section), the resulting scores could be 
either negative or positive (Figs 1 and 2, Table 1, cf 22) In line with earlier studies, 
DPI (5 μg) increased oro-facial behaviours (Fig 1 and Table 1) the frequency of 
chewing (P<0 01), large amplitude chewing (P=0 03), gnawing (P<0 01), tremor 
(P=0 05), tongue protrusions (P=0 02) and sniffing (P<0 01), but not of licking 
(P=0 19) and yawning (P=0 27), was significantly increased DPI also significantly 
increased the duration of chewing (P<0 01), large amplitude chewing (P=0 04), gnawing 
(P<0 01) and sniffing (P<0 01), but not of tremor (P=0 11) and licking (P=0 65) 
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Figure 1. The effects of ïnlra-accumbens administration of Η,Ο, DPI, and co-administration of /- or d-
sulpinde with DPI on the frequency and duration of different oro-facial behaviours. Means and S.E. are 
shown. *: Ρ < 05 (two-tailed l-test between H
:
0 and DPI, or post-hoc Sludent-Newman-Keuls test 
between the different doses of /- or J-sulpiride and DPI). 
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Effects of sulpiride stereoisomers on DPI-induced oro-faaal behaviours 
/-Sulpiride did not affect any behaviour induced by DPI with the exception of sniffing. It 
significantly decreased the sniffing frequency (F(3,27)=4 1, P=0 02). There was an 
apparent dose-dependent effect, and post-hoc analysis showed that the 50 ng l-
sulpinde/DPI group was significantly different from the H20/DPI group (Fig. 1). 
In contrast, ¿-sulpiride strongly affected the oral behaviours induced by DPI- it 
significantly affected the frequency of chewing (F(3,30)=4.9, Ρ<0.01), tremor 
(F(3,30) = 6 2, P < 0 01) and sniffing (F(3,30)=3.7, P=0.02) With respect to the 
chewing frequency there was an apparent dose-dependent decrease, and post-hoc analysis 
showed that the 50 ng ¿-sulpinde/DPI group was significantly different from the H20/DPI 
group (Fig 1) Tremor frequency was potentiated by the lowest dose of ¿-sulpiride 
respectively inhibited by the higher doses of ¿-sulpiride Although these effects were just 
not significant according to the post-hoc analysis, the ¿-sulpinde/DPI groups themselves 
significantly differed (Fig 1) Despite of the fact that ANOVA revealed a significant 
effect of ¿-sulpiride on the DPI-induced sniffing frequency (F(3,30)=3.7, P=0.02), no 
significant differences between the distinct groups were found in the post-hoc test. 
Moreover, ¿-sulpiride strongly attenuated the DPI-induced frequency of large amplitude 
chewing, gnawing and tongue protrusions (Table 1). Although ANOVA with four levels 
revealed no significant effects, ANOVA with two levels (= two-tailed t-test) showed that 
the 50 ng ¿-sulpinde/DPI group significantly inhibited the frequency of large amplitude 
chewing, gnawing and tongue protrusions (Table 1), when compared with the H20/DPI 
control group 
¿-Sulpiride significantly affected the duration of chewing (F(3,30)=4 9, P<0 01), tremor 
(F(3,30) = 6 2, P<0 01) and sniffing (F(3,30)=3 7, P=0 02) With respect to the 
chewing duration, there was an apparent dose-dependent decrease, and post-hoc analysis 
showed that the 50 ng ¿-sulpinde/DPI group was significantly different from the H20/DPI 
group (Fig 1) With respect to the tremor duration, ¿-sulpiride had biphasic effects (Fig. 
1) with potentiation (10 ng) followed by attenuation (50 ng) With respect to the sniffing 
duration, there v-as an apparent dose-dependent effect, and post-hoc analysis showed that 
the 50 ng /-sulpinde/DPI group was significantly different from the H20/DPI group (Fig. 
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1) ¿-Sulpiride also strongly attenuated the DPI-induced duration of large amplitude 
chewing and gnawing (Table 1) Although ANOVA with four levels revealed no 
significant effects, ANOVA with two levels (= two-tailed t-test) showed that the 50 ng d-
sulpinde/DPI group significantly inhibited the duration of gnawing, when compared with 
the H20/DPI control group 
Effects of sulpiride stereoisomers alone on oro-faaal behaviour 
To determine whether the attenuation of the effects of DPI by the sulpiride stereoisomers 
were specific, the effects of the sulpiride stereoisomers itself were studied To be able to 
compare the results directly, these effects were studied in a similar way as were the 
effects of the stereoisomers on DPI (using baseline-controlled values, see Materials and 
methods section) However, the experimental session values of the H20/H20 control 
group for the frequency of gnawing (01 + 0 1), tongue protrusions (51 + 2 0), 
yawning (08 + 0 5), large amplitude chewing (01 ± 0 1 ) and sniffing (11 ± 0 6 ) were 
very low, and therefore a possible attenuating effect of the sulpiride stereoisomers could 
not be determined While a possible decrease in these behaviours could not be 
determined, neither /-sulpiride nor ¿-sulpiride induced an increase in any of these 
behaviours (data not shown) The experimental session value of the H20/H20 control 
group for the tremor frequency was also reasonably low (means ± SEM 118 ± 3 5) 
Therefore, apart from analyzing the tremor frequency in the normal way (using baseline-
controlled values, see above), it was also analyzed by comparing the experimental session 
values of the sulpiride stereoisomer groups with those of the H20/H20 control group (Fig 
2, lower part) /-Sulpiride and d sulpiride did not influence tremor neither the baseline 
controlled values nor the experimental session values were significantly different from 
those of the controls (Fig 2) The experimental session value of the H20/H20 control 
group for the chewing frequency was very high (means + SEM 77 0 + 6 0), therefore, 
this parameter could be analyzed in a normal way None of the doses tested of /-sulpiride 
or ¿-sulpiride affected chewing (Fig 2) With respect to the duration of the different 
behaviours comparable values were observed as for the frequency, and therefore the 
statistical analysis performed was identical This analysis of the parameter duration 
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revealed results similar to those described above for the frequency. 
CHEWING frequency CHEWING duration 
# of chewing bouts 
™Г* iff 1 
ι* SUI Ρ HIDE 
TREMOR frequency 
# of tremor bouts 
¿SULPIRIDE 
TREMOR frequency 
# of Iremor bouts 
(J-SJ.PiROt 
TREMOR duration 
d-SUlP RIOF 
TREMOR duration 
Гіциге 2 The effeus of lnlra-aixumbens administration of H
:
0, /-sulpiride, and d-sulpinde on the 
frequency and duration of chewiny and Iremor The lower part shows the experimental session values, and 
not the baseline-controlled values, for the tremor frequency and duration as explained in the Results section 
Means and S E are shown 
Discussion 
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The effects of intra-accumbens administration of /- and ¿-sulpiride on (3,4-
dihydroxyphenylimino)-2-imidazoline (DPI)-induced oro-facial behaviours were studied in 
freely moving rats. DPI is known to affect oral behaviour when injected into the shell, 
but not into more rostral, ventral, dorsal or caudal regions (see Introduction section). 
Moreover, sulpiride is known to be very hydrophilic and to diffuse hardly after intra-
cerebral administration (2, 18). This, together with the fact that the injections were placed 
in the central nucleus accumbens (the border region of the core and shell, see Introduction 
section), allows the conclusion that all the observed drug-induced effects were due to 
pharmacological actions within the nucleus accumbens. 
In line with an earlier study (22), DPI increased normal oro-facial behaviours (chewing, 
gnawing, tremor, tongue protrusion and sniffing) and induced abnormal behaviour (large 
amplitude chewing). /-Sulpiride decreased only one DPI-induced oro-facial behaviour, 
namely sniffing (frequency). On the other hand, ¿-sulpiride significantly decreased 
chewing, gnawing, tremor, tongue protrusion, sniffing and the abnormal behaviour large 
amplitude chewing. On the basis of these results we conclude that ¿-sulpiride actually 
inhibited all DPI-induced behaviours. As far as it concerns chewing and tremor, this was 
not due to an aspecific effect of ¿-sulpiride, since it did not inhibit these behaviours when 
administered alone (see Results section). The effect of ¿-sulpiride upon the other oro-
facial behaviours could not be determined. 
The finding that ¿-sulpiride attenuates the effects of DPI on oro-facial behaviours suggests 
that dopamine D,
 5 receptors were not involved, since ¿-sulpiride has a relatively small 
affinity for these receptors, apart from a low affinity for dopamine Ü2 and D3 receptors 
(1, 13, 26, 27, 29, 30). Moreover, actions on dopamine D2 or D3 receptors causing the 
attenuation of DPI-induced oral behaviours can be excluded since /-sulpiride which is a 
stronger antagonist of both receptors than ¿-sulpiride (see below), is without effect on 
DPI-induced oral behaviours. This is underscored by the finding that a low dose of l-
sulpiride (2 ng) with a dopamine D, and D3 receptor blockade comparable to the effective 
dose of ¿-sulpiride [50 ng] (1, 11, 26, 27, 28) did not affect DPI-induced behaviours 
(Fig. 1). The stereoselective action of ¿-sulpiride also suggests that the so-called 
mesohmbic /-sulpiride binding site is not involved, since ¿-sulpiride and /-sulpiride have 
identical affinities for this site (9). Still, it cannot be excluded that the ineffectiveness of /-
sulpiride was due to its potency to interact with both the mesolimbic /-sulpiride binding 
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site and the classical dopamine D2 receptor; for, combined binding may limit the relative 
occupancy and, thus, the degree of antagonism of /-sulpiride at each of the binding sites 
separately. Further research is required to characterize the actual target site of ¿-sulpiride. 
Irrespective of the precise mechanism involved, ¿-sulpiride strongly attenuated DPI-
ïnduced oral behaviour. The present data imply that ¿-sulpiride may ameliorate oro-facial 
dyskinesias in man (see Introduction). Since ¿-sulpiride has a very low affinity for 
dopamine D2 receptors, it may have therapeutic effects on oro-facial dyskinesia in 
schizophrenic patients as well as in Parkinson's patients without aggravating the 
extrapyramidal side-effects of neuroleptics or without attenuating the therapeutic effects of 
L-DOPA, respectively. As far as we know, no clinical studies with ¿-sulpiride have been 
performed. However, the racemic mixture of sulpiride has been studied in schizophrenic 
patients: it ameliorates oro-facial dyskinesias when given alone (4, 12, 23), and when 
given on top of other neuroleptics (4, 25). These findings seem to support the clinical 
implication postulated above, although it cannot be excluded that the anti-dyskinetic effect 
of ¿/-sulpiride seen in the clinic was (partly) due to D2 receptor blockade caused by /-
sulpiride. For, D2 antagonists like classical neuroleptics are known to ameliorate oro-
facial dyskinesia (14, 15). Nevertheless, the present findings suggest that ¿-sulpiride may 
have anti-dyskinetic effects. If so, ¿-sulpiride is of interest as an adjuvans to L-DOPA in 
the pharmacotherapy of Parkinson's patients, counteracting the development of oro-facial 
dyskinesias. However, it should be realized that the specificity of ¿-sulpiride will be 
limited to lower doses, since higher doses can affect dopamine D2 receptors as well. 
Furthermore, ¿/-sulpiride may be of interest in the pharmacotherapeutic treatment of 
schizophrenia, having therapeutic effects (/-sulpiride) while counteracting the development 
of oro-facial dyskinesias (¿-sulpiride). Indeed, ¿/-sulpiride chronically administered 
induces less oro-facial dyskinesias than classical neuroleptics (24 and references therein). 
In sum, ¿-sulpiride (10-50 ng) administered into the nucleus accumbens inhibited DPI-
ïnduced oro-facial behaviours in a specific manner: for, ¿-sulpiride did not inhibit oro-
facial behaviour in naive rats. The much more potent antagonist of dopamine D2 receptors 
/-sulpiride (2-50 ng) was ineffective on DPI-induced oro-facial behaviours, apart from a 
single effect on sniffing. 
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Chapter 12. Overall summary of results and discussions 
The studies that are described in this thesis can be divided into two parts- 1) studies using 
the paw test in which the working mechanisms of neuroleptics are studied and 2) studies 
on oro facial behaviour in which the pathophysiology of, and a possible therapy for, oro-
facial dyskinesia is studied In this section we maintain this order. First, the outcome of 
the paw test studies is summarized Next, the clinical implications of these paw test 
studies are described and compared with findings in other studies The last part of this 
chapter is devoted to the studies on oro-facial behaviour 
12 I Evaluai ion of the paw test studies 
12 11 Role of dopaminergic, serotonergic and noradrenergic receptors 
In chapter 3 the interaction between the selective D, antagonist SCH 39166 and the 
selective D2 antagonist raclopnde, namely an atypical neuroleptic, or the less selective D2 
antagonist halopendol, namely a classical neuroleptic, is studied With respect to the 
hindlimb retraction time (HRT, a model for the therapeutic efficacy of drugs, section 
2 2 1), it is shown that SCH 39166 that itself can enhance the HRT does not influence the 
effect of D2 receptor antagonists, and vice versa, except at very high doses 
With respect to the forelimb retraction time (FRT, a model for the extrapyramidal side-
effects of drugs), an ineffective dose of the D, antagonist SCH 39166 that itself can 
enhance the FRT in doses larger than those required for enhancing the HRT, strongly 
enhances the effects of raclopnde and halopendol On the other hand, raclopnde and 
halopendol do not enhance the effects of SCH 39166 on the FRT Thus, while D, and D2 
antagonists seem to affect the HRT in an independent manner, they strongly interact on 
the FRT providing evidence that the HRT and FRT have a different neurobiological 
substrate 
Based on earlier studies (see chapter 2), it was thought that serotonergic drugs would 
modulate the effects of neuroleptics in the paw test The present study shows that not only 
drugs with selectivity for 5-HT,A receptors, but also drugs with selectivity for 5-HT2A/c 
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TABLE 1. Summary of effects of 8-OHDPAT and DOI on effects of neuroleptics 
forelimb retraction lime hind limb retraction time 
0 
g-OHDPAT 
prothipendyl* 
thioridazine3 
risperidone* 
DOI 
Haloperidol 
SCH-39166* 
remoxipnde 
clozapine1 
prothipendyl' 
thioridazine' 
clozapine* halopendol 
fluphen 
SCH-39166* 
remoxipnde 
t 
fluphen 
risperidone 
risperidone' 
SCH-39166' 
clozapine3 
prothipendyl* 
thioridazine* 
1 
clozapine" 
p rot hi pend y 1* 
halopendol 
fluphen 
SCH 39166* 
remoxipnde 
t 
halopendol 
fluphen 
remoxipnde 
thioridazine* 
risperidone3 
0 indícales that the effects of the neuroleptic drugs in this column arc not influenced bv 8 OHDPAT (upper pan nf tablei 01 DOI (louer pani t indícales thai the effects ol the 
neuroleptics in this column are significant]} increased b\ 8-OHDPAT or DOI. I indícales that the effects ol the neuroleptics in this column are decreased b* S OHDPAT or DOI 
'Drugs that act as atypical neuroleptics in the paw test 
receptors strongly modulate the effects of neuroleptic drugs (chapter 4). Interestingly, the 
nature of the interaction depends strongly on the neuroleptic drug studied (Table 1; 
reprinted from chapter 4). For instance, the 5-HT1A agonist 8-OHDPAT enhances the 
effects of prothipendyl, clozapine and thioridazine on the HRT, attenuates the effects of 
halopendol, fluphenazine, SCH 39166 and remoxipnde on the HRT, and does not 
influence the effect of risperidone on the HRT. Similar differences between neuroleptics 
are found with the 5-НТ2л/с agonist l-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane 
(DOI; chapter 4). Interestingly, the varying effects cannot be ascribed to differences 
between classical and atypical neuroleptics, but seem to represent differences between 
neuroleptics irrespective of their EPS profile. 
Furthermore, this study suggests that the strong 5-НТ2л antagonist property of clozapine 
(Leysen et al., 1993) is important for its effect on HRT (chapter 4): for, the 5-HT2A/c 
agonist DOI attenuated the effects of clozapine on the HRT. 
With respect to the FRT, the effect of 8-OHDPAT and DOI differs also between the 
neuroleptics. However, the number of neuroleptics of which the FRT is affected by 
serotonergic drugs (especially DOI) was much smaller than that of which the HRT is 
affected by these agents (for DOI 2 vs 7 respectively, out of a total of 8 neuroleptics), 
underscoring the earleir reported notion that the HRT and FRT have a different 
neurobiological substrate. Conversely, the differential effects of serotonergic drags on 
neuroleptics indicate that the neurobiological substrate of the neuroleptics themselves also 
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differs. 
Finally, the present study suggests that the D2/ 5-HT2A ratio is not essential for the 
atypical profile of neuroleptics in the paw test (cf. Meltzer et al., 1989): 5-HT2A 
stimulation does not increase the FRT of atypical neuroleptics (except from risperidone), 
while 5-HT2A blockade does not attenuate the FRT of all fluphenazine (chapter 4). Thus, 
although a D2/ 5-HT2A ratio may play a role in the EPS profile of risperidone, this ratio 
does not seem to be a crucial factor in the mechanisms of all atypical neuroleptic drugs. 
Table 2. A summary of the modulation by drugs acting on 
adrenoceptors on the effects of haloperidol (section 5.2) and 
clozapine (section 5.1) in the paw test. î/i: a significant 
increase/decrease compared to neuroleptic alone; - no 
significant effect 
ST 587 
Methoxamine 
Phenoxybenzamine 
Clonidine 
Rauwolscine 
L-659,066 
Clenbuterol 
(-)-Isoprenaline 
(-)-Propranolol 
Nadolol 
Table 2 (reprinted from chapter 5) gives a summary of the effects of a number of 
noradrenergic drugs on clozapine and halopendol. Thus, clozapine and halopendol are 
both modulated by noradrenergic drugs, but in a different way. First, the a2-agonist 
Clonidine attenuates the clozapine-induced HRT, and enhances the haloperidol-induced 
HRT Clonidine enhances the haloperidol-induced FRT as well, but does not induce an 
effect in FRT when combined with clozapine. Second, the /32-agomst clenbuterol 
combined with clozapine induces an effect on the FRT, while, on the other hand, 
clenbuterol attenuates the haloperidol-induced FRT. Finally, although the apagonist ST 
587 attenuates the effects of both clozapine and halopendol on the HRT, the effect on 
halopendol requires a minimum dose of ST 587 20 times higher than that on clozapine. 
Together with the binding profile of these drugs, it is concluded that the α,-antagonist 
HAL 
I 
1 
Î 
i 
-
t 
-
HRT 
CLOZ 
1 
Î 
i 
t 
I 
FRT 
HAL 
I 
î 
I 
î 
-
CLOZ 
-
t 
-
î 
-
-
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property of clozapine, but not haloperidol, is important for its effects on the HRT 
(chapter 5). 
Not all effects differ between clozapine and haloperidol: the α,-antagonist 
phenoxybenzamine strongly enhances the effects of haloperidol and clozapine on the HRT 
in an identical minimal effective dose (10 mg/kg; chapter 5). Taken together, the effects 
in the paw test of haloperidol and clozapine are strongly modulated by noradrenergic 
drugs, but in different ways. Together with the results of the serotonergic study 
mentioned above (and chapter 4), showing that the interaction with serotonergic drugs 
varies per neuroleptic studied, it is expected that the same holds true for the interaction 
with noradrenergic drugs. 
An earlier study together with the present findings has shown the importance of the Ot 
receptor (Ellenbroek et al., 1991), the 5-ΗΤ2Λ receptor (chapter 4), and the a,-
adrenoceptor (section 5.1) in the clozapine-induced HRT. On basis of these findings, it 
was hypothetized that blockade of these three receptors may lead to effects in the paw test 
similar to those of clozapine. Indeed, the present data show that combining (sub-threshold 
doses of) D[, 5-HT2A and a, antagonists leads to an effect on HRT, but not on FRT 
(chapter 6). Importantly, combinations of two out of three antagonists do not show any 
interaction on the HRT (chapter 6). Thus, in line with our hypothesis, simultaneous 
blockade of D,, 5-HT2A and a, receptors induces the profile of an atypical neuroleptic. 
12.1.2 The anatomical target sites for the effects in the paw test 
Administration of the D2 antagonist ¿//-sulpiride produced similar effects on the HRT 
following its administration in the dorsal striatum (DS), the nucleus accumbens (ACC) 
and the olfactory tubercle (ОТ; chapter 7), namely a strong increase in the HRT at low 
doses (25 ng). Given the fact that this hydrophilic compound hardly diffuses following 
intra-cerebral administration (chapter 7, and references therein), these data strongly 
indicate that D2 receptors in all three striatal structures independently affect the HRT. On 
the other hand, the D2 receptors in (two of) these structures do not seem to cooperate, 
since simultaneous administration of ¿//-sulpiride in the DS and ACC does not result in 
changes in the size or latency of the effect on HRT (chapter 7). 
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On the other hand, much higher doses of dl sulpiride (100 ng or more) are required to 
increase the HRT compared with the HRT, suggesting that effects on the FRT require 
stronger D2 blockade than effects on the HRT The ability of ¿/-sulpiride to induce effects 
on the FRT differs strongly between the structures ¿/-sulpiride administration in the DS 
produces significant effects on the FRT at lower doses than ¿/-sulpiride administration in 
the ACC (100 and 400 ng, respectively), while ¿/-sulpiride administration (25-400 ng) in 
the ΟΓ does not affect the FRT It is concluded that D2 blockade in the DS produces 
stronger effects on the FRT than that in the ACC It has to be noted, however, that dl-
sulpinde has also a high affinity for a mesohmbic binding site (Csemansky et al, 1985) 
and that ¿sulpiride antagonizes DPI induced effects in the ACC (chapter 11) To what 
extent the effects of ¿/-sulpiride in the ACC are at least partly due to additional effects on 
this mesohmbic binding site remains to be established 
12 2 Preclinical evaluation of neuroleptics clinical implications 
Given the fact that the paw test is a well validated animal model for the therapeutic 
efficacy and the extrapyramidal side-effects of neuroleptics (cf chapter 2), the results 
summarized in the previous section are used to discuss their clinical impact in this 
section As such, these results are compared with studies on other animal models (cf 
chapter 2) 
12 2 I Role of dopaminergic, serotonergic and noradrenergic receptors 
For years, the therapeutic effects of neuroleptic drugs are considered to be due to their 
effect on D2 receptors (cf section 2 11) Recent studies, however, have suggested that 
selective antagonists of D, receptors may have antipsychotic effects as well (cf section 
2 11) The present data indeed show that the Di antagonist SCH 39166 acts as an 
atypical neuroleptic in the paw test (enhancing the HRT in doses lower than those 
enhancing the FRT, chapter 4) Until now, no data on the clinical efficacy of SCH 39166 
have been reported Interestingly, the D, antagonist NNC 756 has recently been reported 
to ha\c antipsychotic effects in schizophrenic patients (Lublin et al , 1994) 
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If indeed both D, and D2 receptors have antipsychotic properties, the question anses 
whether simultaneous blockade of both receptors may have additional effects compared 
with selective blockade. The interaction between D, and D2 receptors on therapeutic effect 
has not been systematically studied, although two studies have found indirect evidence 
that these receptors act independently (cf section 2 1 1) a CAR study (McQuade et al., 
1992), and a study on schedule-controlled behaviour (Bergman et al, 1991) The present 
study shows that D, receptor antagonists do not influence the effect of D2 receptor 
antagonists on the HRT, and vice versa (chapter 3) This finding suggests that combining 
Ό
ι
 and D2 antagonists does not produce additional antipsychotic effects On the other 
hand, Dt receptor antagonists potentiate the effect of D2 receptor antagonists on the FRT, 
but not vice versa (chapter 3), predicting that combining D, and D2 antagonists may 
produce an increase in EPS Synergistic effects between D, and D2 antagonists have also 
been reported for catalepsy (Undie and Freedman, 1988, Parashos et al , 1989, 
Wanibuchi and Usuda, 1990) 
As described in chapter 2, two important hypothesis have been raised with respect to the 
interaction between serotonergic drugs and neuroleptic drugs 1) stimulation of 5-HT,A 
receptors enhances the therapeutic effects of neuroleptics (Wadenberg et al , 1991), and 
2) the 5 HT2A/D2 ratio determines the EPS profile of drugs (Meltzer et al , 1989) 
In chapter 4 these predictions are further tested with the help of the paw test The paw 
test data show that combining the 5-HT1A agonist 8-OHDPAT with halopendol, 
fluphenazine, remoxipnde or SCH 39166 attenuates the effect on the HRT of these 
neuroleptics On the other hand, combining 8-OHDPAT with prothipendyl, clozapine or 
thioridazine enhances the effect on the HRT of these neuroleptics Thus, these data 
predict that 5-HT1A stimulation may enhance the therapeutic effects of some neuroleptics, 
but may diminish the therapeutic effects of other neuroleptics Nevertheless, the 
attenuation of the effect on the HRT of the D2 antagonists remoxipnde and halopendol by 
8-OH-DPAT is in contrast with the enhancement of the effect of the D¡ antagonists 
raclopnde and halopendol in the CAR (Wadenberg and Ahlenius, 1991; Shropshire and 
Marquis, 1992) At the moment, this discrepancy is difficult to explain 
With respect to side-effect profile of neuroleptics, the paw test data show that combining 
8-OHDPAT with classical neuroleptics attenuates their effects on the FRT Although this 
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predicts that 5 HT,A stimulation decreases the EPS induced by classical neuroleptics, the 
neuroleptics that produce this effect show a concomitant decrease in HRT (modelling 
therapeutic efficacy), suggesting that adding a 5 HT,A-agomst to a classical neuroleptic is 
not a sensible strategy to treat schizophrenia Taken together, the modulation of 
neuroleptic drugs by 5-HT1A stimulation is complex and controversial, and further 
research is necessary 
To analyse the second prediction, namely that the 5-HT2A/D2 balance determines the EPS 
profile of neuroleptics, the selective 5-HT2A antagonist ketansenn and the 5-HT2A/c agonist 
DOI are combined with a number of neuroleptics 
As discussed in chapter 4, this hypothesis is not supported by the results of the present 
study First, the 5-HT2A antagonist ketansenn attenuates the halopendol-induced FRT, but 
not that of fluphenazine (chapter 4) Second, adding DOI to atypical neuroleptics does not 
produce an effect on the FRT (except from risperidone) Thus, although the 5-HT2A/D2 
balance may play a role in the EPS profile of some neuroleptics, the present data sugggest 
that it has no general validity in explaining the EPS profile of neuroleptic drugs 
Interestingly, the 5-HT2A/c agonist DOI attenuates the effects of clozapine on the HRT, 
suggesting that the strong 5 HT2A antagonist property of clozapine (Leysen et al , 1993) is 
important for its therapeutic effect (chapter 4 and below) 
As described in chapters 1 and 2, noradrenergic drugs have been found to modulate 
certain preclinical and clinical effects of neuroleptic drugs To further analyse this 
phenomenon in the paw test, noradrenergic drugs are combined with the classical 
neuroleptic halopendol and the atypical neuroleptic clozapine Since some of the reported 
interactions involve peripheral noradrenergic receptors (Yntema and Korf, 1987), 
noradrenergic drugs that do not pass the blood brain barrier are included in the study 
The data show that an α,-antagonist enhances the halopendol induced HRT (chapter 5), 
suggesting that the combination may have supenor therapeutic effects Remarkably, in a 
CAR study, an a,-antagonist has been found to enhance the effect of cis-flupentixol, but 
not that of halopendol Nevertheless, both studies predict that a, blockade may enhance 
the therapeutic effects of some neuroleptics 
The a, antagonist property of clozapine, but not halopendol, is found to be crucial for its 
effects on HRT (section 5 2) Thus, the a, antagonist property of clozapine itself may be 
essential for its antipsychotic effects (see also below) 
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With respect to the role of α,-adrenoceptors in EPS, the present data shows that 
(peripherally working) α,-agonists, but not -antagonists, attenuate the EPS of halopendol 
(section 5.2). In contrast, Chiodo and Bunney (1985) have suggested on basis of their 
electrophysiological data that a, blockade on top of halopendol attenuates the 
halopendol-induced EPS An explanation for these differential results is not yet available, 
although the use of different drugs (phenoxybenzamine vs. prazosin) may have 
contributed to this discrepancy. 
Combining α,-agonists with clozapine does not increase the FRT, indicating that the 
potent a
r
antagonist property of clozapine does not play a role in its lack of EPS (section 
5.1). 
The a2-agomst Clonidine enhances the HRT of a low dose of halopendol without inducing 
an effect on the FRT. However, Clonidine enhances the FRT of a higher dose of 
halopendol (section 5.2) In line with the foregoing, the a2-antagonist rauwolscine 
decreases the halopendol-induced HRT Nevertheless, a clinical study has shown that the 
a2-antagonist idazoxan enhances the therapeutic effects of fluphenazine (section 2.2; 
Litman et al , 1993) Given the fact that the interactions with a neuroleptic can differ per 
neuroleptic studied (chapter 4), this is not perse in contrast with each other. 
The β antagonist (-)-propranolol enhanced the HRT of halopendol (section 5 2), in line 
with clinical studies, in which where propranolol has been found to enhance the 
therapeutic effects of neuroleptics, at least in 'treatment-resistant' patients (Berlant, 1987; 
section 2 2) On the other hand, in contrast with halopendol, the clozapine-induced HRT 
is attenuated by /3-antagonists. This effect seems to involve penpheral receptors. An 
explanation for this phenomenon is not yet available (cf section 5.1). 
Thus, the present paw test data predict that there are several noradrenergic drugs that 
together with a low dose of halopendol may produce an atypical profile: the (^-antagonist 
phenoxybenzamine, the a2-agonist Clonidine and the ^-antagonist (-)-propranolol The 
combination with phenoxybenzamine is most interesting from a clinical point of view, 
since it does not enhance the FRT induced by higher doses of halopendol, in contrast 
with Clonidine and (-)-propranolol 
As discussed above, the 5-HT2A and the α,-antagonist properties of clozapine may be 
important for its effects in the paw test An earlier study has shown that the D, antagonist 
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property of clozapine is important as well Therefore, it was hypothetized that combined 
antagonism of these receptors simultaneously would lead to a clozapine-like profile 
Indeed, combining dopamine D,, 5 HT2A and adrenergic a, antagonists produces 
synergistic effect on the HRT, but no effects on the FRT (chapter 6) Thus, combining 
dopamine D,, serotonin 5 HT2A and adrenergic a, antagonists leads to a drug with a 
neuroleptic profile that is similar to that of clozapine accordingly, it can be predicted to 
exert antipsychotic effects without EPS Interestingly, there are compounds that have a 
comparable profile to clozapine with respect to these receptors (e g tilozepine, Coward, 
1993 olanzepine, Moore et al , 1993), future studies will have to show their effectiveness 
in schizophrenia treatment 
12 2 2 Anatomical target sues for the clinical effects of neuroleptics 
As discussed in section 12 1 2, the effects in the paw test following intra-cerebral 
administration of sulpiride strongly indicate that D2 receptors in the DS, the ACC and the 
ОТ independently affect the HRT Given the predictive validity of the paw test, this may 
imply that D2 receptors in all three structures are involved in the antipsychotic effects of 
neuroleptic drugs 
The assumption that there are multiple sites where D2 antagonists induce antipsychotic 
effects opens completely new perspectives As outlined by Bobon and colleagues (1972), 
distinct neuroleptics differentially affect separate symptoms of schizophrenia In other 
words, each neuroleptic has its own specific therapeutic profile as far as it concerns its 
potency to ameliorate delusions, mania, autistic behaviour, etc Previously, it has been 
shown that each of the brain regions that appear to mediate antipsychotic effects, has its 
own function (cf Van de Bos, 1991, Jaspers, 1991, Cools et al , 1993) So, it can be 
speculated that whether a brain region contains binding sites for a particular neuroleptic is 
decisive for the therapeutic profile of that neuroleptic Therefore, it is hypothetized that 
the regional selectivity of each distinct neuroleptic determines the precise nature of its 
therapeutic profile 
It has to be noted that the effects of neuroleptics are not limited to striatal areas other 
areas such as the prefrontal cortex may be target areas for neuroleptics as well (Deutch, 
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1991) 
With respect to the EPS of D2 antagonists, it is predicted that D2 receptors in the ACC 
and, in particular, the DS play a role (chapter 7), which is largely in line with catalepsy 
studies (Ossowska et al , 1990) These data suggest that the putative regional selectivity 
of a neuroleptic also determines its EPS profile Indeed, several studies have shown that 
classical and atypical neuroleptics have different regional selectivity for striatal structures 
First, as descnbed in section 2 2, atypical neuroleptics have selective effects on the 
dopamine AIO cells, while classical neuroleptics affect both dopamine A9 and AIO cells 
Second, atypical neuroleptics bind to D2 receptors in the ОТ stronger than to D2 receptors 
in the DS (LeFur et al , 1979, Altar et al , 1986, Meltzer, 1992, but see Seeman and 
Ulpian, 1983, Meltzer and Nash, 1991) Taken together, a number of studies have shown 
that drugs that affect the A9 system (DS) stronger than the AIO system (ACC and ОТ) 
have a stronger propensity for inducing EPS, and vice versa Furthermore, even within 
the AIO system, classical and atypical neuroleptics can be differentiated with respect to 
their effects on the ACC and the ОТ Thus, atypical neuroleptics block locomotor activity 
elicited from the ОТ in lower doses than that elicited from the ACC (Cools et al , 1992, 
1994) The ìntra-ACC injections in the latter studies are aimed particularly at the core of 
the ACC (Cools et al , 1994) Given the fact that the core of the ACC shares many 
similarities with the DS (Deutch and Cameron, 1992), the different effects of classical 
and atypical neuroleptics becomes understandable in view of the above-descnbed 
differences between the DS and the ACC 
12 3 Studies on oral behaviour in rats implications for tardive dyskinesia 
As discussed in section 2 2 2 dopamine DA, receptors in the ACC are thought to play a 
role in OFD In the present thesis the behavioural effects of intra-ACC administration of 
the DA, agonist (3,4-dihydroxyphenylimino)-2-imidazoline (DPI) are studied in rats For 
comparison, the effect of D,, D2 stimulation and their combination is studied as well 
Chapters 8-10 show that administration of D^ D2 and DA, agonists in the ACC all 
produce different effects on oral behaviour First, stimulation of D, receptors with SKF 
38393 produces relatively small increases in all oral behaviours (chew, tremor, tongue 
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protrusion, and lick; chapter 9) and in EMG activity of the masseter muscle (frequency 
ranges 4-5 to 13-14 Hz; chapter 8). On the other hand, D2 stimulation with quinpirole 
clearly attenuates tremor, but strongly increases a number of other oral behaviours (chew, 
tongue protrusion, yawn and lick; chapter 9). The attenuation of tremor is reflected by 
changes in the EMG activity of the jaw muscles (decrease in frequency ranges 6-7 to 13-
14 Hz; chapter 8). When combined, SKF 38393 and quinpirole have additive effects on 
tremor, and opposite effects on chew, tongue protrusion and yawn (chapter 9). 
A low dose of DPI (5 μg) strongly enhances, among others, chewing (vacuous) (chapters 
10 and 11). A high dose of DPI (10 μg), induces, in addition, large amplitude chewing, 
an abnormal, dyskinetic-like behaviour (chapter 10). 
Thus, only stimulation of DA, receptors in the ACC leads to clear abnormal oral 
behaviour, that can be labeled dyskinetic. Together with the reported studies in cats 
(section 2.2.2), this lays a firm foundation for the role of these receptors in OFD. 
Moreover, the effect of DPI in rats is restricted to the shell region of the ACC (chapter 
10; Fig.; Cools et ai, 1993), which is known to play a role in stress (Deutch, 1993). On 
the basis of these, and related findings, it is suggested that DPI-induced behaviour is a 
valid model for OFD in man (chapter 10). If so, our finding that d-sulpiride significantly 
inhibits the DPI-induced behaviours, implies that ¿-sulpiride may have therapeutic value 
for the treatment of OFD (chapter 11). This is of special interest since ¿-sulpiride has a 
relatively weak affinity for D2 receptors (chapter 11), and, thus, may be free of side-
effects itself. 
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Samenvatting 
Het eerste deel van dit proefschrift (hoofdstuk 1) gaat in op de ziekte schizofrenie en de 
behandeling daarvan Uit de literatuur blijkt dat verschillende gebieden betrokken zijn 
bij de palhofysiologie van schizofrenie, waaronder de prefrontale cortex, de hippocampus 
en het dorsale en ventrale striatum Verder spelen dopaminerge, serotonerge en 
noradrenerge receptoren mogelijk een belangrijke rol bij de pathofysiologie van 
schizofrenie Vervolgens wordt ingegaan op de behandeling van deze ziekte met 
geneesmiddelen, de zogenaamde neuroleptica, en de mogelijke werkingsmechanismen van 
deze geneesmiddelen Uit publicaties is gebleken dat er nog veel te verbeteren valt aan 
deze neuroleptica In de eerste plaats is het therapeutische effect van deze stoffen beperkt 
lot een deel van de symptomen Op de tweede plaats hebben de neuroleptica 
bijwerkingen, waarvan vooral de zogenaamde extrapyramidale bijwerkingen, zoals 
spierstijfheid en bewegingsarmoede, zeer hinderlijk zijn Van de vele extrapyramidale 
bijwerkingen die neuroleptica kunnen induceren is oro-faciale dyskinesie de meest 
ernstige, die ook niet goed te behandelen is De pathofysiologie van en een mogelijke 
therapie voor oro faciale dyskinesie is bestudeerd in het laatste deel van deze studie 
br beslaat echter een select groepje neuroleptica dat minder bijwerkingen heeft, deze 
worden atypische neuroleptica genoemd, zoals bijv clozapine (t o ν klassieke 
neuroleptica, zoals bijv halopendol) Sommige van deze atypische neuroleptica hebben 
mogelijk ook een breder therapeutisch effect, dit is speciaal aangetoond voor clozapine 
(zie hoofdstuk 1) De klinische toepasbaarheid van clozapine is echter beperkt omdat het 
middel als bijwerking agranulocytose (vermindering van witte bloedlichaampjes) heeft, 
hetgeen fatale gevolgen kan hebben Onderzoek aan het werkingsmechanisme van 
neuroleptica is dus van groot belang om de ontwikkeling van nieuwe neuroleptica met een 
superieure werking mogelijk te maken Preklinisch onderzoek (hoofdstuk 2) heeft laten 
zien dat dopaminerge receptoren een cruciale rol spelen in de effecten van neuroleptica 
Aan de andere kant worden de dopamine-geinduceerde effecten gemoduleerd door 
serotonerge en noradrenerge farmaca Dergelijke interacties spelen waarschijnlijk ook een 
rol in de klinische effecten van neuroleptica aangezien de meeste neuroleptica significante 
affiniteit hebben voor al deze receptoren De precieze rol van dopaminerge, serotonerge 
en noradrenerge receptoren in de effecten van neuroleptica is echter voor een groot deel 
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nog onbekend. De huidige studie richt zich dan ook vooral hierop. 
In deel twee zijn de dierexperimentele studies beschreven dat in het kader van het 
onderzoek naar de rol van dopaminerge, serotonerge en noradrenerge receptoren in de 
effecten van atypische en klassieke neuroleptica is verricht. Hierbij is gebruik gemaakt 
van de zogenaamde poottest, een diermodel voor de klinische effecten van neuroleptica. 
In deze test wordt de terugtrektijd van de voor- en achterpoten van een rat gemeten. De 
rat wordt op een platform gezet met elk van zijn poten in een opening. Afhankelijk van 
het type neurolepticum dat wordt toegediend, wordt de terugtrektijd van voor- en/of 
achterpoten verlengd. Grondig onderzoek heeft uitgewezen dat het optreden van een 
verlengde achterpootterugtrektijd een voorspellende waarde heeft voor de therapeutische 
werking van neuroleptica, terwijl de verlenging van de voorpootterugtrektijd een 
voorspellende waarde heeft voor de extrapyramidale bijwerkingen van neuroleptica. 
Als eerste werd bestudeerd of selectiviteit voor dopamine D, of D2 receptoren van invloed 
is op het atypische of klassieke karakter van neuroleptica (hoofdstuk 3). Dit hoofdstuk 
toont aan dat het combineren van ineffectieve doseringen van D, en D2 antagonisten een 
verlenging van de voorpootterugtrektijd, maar niet van de achterpootterugtrektijd, geeft. 
Deze data suggereren dat simultane blokkade van beide receptor-typen tot ernstigere 
bijwerkingen leidt dan selectieve blokkade van hetzij D, receptoren, hetzij D2 receptoren. 
Vervolgens werd de rol van serotonerge receptoren in de gedragseffecten van neuroleptica 
bestudeerd (hoofdstuk 4). Een aantal stoffen met selectiviteit voor serotonerge receptoren 
waarvan gedacht werd dat zij een rol zouden kunnen spelen bij de effecten van 
neuroleptica werd gecombineerd met een aantal neuroleptica. Zowel de serotonine 5-HT1A 
agonist 8-hydroxy-2-(propylamino)tetralin (8-OHDPAT) als de 5-HT2A/c agonist l-(2,5-
dimethoxy-4-iodophenyl)-2-aminopropane (DOI) bleek de gedragseffecten van 
neuroleptica in de poottest sterk te beïnvloeden. De richting van de effecten bleek echter 
per neurolepticum te verschillen. Belangrijk was dat deze verschillen niet direct 
samenhingen met het klassieke dan wel atypische profiel van de neuroleptica. 
Geconcludeerd kon worden dat 8-OHDPAT weliswaar de effecten op de 
voorpootterugtrektijd van een aantal neuroleptica kan remmen, maar dat dit gepaard gaat 
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met een remming van de achterpootterugtrektijd In bepaalde gevallen heeft het toevoegen 
van een specifieke serotoncrge receptor ligand wel een positief effect op het profiel van 
een neurolepticum bijv de 5-HT2A antagonist ketansenne remt de voorpoot- maar niet de 
achterpooteffecten van halopendol Het atypische karakter van een aantal atypische 
neuroleptica leek echter niet samen te hangen met hun affiniteit voor 5-HT2A receptoren, 
zoals dat in de literatuur wel gesuggereerd is 
Daarnaast werd gevonden dat de affiniteit van clozapine voor de 5-HT2A receptor van 
belang is voor de effecten van dit farmacon op de achterpootterugtrektijd Deze bevinding 
vormt uitgangspunt voor een nadere studie waann ook de rol van dopaminerge en 
noradrenerge receptoren betrokken wordt 
De rol van noradrenerge receptoren in de gedragseffecten van neuroleptica werd 
bestudeerd aan de hand van het klassieke neurolepticum halopendol en het atypische 
neurolepticum clozapine (hoofdstuk 5) Ook hier bleken grote verschillen op te treden 
tussen de beide neuroleptica voor wat betreft hun modulatie door noradrenerge farmaca 
Geconcludeerd kon worden dat er verscheidene mogelijkheden zijn om het klassieke 
profiel van halopendol te veranderen in een atypisch profiel de combinatie van een <*,-
antagonist, een a7 agonist of een /3-antagonist met een lage dosenng halopendol leidt tot 
achterpoot-, maar niet voorpooteffecten De combinatie met een α, antagonist lijkt de 
meest veelbelovende omdat er, ook bij hogere doseringen van halopendol, geen verhoging 
van de voorpootterugtrektijd optrad Daarnaast werd gevonden dat de affiniteit van 
clozapine voor de α, receptor belangnjk is voor de effecten van dit farmacon op de 
achterpootterugtrektijd Deze bevinding vormt uitgangspunt voor een nadere studie waann 
ook de rol van dopaminerge en serotonerge receptoren betrokken wordt 
In een volgende studie werd het werkingsmechanisme van clozapine nader bestudeerd 
(hoofdstuk 6) Een eerdere studie had laten zien dal de affiniteit van clozapine voor de D, 
receptor van belang is voor zijn effecten m de poottest, terwijl de huidige, 
bovengenoemde, studies laten zien dat ook clozapine's α, en 5-HT2A componenten van 
belang zijn Deze bevindingen hebben geleid tot de suggestie dat clozapine zijn effecten in 
de poottest via simultane blokkade van D,, 5-ΗΤ2Λ en α, receptoren bewerkstelligt Op 
grond hiervan werd verondersteld dat blokkade van deze dne receptoren tot een atypisch 
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profiel in de poottest leidt. Deze hypothese werd met behulp van selectieve antagonisten 
voor de dne bovengenoemde receptoren getoetst. Het experiment liet zien dat de 
combinatie van ineffectieve doseringen van selectieve antagonisten voor de 
bovengenoemde receptoren tot een sterk effect op de achterpootterugtrektijd, maar niet de 
voorpootterugtrektijd, leidt, oftewel tot het profiel van een atypisch neurolepticum. 
Bovendien bleken geen van de combinaties van twee antagonisten in staat te zijn zo'n 
effect op te roepen. M.a.w., dit experiment, samen met de voornoemde studies, geeft 
sterke aanwijzingen dat clozapine via simultane blokkade van D,, 5-HT2A en a¡ receptoren 
zijn effecten in de poottest heeft. Gezien de voorspellende waarde van de poottest (zie 
boven) geldt dit mogelijk ook voor clozapine's klinische effecten 
In de laatste pootteststudie werd de rol van striatale structuren bestudeerd d.m.v ïntra-
cerebrale toediening van het neurolepticum (en D2 antagonist) ¿/-sulpiride (hoofdstuk 7). 
¿//-Sulpiride toediening in het dorsale striatum, sterker dan in de nucleus accumbens, gaf 
een verlenging van de voorpootterugtrektijd, terwijl ¿/-sulpiride toediening in het 
tuberculum olfactonum hierop geen effect had Anderzijds was het effect op de 
achterpootterugtrektijd nagenoeg gelijk na toediening van sulpiride in de dne gebieden 
Deze data suggereren dat het dorsale striatum, de nucleus accumbens en het tuberculum 
olfactonum in gelijke mate bijdragen aan de therapeutische effecten van neuroleptica, 
terwijl met name het dorsale stnatum, en in mindere male de nucleus accumbens, maar 
niet het tuberculum olfactonum bijdragen aan de extrapyramidale bijwerkingen van 
neuroleptica. Deze resultaten ondersteunen de observaties dat de regionale selectiviteit van 
een neurolepticum de mate kan bepalen waann een neurolepticum extrapyramidale 
bijwerkingen heeft. 
In deel 3 is onderzoek beschreven, waarin het meest ernstige bijeffect van neuroleptica, 
namelijk oro-faciale dyskinesieen is bestudeerd De mate waarin dopamine receptoren in 
de nucleus accumbens, een mogelijk substraat van deze dyskinesieen, betrokken zijn bij 
de sturing van het orale gedrag van de rat werd bestudeerd. Eerst werden de effecten van 
ïntra-accumbens toediening van dopamine D, en/of D2 agonisten onderzocht m.b.v. 
electromyografïsche (EMG) afleidingen van de kaakspieren (hoofstuk 8) en d.m ν 
gedragsobservaties (hoofdstuk 9) Deze studies heten zien dat zowel een D, agonist als 
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een D2 agonist specifieke veranderingen veroorzaakt in orale gedragingen alsmede in het 
EMG patroon Echter, abnormale gedragingen, die overeenkomsten vertonen met 
dyskinesieen, werden niet waargenomen In hoofdstuk 10 werd het effect van ïntra-
accumbens toediening van de DA, agonist (3,4-dihydroxyphenyhmino)-2-imidazoline 
(DPI) bestudeerd d m v gedragsobservatie I 11 de D, en D2 agonisten, leidde toediening 
van DPI wel tot abnormaal gedrag met dyskinetische kenmerken Dus, stimulatie van DAi 
receptoren, maar niet van D, of D2 receptoren leidde tot het gewenste abnormale orale 
gedrag Daaropvolgend werd het specifieke gebied binnen de nucleus accumbens waar 
deze dyskinesieen op te roepen zijn met DPI verder geanalyseerd Uit deze studie bleek 
dat de effecten van DPI op te roepen zijn vanuit de shell, maar niet de rostral pole van de 
nucleus accumbens (hoofdstuk 10) Als laatste werd een onderzoek uitgevoerd naar 
mogelijk anti dyskinetische middelen een mogelijk remmende werking van de 
enantiomeren van het neurolepticum sulpiride op de effecten van DPI werd bestudeerd 
(hoofdstuk 11) De resultaten heten zien dat de enanliomeer die veel minder effectief is 
op de D2 receptor, d sulpiride, in dit model juist veel effectiever de DPI geïnduceerde 
oro-faciale dyskinesieen remde Er werd geconcludeerd dat ¿/-sulpiride mogelijk ook 
effectief is bij oro-faciale dyskinesieen bij de mens Het feit dat ¿-sulpiride zelf niet tot 
ernstige bijwerkingen leidt (dl sulpiride is als racemisch mengsel veelvuldig toegediend bij 
de behandeling van schizofrenie) maakt dat er geen belemmeringen zijn om rf-sulpinde 
klinisch te testen 
In deel 4 worden de belangrijkste bevindingen samengevat en vergeleken met andere 
dierexperimentele studies (hoofdstuk 12) 
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